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Summary 
 
Phospholipases C (PLCs) are a large family of enzymes that regulate the cleavage of 
phosphatidylinositol-4,5- bisphosphate into Inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). This project included research on PLCζ and PLCβ1 on male infertility 
and thyroid cancer respectively.  
Human PLCζ (hPLCζ) is the key protein for egg activation following sperm-egg fusion and 
triggers the release of Ca2+ producing a series of oscillations which initiate embryogenesis. 
Defects in hPLCζ lead to infertility, thus the project aimed at its expression and enrichment 
suitable for biomedical applications.  
The results included 1) Comparison of hPLCζ bacterial expression from twenty four plasmid 
constructs with varying protein tags. 2) Expression of active soluble hPLCζ, free from its 
bacterial solubility partners. 
The PLCβ1 project involved a novel InDel (1076 bp deletion, ATAA junction insertion) 
identified in the 3rd intron of PLCβ1 (Chr 20) by genome-wide linkage analysis (GWLA, LOD 
score 3.01) of a large kindred with multinodular goitre (MNG) progressing to papillary thyroid 
cancer (PTC). Affected individuals exhibited increased PLCβ1 transcript levels in their thyroids 
and the InDel has a putative ERα binding site. 
The project aimed to, 1) Develop a genotyping technique for high-throughput PLCβ1 InDel 
screening in large cohorts 2) Determine the InDel’s mechanism of action in modifying thyrocyte 
proliferation. 3) Next generation sequencing (NGS) of the chr20 region identified by GWLA to 
identify potential variants responsible for MNG.  
1) A QPCR genotyping method was established and the InDel identified in patients with benign 
thyroid disease. 2) Reporter gene assays suggested silencer elements within the InDel. 3) 
PLCβ1 knockdown using siRNA exhibited a trend in inhibiting proliferation of a thyroid cell-
line. 4) NGS of the 20cM-Chr20 GWLA identified region found no additional disease loci 
confirming a role for the PLCβ1 InDel. The InDel provides a biomarker for MNG patients most 
likely to develop PTC.   
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Chapter 1. General Introduction
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1.1 Phospholipases C (PLCs) 
PLCs are a large family of enzymes that have an essential role in the signalling cascade of 
many receptors as described below. Phosphoinositide-specific phospholipase C is comprised 
of six families of multi-domain eukaryotic proteins and is known to be involved in various 
biological processes (Bunney and Katan 2011). PLCs are known to regulate the cleavage of 
the polar head group from phosphatidylinositol 4,5- bisphosphate also known as PtdIns(4,5)P2 
(PIP2) resulting in the generation of Inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). 
These are second messengers known to have calcium-mobilizing properties by activating a 
variety of proteins. More specifically, Inositol 1,4,5-trisphosphate (IP3) diffuses into the cytosol 
and binds to intracellular IP3 receptors in the endoplasmic reticulum (ER) and sarcoplasmic 
reticulum (SR) leading to Ca2+ release from the intracellular calcium stores into the cytoplasm 
(Katan and Williams 1997; Futatsugi et al. 2005). On the other hand, (DAG) activates protein 
kinase C (PKC) which in turn regulates transcription cell growth and survival (Hisatsune et al. 
2005).   
 
1.2 The structure of PLC proteins  
Evidence regarding PLCs activity has been revealed in 1953 by (Hokin and Hokin 1953) with 
the first PLC being purified in 1981 by (Takenawa and Nagai 1981). Since then six families of 
mammalian PLC (β, γ, δ, ε, ζ and η) have been identified (Suh et al. 2008; Bunney and Katan 
2011). All PLCs excluding PLCζ which is lacking the PH domain, have a conserved structure 
comprised of a PH domain, a series of EF hands, the X and Y domains which form the 
triosephosphate isomerase (TIM) α/β-barrel which is considered to be the most conserved 
domain among PLCs and finally a C2 domain (Figure 1.1,1.2). The subdomains in the different 
isozymes have also been found to play key role in the isozyme’s activity, such as in PLC-γ 
which is known to contain two src homology 2(SH2) domains and an SH3 domain. Studies 
have revealed that these domains promote protein interactions with protein kinases which 
activate PLC –γ. Also, PLC ε contains a CDC25 domain at the N-terminus and RA domains at 
the C terminus which are known to regulate GTP-dependent interactions with proteins of the 
RAS family (Figure 1.1) (Rotin et al. 1992; Fukami 2002; Wen et al. 2006; Bunney and Katan 
2011).   
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Figure 1.1 The structure of the different PLC isoenzymes. Phospholipases consist of 6 is 
families with distinct structure and biodistribution. PH: Pleckstrin Homology domain, SH: Src 
homology domain, RA: Ras association 1 domain, Ras:Rat sarcoma, GEF: Guanine 
nucleotide exchange factor.  
 
 
Figure 1.2 The level of conservation of the various domains across PLCs is illustrated by 
the red line, which give the percentage similarity. Adapted from (Hicks et al. 2008). 
 
The aim of this project was the investigation of the potential use of human PLCζ in therapeutic 
applications such as male infertility and the role of a human PLCβ1 InDel in MNG patients 
likely to develop papillary thyroid cancer.   
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1.3 Phospholipase C ζ (PLCζ) 
PLCζ it is a sperm specific protein with a molecular weight of approximately 70kDa which is 
the smallest among mammalian PLCs (Saunders et al. 2002). It is structurally similar to PLCδ1 
with the distinct difference that it lacks a PH domain (Saunders et al. 2002). It is considered to 
be the ideal candidate for ‘egg activation factor’ as it causes multiple Ca2+ oscillations having 
a similar pattern to those occurring with in vitro fertilization (Saunders et al. 2002; Kouchi et 
al. 2004). Also, it has approximately 100 fold higher calcium sensitivity than PLCδ, requiring a 
Ca2+concentration of only a few nanomolar in order to be activated.  Studies have shown that 
the cytosolic Ca2+ concentration is about 50-80nM indicating that is enough concentration to 
activate PLCζ but not δ which requires micromolar concentration (Nomikos et al. 2005).  
 
1.4 PLCζ structure 
1.4.1 EF hands 
The EF hand motif is a well-studied domain as it is one of the most common in animal cells 
with over 1000 having been identified so far within 66 protein subfamilies (Nelson et al. 2002). 
The name EF-hand derived from the calcium-binding motif identified in parvalbumin and was 
given by Kretsinger and Nockolds in 1973 (Figure 1.3). EF-hand motif proteins have been 
classified into two different types, the Ca2+ sensors and the Ca2+ signal modulators, where the 
Ca2+ signal is transduced and the shape and duration of Ca2+ signals are modulated 
respectively (Nelson et al. 2002). The motif was found in the vast majority of the proteins 
where it was identified to bind Ca2+ and in few cases magnesium (Lewit-Bentley and Réty 
2000) (Figure 1.3).  
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Figure 1.3 The typical structure of EF hand motif. A) EF hands motif is characterised by its 
helix loop helix motif. B) The sequence pattern is X.Y.Z.-Y.-X..-Z, with the letters representing 
the ligands in metal coordination and the dots the intervening residues.  Adapted from (Lewit-
Bentley and Réty 2000). 
 
The typical structure of the EF-hand motif is comprised usually from 40 residues forming a 
helix-loop-helix motif where two a-helices are bridged by a Ca2+ chelation loop (Taylor et al. 
1991; Lewit-Bentley and Réty 2000; Gifford et al. 2007). The sequence pattern is X.Y.Z.-Y.-
X..-Z, with the letters representing the ligands in metal coordination and the dots the 
intervening residues (Lewit-Bentley and Réty 2000) (Figure 1.3).  In order for the interaction 
of the EF-hands and the Ca2+ to be maximised, the EF loops are rich with negatively charged 
amino acids such as glutamic acid and aspartic acid with the latter being the more common of 
the two (Gifford et al. 2007). The EF- hand motif has been found to be present in pairs forming 
a four-helix bundle with amphipathic helices following packaging which lead to the formation 
of a hydrophobic core. This structure is stabilised further from the β-sheets which are formed 
between the EF-loop pairs (Gifford et al. 2007). 
Mammalian PLCζ consists of 4 domains, 2 pairs of EF hand domains, the X and Y catalytic 
domains, an intervening region known as the XY linker and the C2 domain (Figure 1.4). The 
EF hands consist of 4 EF hand motifs, which exist in pairs in order to stabilize each other. EF-
hands have been shown by a number of studies to play an important role in the proteins’ 
calcium sensitivity and activity. Mutational studies revealed that the EF hand domains are 
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critical for Ca2+ oscillation- inducing activity (Kouchi et al. 2005; Nomikos et al. 2005). The PLC 
activity of PLCζ was remarkably reduced when the EF-hand domains were deleted one by 
one from the N-terminus, with the data indicating that EF-1 and EF-2 are responsible for the 
PLC activity and EF-3 contributing to the high Ca2+ sensitivity (Kouchi et al. 2005; Nomikos et 
al. 2005). EF hands were found to be important for the interaction of the X and Y domains with 
the PIP2 substrate and therefore for PLC enzyme activity. The removal of EF hands reduced 
the minimum number of interacting sites from 4 to 1 and deletion of the EF hands abolished 
the PLC activity in vivo (Nomikos et al. 2005). Studies performed in PLCδ1 have indicated that 
the loop regions of EF-hands 3 and 4 do not have metal binding sites. In contrast, EF hands 
1 and 2 contain calcium ligands suggesting that calcium binding will occur at least to the first 
EF hand loop (Essen et al. 1997). Also it has been suggested that EF hands may have a role 
in substrate targeting. Replacement of human PLCζ EF hands with mouse led to the decrease 
of Ca2+ sensitivity combined with a 6 fold decrease in substrate affinity (Nomikos et al. 2014) 
 
Figure 1.4 The structure of human PLCζ. PLCζ differs from the other PLCs, as it does not 
contain a PH domain. Recent studies have revealed the role of its domains in egg activation. 
The EF –hand domain is shown to be responsible for the Ca2+ sensitivity, The X and Y domains 
are the catalytic domains, the X-Y linker has a critical role in PIP2 binding and the C2 domain 
has been shown to assist in maintaining Ca2+ sensitivity. Studies have also indicated possible 
binding of C2 domain to PI3P. 
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1.4.2 XY catalytic domain and linker  
The XY catalytic domain is one of the most conserved regions, with about 64% similarity with 
PLCδ1 and is responsible for PLC enzymatic activity (Swann et al. 2006). The X and Y 
domains are intervened by a region known as the XY linker. This region is considered to be 
the least conserved among the species and is comprised mainly of basic residues (Nomikos 
et al. 2007). Recent studies have revealed that XY linker due to its positive charge, interacts 
with the negatively charged membrane surface, resulting in the binding of PLCζ to PIP2 
(Nomikos et al. 2011b). Interestingly, a negative charge in the XY linker region has been 
observed in PLCβ, δ and ε which regulates PIP2 hydrolysis regulating an auto-inhibition of 
PLC activity, which can occur only following a conformation change which keeps away the X-
Y linker allowing the binding of PLC to PIP2 (Hicks et al. 2008). Studies have shown that 
substitution of three of the lysines to alanines (K374A, K375A and K377A) in PLCζ X-Y linker, 
reduced in vivo Ca2+ oscillations and in vitro activity as, the positive charge was significantly 
reduced disrupting the PIP2 binding efficiency (Nomikos et al. 2013a). Replacement of human 
X-Y linker with the mouse region had a significant effect on calcium oscillations confirming its 
vital role in enzymatic activity (Nomikos et al. 2014). Also a nuclear localisation signal (NLS) 
has been predicted within the X-Y linker and is suggested to have a key role in the shuttling 
of the protein between the cytoplasm and the nucleus following egg activation, in mouse 
oocytes (Nomikos et al. 2013a; Kashir et al. 2015).  
    
1.4.3 The C2 domain  
The C2 domain is a conserved region among PLCs comprising approximately 120 amino acids 
and having an important role in membrane anchoring (Amdani et al. 2013). In PLCζ, it is 
suggested to have an important role in in vivo activity, as removal of C2 abolished Ca2+ 
oscillations in mouse eggs (Nomikos et al. 2014).  The C2 domain has also been suggested 
to have a potential role in activation of PLCζ. It has been found that interacts with PI3P reducing 
PLCζ in vitro activity (Kouchi et al. 2005) suggesting that this interaction could be responsible 
for its inactive status in sperm prior sperm – egg fusion. Also, it has been suggested to have 
a role in PLCζ localisation. A computational prediction has suggested that C2 may interact 
with the EF hand hydrophobic residues forming a loop which in turn exposes the NLS region 
of the X-Y linker (Kuroda et al. 2006)(Figure 1.5). 
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Figure 1.5 Illustration of the predicted interaction of C2 with the hydrophobic residues 
of EF hands forming a loop exposing the NLS region of XY the linker. Adapted from 
(Kuroda et al. 2006). 
 
1.5 Human PLCζ 
1.5.1 Signalling  
Calcium (Ca 2+) signalling is known to have a vital role in a wide range of cellular mechanisms. 
However, studies have found that all calcium signalling systems share a common 
characteristic, i.e. they cause calcium pulses. This calcium release has been shown to be 
regulated by a number of messengers such as Inositol- 1, 4, 5-trisphosphate (InsP3), cyclic 
ADP ribose (cADPR) and others. A number of studies by (Burgess et al. 1983) in hepatocytes, 
(Streb et al. 1983) in permealized pancreatic acinar cells and others using a range of different 
cells revealed that ER is the major Ca2+ store which triggers Ca2+ release due to IP3 activity 
(Taylor and Tovey 2010). During fertilization, the calcium oscillations were indicated to be 
regulated by IP3 which is generated by the activity of PLCζ (Berridge et al. 2003) (Figure 1.6).  
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Figure 1.6 The cell signalling of PLCζ. The fusion of sperm with the egg is followed by a 
series of events. 1) PLC is released hydrolysing PIP2 at internal vesicles. 2) PIP2 hydrolysis 
leads in the formation of IP3 and DAG. 3) IP3 binds to the IP3 receptor at the ER, 4) releasing 
intracellular calcium stores forming a positive feedback loop with PLCζ activity.  
 
1.5.2 IP3 receptor 
The IP3 receptors are Ca2+ channels which are comprised of 4 closely associated subunits, 
each of approximately 2700 amino acid residues. Each subunit has a single IP3 binding site 
where, the binding of IP3 leads to the opening of the channel and release of intracellular Ca2+ 
(Taylor et al. 2004; Taylor and Tovey 2010). Studies have suggested that binding to less than 
four IP3-binding sites can lead to opening of the channel (Boehning and Joseph 2000); release 
of intracellular Ca2+ stores requires the binding of IP3 to at least one of the four IP3- binding 
sites of the receptor (Taylor and Tovey 2010). The binding of the IP3 causes a large 
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conformational change in the receptor making the stimulatory site accessible whilst the 
inhibitory site is hidden. In addition intracellular Ca2+ store has an essential role in IP3R 
sensitivity, with high stores increasing sensitivity leading to opening of the pore and loss of the 
Ca2+ store. Furthermore, the loss of Ca2+ desensitises the receptor to IP3 resulting in closing 
of the pore until the stores are eventually refilled (Berridge 2007; Taylor and Tovey 2010).  
 
1.6 Egg activation theories  
There were a number of hypotheses proposed (Figure 1.7), until (Saunders et al. 2002) 
suggested that PLCζ is the sperm factor responsible for oocyte calcium oscillations and 
therefore initiation of embryo development.  
 
1.6.1 Calcium bomb 
The first hypothesis was known as the ‘’calcium bomb’’ according to which the egg, calcium 
stores from sperm cytosol are inserted into the egg resulting in its activation (Jaffe 1983). 
Studies performed by (Steinhardt et al. 1974; Fulton and Whittingham 1978) revealed that 
microinjection of Ca2+ or of the divalent transporting ionophore A23187 were capable of 
promoting Ca2+ release from intracellular stores in the egg resulting in its activation. However, 
the major argument against the bomb theory was the fact that spermatozoa volume is only a 
marginal proportion compared to the egg volume with less than 1%, therefore it was suggested 
that the amount of calcium located in the sperm head would not be sufficient to initiate Ca2+ 
release (Nomikos et al. 2011b). In addition, studies by (Lawrence et al. 1997) indicated a delay 
known as the ‘latent period’ between sperm fusion and Ca2+ release, which supported the 
soluble sperm factor theory.  
 
1.6.2 Calcium conduit 
The second hypothesis, was the ‘’Calcium conduit’’ which suggested the flow of extracellular 
calcium into the egg, through the sperm fusion with the egg (Jaffe 1983). Although, if the theory 
was correct, elevated levels of Ca2+ at the location of sperm–egg fusion would be expected 
(Jaffe 1991). Investigation with indo-1 dextran dye (Jones et al. 1998) indicated that there is 
no such increase and in the same study illustrated that reducing extracellular Ca2+ to 13nM 
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using chelating agents such as EGTA, did not prevent the first Ca2+ spike indicating that an 
extracellular source for the Ca2+ trigger is unlikely (Jones et al. 1998). 
 
1.6.3 Membrane receptor hypothesis 
The third hypothesis was the membrane receptor hypothesis, according to which the 
interaction of the sperm with a receptor at the egg surface would eventually lead to increase 
of the InsP3 and egg activation. Initially, PLCβ was proposed to have the oscillatory role 
through a GTP binding protein, since in hamster eggs inhibition of G proteins lead to silencing 
of Ca 2+ release.  Although, inhibition of the Gaq proteins failed to eliminate Ca2+ oscillations 
in mouse eggs (Miyazaki et al. 1993; Williams et al. 1998). 
 
1.6.4 Sperm factor  
This theory was introduced  when injection of cytosolic sperm extracts into hamster eggs 
caused Ca2+ oscillations as observed in fertilized mammalian eggs (Swann 1990). In addition, 
studies (Rice et al. 2000) in which they have used sperm extracts revealed that the sperm 
factor was calcium dependent and its activity was solely due to IP3 production. To support that 
hypothesis, U73122 PLC inhibitor was used to assess the ability of PLCs to produce Ca2+ 
oscillations, which led to the conclusion that the soluble sperm factor is a PLC (Wu et al. 2001). 
Initially, activation was thought to occur via activation of PLCβ and later with PLCγ; although 
experiments have shown that both models were misleading (Miyazaki 1988; Runft et al. 1999).  
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Figure 1.7 A summary of the egg activation theories. The evolution of the different 
hypotheses which eventually led to the sperm factor hypothesis and PLCζ. ER: Endoplasmic 
Reticulum, IP3: Inositol trisphosphate, PLC: Phospholipase C, SF: Sperm Factor. 
 
1.7 Calcium oscillations  
The discovery of hPLCζ, (Saunders et al. 2002) confirmed the sperm factor hypothesis as this 
PLC isoform proved to be the best candidate. It is considered to be ideal candidate for egg 
activation as it causes multiple oscillations that mimic physiological fertilization (Saunders et 
al. 2002; Kouchi et al. 2005). PLCζ has approximately 100 fold higher calcium sensitivity than 
hPLCδ1, requiring only few nanomolar of Ca2+ in order to be activated.  Studies have shown 
that the cytosolic Ca2+ concentration that is required for PLCζ activity is about 50-80nM in 
contrast with PLCδ1 which is approximately 100 times less sensitive to Ca2+ concentrations 
(Nomikos et al. 2005) (Figure 1.8).  
 
Calcium release is a universal requirement for mammalian egg activation. Calcium release 
was found as either a single transient or in series of oscillations (Figure 1.9). Studies in mouse 
have revealed that PLCζ is causing oscillations in approximately a minute following sperm-
egg fusion. In vivo studies have shown that calcium transient is mouse egg follows two stages, 
with initially a slower transient rate followed by a rapid oscillation rate. Oscillations continue 
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for approximately 3 hours following the first transient the frequency drops to approximately 1 
every 10 minutes. 
 
 
Figure 1.8 Fertilisation calcium transient across different species and the variety of 
different calcium transient patterns required for egg activation. Adapted from (Miyazaki 
and Ito 2006). 
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Figure 1.9 The calcium oscillations of human and mouse PLCζ in mouse egg following 
mathematical modelling simulation based on their in vivo enzymatic characteristics. 
Adapted from (Nomikos et al. 2013a). 
 
1.8 Spermiogenesis 
The maturation process of spermatids into mature spermatozoa is known as spermiogenesis. 
It is a long process which requires approximately 14 days until the sperm travels along the 
ductus deferens and stored for the ejaculation as seen in (Figure 1.10)(Knobil and Neill 1998). 
The process is initiated by formation of the acrosome, in the Golgi apparatus; vesicles migrate 
at the pre-acrosomal location and then the axoneme develops. A large acrosome is generated, 
a cup-like structure which is applied to the elongating nucleus. The acrosome functions as a 
modified lysosome to enable the spermatozoon penetrate the zona pellucida and fertilization 
to be achieved (Dale et al. 2010). During the acrosome stage the nucleus condenses, such 
that the sperm head is formed, condensation also initiates mitochondrial migration and 
midpiece formation at the opposite pole of the pre-acrosome. This is accompanied by 
inactivation of mRNA transcription and replacement of histones by protamines. As the 
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spermatids elongate, a flagellum is formed a structure which is responsible for sperm 
movement as seen in (Figure 1.11) (Knobil and Neill 1998; Falcone and Hurd 2007)  
 
Figure 1.10 A map of Spermiogensis. Spermatogenesis takes place in seminiferous tubules 
where Sertoli cells are located; the epididymis is a vital structure which is involved in sperm 
maturation and storage. Taken from www.anatomytopics.wordpress.com                   
 
1.9 Spermiation 
The change in sperm morphology is followed by spermiation, a process where mature 
spermatids are transferred from Sertoli cells into the lumen and towards the rete testis. 
Cytoplasmic portions often remain on the spermatozoon after spermiation which indicates the 
level of sperm maturity(Ross and Dobler 1975). 
15 
 
 
Figure 1.11 The mature spermatozoon consists of three main structures, the head, the 
midpiece and the tail. From www.uwstudentweb.uwyo.edu 
 
1.10 Sperm Maturation  
The spermatozoon then enters the epididymis and travels along in order for motility etc. to be 
acquired. Spermatozoa are first inserted into the caput epididymis where approximately 90% 
of the fluid secreted by the testis is absorbed (Aitken et al. 2007). Throughout the migration 
from caput epididymis to corpus and eventually to cauda epididymis where spermatozoa are 
stored for ejaculation, the sperm gains the ability of forward progressive movement in 
response to elevated cAMP, ATP Mg2+ and protein carnitine. In addition, sperm head acquires 
proteins from epididymis in order to be able to recognize and bind to the zona pellucida of the 
oocyte (Kirchhoff 1998; Dacheux et al. 2003). Through this migration, the sperm plasma 
membrane undergoes great changes as proteins are being modified by proteases and 
epididymal proteins bound to the surface stabilizing the membrane. Also some proteins have 
a decapacitation function to prevent premature sperm activation. Epididymal proteins such as 
fertilin proacrosin, membrane-bound hyaluronidase, 1,4-galactosyltransferase, sp56 and p59 
represent some of the proteins which are bound to the sperm plasma membrane. In humans 
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this process takes approximately 2 days until the mature sperm is eventually stored at cauda 
epididymis (Lasserre et al. 2001; Dale et al. 2010). 
Mature spermatozoa remain stabilized in the corpus epididymis at low pH in seminal fluid. To 
be capable of fertilization they need to become motile which is achieved only after ejaculation 
and the capacitation stage (Gadella et al. 2008). Once spermatozoa are inserted into the 
female genital tract after ejaculation, their seminal plasma is removed by cervical mucus which 
also prevents infection in the uterus (Florman et al. 2008). Sperm plasma proteins with 
decapacitating function are removed allowing initiation of capacitation, which also involves 
extensive rearrangement of e.g. lipid structure, this enables sperm binding to the zona 
pellucida and triggers the acrosome reaction as seen in (Figure 1.12) (Gadella et al. 2008).  
 
1.11 Sperm Capacitation 
Studies have revealed that capacitation is initiated by cholesterol efflux from sperm, resulting 
in plasma membrane destabilization and increased permeability. Plasma membrane 
permeability leads to influx of bicarbonate (HCO3-) and Ca2+ which increase intracellular pH 
and initiate intracellular Ca2+ signalling respectively (Florman et al. 2008; Gadella et al. 2008; 
Abou-haila and Tulsiani 2009). Initiation of the signalling results in adenylate cyclase activity, 
adenosine monophosphate (cAMP) production, in protein kinase activation, protein tyrosine 
phosphorylation and sperm hyperactivation required for reaching the ampulla and undergoing 
the acrosome reaction. Also, studies have shown that during capacitation, plasma membrane 
phospholipids undergo methylation as phospholipids were found to be in different distribution 
(Abou-haila and Tulsiani 2009). Capacitation which is considered vital for fertilization requires 
approximately 6 hours in humans under optimal conditions (Dale et al. 2010).    
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Figure 1.12 Sperm capacitation. Capacitation is required for the sperm to undergo the 
acrosome reaction and fertilization to occur. Capacitation involves cholesterol efflux and 
calcium bicarbonate influx such that sperm hyperactivation is achieved. From (Abou-haila and 
Tulsiani 2009). cAMP: Cyclic adenosine monophosphate, CaM: Calmodulin, HCO3-: 
Bicarbonate.  
 
1.12 Acrosome reaction 
The sperm then enters the oviduct and reaches the ampulla where the oocyte is located 
enveloped by cumulus cells. The cumulus contains hyaluronidase which is also present in the 
capacitated acrosome resulting in sperm penetration of the cumulus layer (Figure 1.12, 1.13). 
It has been suggested that the attachment of sperm to zona pellucida of the oocyte is the 
starting point of the acrosome reaction. The zona pellucida is a barrier which surrounds the 
oocyte and consists of three glycoproteins, (zona pellucida 1) ZP1, ZP2 and ZP3. The last 
glycoprotein has been found to be the first ligand between the zona and the sperm. The 
contact of sperm and egg through ZP3, results in opening of Ca2+ ions and increase of 
intracellular pH which, in the presence of progesterone, triggers the acrosome reaction. Zona 
pellucida also activates phospholipase C which regulates calcium influx and generates IP3 and 
diacyglecerol (DAG) for acrosome reaction induction. Once induced, acrosomal granules 
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break down by acrosin enzyme resulting in fusion of zona pellucida and exocytosis of 
acrosomal compartments (Florman et al. 2008; Gadella et al. 2008; Abou-haila and Tulsiani 
2009).  
a 
 
b 
 
Figure 1.13 The maturation process of the human oocyte. a) The Maturation of the human 
oocyte Primordial is the first form of ovarian follicle which develops into primary and secondary 
form until it reaches either the preovulatory stage or undergoes atretic degeneration (corpus 
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luteum). Adapted from (http://classes.midlandstech.edu/). b) The structure of late primary 
follicle. In mammals have a defined structure, they consist of an oocyte which is surrounded 
by granulosa cells, membrane propria and a layer of theca cells which is located at the outer 
side of the follicle 
 
1.13 Sperm-egg fusion 
The penetration of the zona pellucida is followed by sperm oolemma binding and fusion.  The 
sperm binds to the oolemma at the equatorial region where oolemma integrins interact with 
proteins of the ADAM family on the sperm. Also, it has been found that sperm fusion is 
regulated by CD9 protein which functions as a linker between sperm functional domain linker 
and glycosylphosphatidylinositol (GPI-) anchored proteins (Evans 2002; Kaji and Kudo 2004; 
Primakoff and Myles 2007). 
 
Figure 1.14 Acrosome reaction. Acrosome reaction allows the penetration of zona pellucida 
by the sperm and the equatorial binding and fusion of sperm to oolemma the completion of 
fertilization. From www.legacy.owensboro.kctcs.edu  
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1.14 Cortical reaction and embryogenesis activation 
Sperm-oocyte fusion is followed by cortical reaction where enzymes released from the cortical 
granules of the oocyte cause rearrangement of the zona pellucida to avoid polyspermic 
fertilization. Once sperm fuses with the oocyte, there is a rapid increase in extracellular 
calcium which is followed by calcium oscillations. Recent studies have revealed that PLCζ, 
which is located in the post-acrosomal region, is responsible for the rapid calcium release. 
PLCζ regulates PIP2 hydrolysis which results in calcium release regulated by IP3 and initiation 
of embryonic development. Studies in mouse embryo have shown that PLCζ injection can 
initiate calcium oscillations and immunodepletion of it leads to inhibition of embryos 
development (Kashir et al. 2010). The naked sperm, having fused with the oocyte, rotates 
approximately 180 degrees and then forms the male pronucleus. The sperm midpiece and tail 
degrade and the embryo forms a zygote which is the beginning of embryonic development 
(Dale et al. 2010).    
 
1.15 Therapeutic applications  
Infertility affects approximately 15% of the couples and can be either due to male or female 
causes.  In vitro fertilisation since the first successful birth in 1978 has become increasingly 
popular accounting for up to 7% of total births in some countries. Severe infertility affects 
approximately 19% of the infertile couples. In the case of severe male factor the standard 
approach in assisted reproduction is Intracytoplasmic sperm injection (ICSI) (Nomikos et al. 
2013a). However, even the extremely successful ICSI does not solve the problem completely 
as about 5% of the cycles still fail (Ramadan et al. 2012). Lack of egg activation following ICSI 
treatment has been observed in a number of cases. Also in patients with mutated PLCζ and 
globozoospermic patients where PLCζ is absent, egg activation was abolished. Calcium 
ionophore has been used successfully to overcome this issue however, it causes a single Ca2+ 
transient rather than multiple oscillations as in fertilisation, failing to mimic physiological 
conditions. Also, such applications can be potentially toxic and teratogenic therefore PLCζ the 
physiological sperm factor has been suggested (Chapter 2 and 3) to be an effective potential 
treatment for such cases mimicking physiological conditions without affecting embryonic 
development (Nomikos et al. 2013a).  
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1.16 The role of PLCβ1 in health and disease 
Phospholipases C have a key role in a range of biological processes, above it was described 
the role of PLCζ in infertility. In this project another PLC, the PLCβ1 was investigated for its 
role in thyroid cancer. 
 
1.16.1 The structure of PLCβ1 
PLCβ is an important phospholipase as there is a number of studies indicating that it has a 
role in a wide range of biological processes such as cell growth, differentiation and metabolism 
(Suh et al. 2008). PLCβ is a member of the PLC family consisting of 4 isozymes.  It is activated 
by G - protein coupled receptor (GPCR) at the plasma membrane. It has a conserved structure 
comprised of a PH domain which is considered to be involved in the plasma membrane 
localization of the protein and its activation as it interacts in a cooperative manner with 
phosphatidylinositol 3 phosphate and the Gβγ subunit (Razzini et al. 2000; Wang et al. 2000). 
The series of EF hands, which function as a scaffold, regulate the initiation of GTP hydrolysis 
following the binding of Gαq (Dowal et al. 2006; Lyon et al. 2013). The X and Y domains form 
the (TIM) α/β-barrel and are considered to be the most conserved domains among PLCs. 
Studies have indicated that Gβγ interacts with both PH and X and Y catalytic domains (Rhee 
2001) (Figure 1.14). A C2 domain which contributes to inter-intra molecular binding sites (Lyon 
et al. 2013) and a C terminal extension, where Gaq binds in order to activate PLCβ1 and is 
also important for the intracellular localization of the protein (Rhee 2001; Fukami 2002). 
 
Figure 1.15 The binding of PLCβ1 to PIP2. In PLCβ the Χ-Υ linker is negatively charged 
inhibiting the binding of the molecule to PIP2, only a conformational change following its 
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activation by Rac allows the binding of PLC to the negatively charged membrane. Adapted 
from (Hicks et al. 2008). 
 
1.16.2 The PLCβ1 isozymes 
PLCβ isozymes differ from the other members of the PLC family as they contain an elongated 
C- terminus. This C terminal extension consists of about 400 amino acids and is highly 
conserved. The C terminal extension, is subdivided into three sections, the N-terminus, the 
28-61 residue linker region and the elongated coiled coil domain of approximately 300 amino 
acids (Lyon et al. 2013). PLCβ1 is present in two forms as result of alternative splicing, 
PLCβ1a and PLCβ1b. The two splice variants PLCβ1a (150 kDa) and PLCβ1b (140 kDa), 
differ in a region of the C- terminus (Suh et al. 2008; O'Carroll et al. 2009). They share a 94% 
homology with PLCβ1a being 43 amino acids longer than the PLCβ1b. PLCβ1a has 
cytoplasmic localization containing a nuclear export sequence at its C terminal extension, in 
contrast with PLCβ1b which is mainly localized within the nucleus (Figure 1.15) (Piazzi et al. 
2013). The last 3 amino acids of the C terminal region of PLCβ1a constitute a consensus post 
synaptic density protein/Drosophila disc large tumour suppressor/ zona occludens-1 protein 
motif. This motif is considered to have a key role in the localization of the enzyme. On the 
other hand the 10 amino acids at the C terminus of PLCβ1b contain a proline rich sequence 
(Grubb et al. 2008; Lyon et al. 2013).  
 
Figure 1.16 The PLCβ1 splice variants. PLCβ1 has two splice variants PLCβ1 α (150kDa) 
and β (140kDa). They differ at their C-terminal extension as PLCβ1α contains an NES.  
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1.16.3 PLCβ1 activation  
PLCβ1 has multiple activation mechanisms. The cytoplasmic activation of PLCβ1 requires 
both Gaq and Gβγ subunits.  In an inactive stage Gβγ is attached tightly to the GDP bound 
Gaq, keeping the molecule inactive (McCudden et al. 2005; Golebiewska and Scarlata 2010). 
Gβγ acts as guanine nucleotide dissociation inhibitor (GDI) and consequently it decreases the 
rate of GDP release significantly. Upon activation via an extracellular signal which binds to the 
G protein coupled receptor (GPCR), a conformational change occurs on the receptor which in 
turn initiates the exchange of GDP to GTP. The conformational change enables the interaction 
of Gaq with the receptor which dissociates from the Gβγ subunit. The dissociation of Gβγ 
exposes protein regions on Gaq which in turn binds to PLCβ1 and activates it. Gaq has an 
intrinsic GTPase activity, causing hydrolysis of GTP to GDP which in turn terminates the signal 
and re-association with Gβγ takes place returning the complex to its initial inactive state 
(Figure 1.16) (Dowal et al. 2006; Golebiewska and Scarlata 2010). 
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Figure 1.17 a) Activation of PLCβ1. At inactive state Gβγ is bound tightly to the GDP bound 
Gaq. b) The GPCR undergoes conformational change once an extracellular signal is attached 
and enables the binding of Gaq to the receptor and the exchange of GDP by GTP. The Gβγ 
dissociates from Gaq allowing the interaction of PLCβ1a leading to its activation. c) Activated 
PLCβ1a hydrolyses PIP2 generating IP3 and DAG.  
 
1.16.4 Subcellular distribution mechanism 
The mechanism of how the two splice variants are localized within the cell is still unclear.  A 
recent study (Piazzi et al. 2013) reported that the variants interact with kpna and kpnb1 
proteins, also known as importins. PLCβ1 splice variants as previously mentioned, contain a 
nuclear localisation sequence (NLS) at their C terminal extension.  It has been suggested that 
a b 
c 
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importin α (kpna) binds to this NLS sequence and promotes the binding of importin b (kpnb1) 
forming a complex which in turn is transferred into the nucleus. Nuclear importation occurs 
when importin b binds to the proteins of the pore complex leading to the dissociation of the 
complex and the insertion of the protein into the nucleus (Figure 1.17a). It is thought that both 
splice variants are imported however PLCβ1α, due to its nuclear export sequence (NES) which 
is present at its exclusive 75 amino acid region, is exported back to the cytoplasm. This also 
explains the fact that whilst both variants are found in the nucleus, the highest concentration 
of PLCβ1a and PLCβ1b is found in the cytoplasm and the nucleus respectively. The export of 
PLCβ1a is possibly operated by the binding of exportin 1 via its binding at the leucine rich 
region of the NES as observed with PLCδ1 (Figure 1.17b) (Okada et al. 2002).   
 
 
Figure 1.18 The nuclear import and export of PLCβ1. a) The import mechanism of PLCβ1, 
where importin a (A) binds to the nuclear localization sequence promoting the association of 
importin b (B) which in turn translocates the complex into the nucleus. The complex via a Ran 
dependent reaction, is dissociated with importins a and b being transferred back to the 
cytoplasm. b) The nuclear export of PLCβ1a is possibly operated by the exportin1 via its 
binding to the leucine rich region of the nuclear export sequence.  
 
The two splice variants not only differ in their C terminal domain but also in their intracellular 
localization and mode of activation (Molinari et al. 2012). PLCβ1a has been found to be 
predominantly in the cytoplasm in contrast with PLCβ1b which is located in the nucleus and 
a b 
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more specifically at the nuclear speckles. This nuclear organelle is composed of clusters of 
interchromatin granules and is known to be rich with pre messenger RNA splicing factors. 
Little is known about the exact function of speckles, however a number of studies have 
indicated that transcriptionally active genes localise to the speckle area suggesting an active 
role in transcriptional pre mRNA regulation of the cell (Lamond and Spector 2003; Hall et al. 
2006; Hu et al. 2009; Zhao et al. 2009; Tripathi et al. 2012). A cluster of lysines at their C-
terminal have been shown to have a key role in the nuclear translocation of the protein as they 
provide interaction sites which retains PLCβ1 inside the nucleus (Piazzi et al. 2013). Also, 
another study indicated that the phosphorylation on S867 by PKC also regulates the 
localization of the protein as PLCβ1 remained within the nucleus due to the lack of 
phosphorylation. The subcellular localization mechanism of the PLCβ1 isoforms therefore 
includes translocation of both isoforms into the nucleus with the assistance of α/β importins 
with which they form complexes and are transported inside the nucleus. Then PLCβ1 interacts 
with negatively charged proteins and is retained within the nucleus, whereas PLCβ1a is 
exported back to the cytoplasm via its NES predicted by NetNES 1.1 (Piazzi et al. 2013). 
 
1.16.5 The presence of PLCβ1 in human cancer 
1.16.5.1 The role of PLCβ1 in Cancer 
According to world health organization (WHO) and the International Agency for Research on 
cancer (IARC), cancer is the main cause of death globally with more than 7 million deaths for 
the year 2008 and more than 12 million new cases for the same year worldwide. In 2010, more 
than 1.5 million new cases were reported in the United States (Jemal et al. 2010). The 
molecular pathology of the disease is considerably complex and not fully yet understood. 
Carcinogenesis arises after the disruption or malfunction of the cell cycle control mechanisms, 
resulting in uncontrolled cell division, growth and death (Fresno Vara et al. 2004; Knowles et 
al. 2005; Gabriel 2007). The processes involved in carcinogenesis have long been extensively 
studied forming a complex network where signalling pathways and proteins control gene 
expression, cell growth and differentiation. A human phospholipase and more specifically 
PLCβ1 has been shown in many studies to be involved in such processes and to have a 
central role in various types of human cancer.  
The gene for PLCβ1 is located at the short arm of chromosome 20 (Figure 1.18). Interestingly, 
chromosome 20 has been shown to be altered or to be involved in a variety of cancers, such 
as prostate, colon, breast, leukaemia and ovarian cancer (Friederichs et al. 2000; Kristiansen 
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et al. 2002; Follo et al. 2009; Molinari et al. 2012; Ribeiro et al. 2012; Jia et al. 2013). PLCβ1, 
is present in most somatic cells and being involved in a range of different cancers makes it a 
good candidate for the study of cell proliferation and differentiation, (Table 1.1).  
 
 
Figure 1.19 Chromosomal location of PLCβ1. PLCβ1 gene is located at the short arm of 
chromosome 20. Copy number variation at the long arm have been associated with the 
presence of different types of cancer such as breast, colorectal and prostate cancer 
(Friederichs et al. 2000; Kristiansen et al. 2002; Follo et al. 2009; Molinari et al. 2012; Ribeiro 
et al. 2012; Jia et al. 2013). 
 
A recent study examining a number of patients with breast cancer identified that the majority 
had aneusomies and genetic amplifications in the PI-PLCβ1 locus (Molinari et al. 2012). In 
addition, PLCβ1 has been found to be overexpressed in colorectal cancer tissue as a specific 
SNP has been detected to be present in colorectal cancer patients (Gundem et al. 2010; Jia 
et al. 2013). It has also been found to be overexpressed in the periprostatic (PP) tissue of 
patients with prostate cancer (Ribeiro et al. 2012). Furthermore, PLCβ1 has been suggested 
to have a role in ovarian cancer (Kristiansen et al. 2002) and adenocarcinomas (Friederichs 
et al. 2000) due to its effect on CD24 which in turn promotes cell cycle progression (Fiume et 
al. 2005). Moreover, a mono-allelic cryptic deletion in PLCβ1 gene was identified to worsen 
the clinical profile of patients with myelodysplasmic (MDS) syndromes and increased the risk 
in developing acute myeloid leukaemia (Follo et al. 2009). 
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Table 1.1 List of cells expressing PLCβ1. PLCβ1 is expressed in most somatic cells of the 
human body including cells from the immune, nervous, muscle, internal, secretory and 
reproductive system.  
 
 
1.16.7 PLCβ1 in Thyroid Cancer 
A family with high prevalence of multinodular goitre (MNG), progressing to papillary thyroid 
cancer (PTC) will be described in more detail in chapter 4.  Previous studies conducted by Dr. 
Ameen Bakhsh using Genome Wide Linkage Analysis (GWLA) and non-parametric linkage 
analysis revealed a high LOD (3.01) score region on chromosome 20. Further investigation 
using techniques to assess copy number variation in the high-LOD score region indicated that 
affected family members are heterozygous for an insertion-deletion (InDel) in the PLCβ1 gene. 
In addition patients carrying the PLCβ1 InDel exhibited elevated PLCβ1 transcript levels in 
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their thyroids compared with subjects without the InDel. The high prevalence of patients 
progressing from MNG to PTC and the elevated transcript levels of thyroid PLCβ1 led to the 
hypothesis that the PLCβ1 inDel could be involved in benign thyroid proliferation. 
  
1.16.8 Structure and Function of the Thyroid Gland 
The thyroid gland is located in the neck forming two lobes connected by an isthmus. Its name 
is derived from the Greek ‘’θυρεός’’ which stands for shield and describes its shape. The 
thyroid gland is the largest among the endocrine organs responsible for the synthesis of three 
hormones, the 2 thyroid hormones and calcitonin. The synthesis of these hormones takes 
place in follicular cells and parafollicular C cells respectively. Follicular cells which is the 
dominant cell population constitute the epithelium and originate from the endoderm (Werner 
et al. 2005; Kondo et al. 2006). 
 
1.16.8.1 Thyroid hormone synthesis  
The thyroid gland is responsible for the synthesis of Thyroxine (T4), Tri-iodothyronine (T3) and 
Calcitonin. The synthesis of T4/T3 occurs in the lumen of follicular cells with Iodide being 
initially transported by the sodium iodide symporter (NIS) into follicular cells. Iodide which is a 
rate limiting substrate is inserted partially into the lumen via the activity of Pendrin (PDS) 
transporter in a process known as Iodide trapping. Iodide is then attaching to tyrosine 
molecules of the thyroglobulin. However, prior to this binding, Iodide undergoes oxidation in 
the apical lumen under the activity of thyroperoxidase (TPO). The oxidation reaction is 
operated in the presence of hydrogen peroxidase (H2O2) which in turn is generated by the 
enzymatic activity of dual oxidase (DUOX1/2). Thyroglobulin which is synthesized in the lumen 
and contains numerous tyrosine residues at its N and C termini, is iodinated following the 
attachment of oxidised iodide to the tyrosine molecules which contain iodide acceptors in 
excess to prevent free iodide accumulation. The binding is catalysed by TPO in a process 
known as organification. The binding of iodine molecule to tyrosine lead to the formation of 
Μonoidotyrosine (MIT-T1) and Diiodotyrosine (DIT-T2). In physiological conditions more DIT 
is generated than MIT. The following step is known as the coupling, it is noteworthy that only 
20% of the tyrosine molecules which have been iodinated go through the coupling process. 
The reaction is catalysed by TPO and results in in the formation of Tri-iodothyronine (T3) 
following the coupling of one MIT and one DIT and Tetra-iodothyronine or thyroxine (T4) with 
the coupling of two DIT (Goodman 2003; Werner et al. 2005) (Figure 1.19).  
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Figure 1.20 The chemical structure of the thyroid hormones. The thyroid hormones 
synthesized in the follicular cells of thyroid gland. T3 and T4 are the result of the coupling 
process where T1 and T2 are coupled T1+T2, T2+T2 to form T3 and T4 respectively.  
 
Iodinated Tg is then fused with lysosome which results in the proteolytic degradation and 
release of T4, T3 and iodotyrosines (Wermer and Ingbars 2012). The degradation of iodinated 
Tg and subsequent release of T4 and T3 hormones lead to their release into the bloodstream 
via the transporter monocarboxylate 8 (MCT8). Thyroid hormones in the circulation are bound 
to thyroid hormone binding proteins (THBP) which maintain them in an inactive state and act 
as thyroid hormone storage for uninterrupted tissue supply (Bhatkar et al. 2004) (Figure 1.20). 
The small amount of iodotyrosines released MIT and DIT are deiodinated by dehalogenase 
enzyme (DEHAL1) which recycles iodide for thyroid hormone production (Werner and Ingbars 
2012). The main thyroid hormone which is released is T4 with 80% of the resulting T3 to 
emerge from the deiodination of T4 by type I and type II deiodinase (D1), (D2) (Chi et al. 2013). 
D2 is considered to have greater impact than D1 and have an essential role in T3 homeostasis 
in conditions such as hypothyroidism. On the other hand deiodinase type III (D3) deactivates 
T3 and T4 generating T2 and inactive reverse triiodothyronine (rT3) respectively in conditions 
such as hyperthyroidism (Williams and Bassett 2011).  
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Figure 1.21 Thyroid hormone synthesis. 1) Iodide is taken up by follicular cells through NIS 
transporter and 2) is oxidised in the presence of H2O2.3) Thyroglobulin is synthesized by the 
Endoplasmic Reticulum, 4) contains tyrosine molecules with iodide acceptors and is 5) 
iodinated with oxidised iodide by TPO forming T1 and T2. 6) The coupling of T1 and T2 result 
in the formation of T3 and T4. The thyroid hormones are then inserted through pinocytosis 
into the cell. 7) The vesicle containing the Thyroid hormones is fused with lysosome where 
proteolysis takes place.8) Thyroid hormone is then released into the bloodstream.  
 
1.16.9 Thyroid homeostasis 
Thyroid stimulating hormone (TSH) is the essential regulatory protein of thyroid function. It is 
an approximately 30kDa glycoprotein secreted by the anterior pituitary gland. It is synthesized 
by the thyrotrophs and has a central role in maintaining the circulating levels of thyroid 
hormones, iodine uptake and thyroid growth (Szkudlinski et al. 2002). It is regulated by 
hypothalamic- thyrotropin- releasing hormone (TRH) and the level of circulating thyroid 
hormones by positive and negative feedback loops respectively (Ock et al. 2013). TSH acts 
via its binding to thyroid stimulating hormone receptor (TSHR), a 7 transmembrane G protein 
linked receptor leading to dissociation of G complex and the release of Gα and Gβγ subunits 
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(Szkudlinski et al. 2002; Davies et al. 2005; Werner et al. 2005). The dissociation of the G 
subunits activates cAMP and DAG pathways regulating thyroid gene expression, proliferation 
and thyroid hormone synthesis (Szkudlinski et al. 2002) (Figure 1.21).  
 
Figure 1.22 The euthyroid state. TRH is synthesized by the hypothalamus and triggers the 
secretion of TSH from the pituitary. TSH in turn following it’s binding to TSHR in the thyroid 
follicular cells, initiates thyroid hormone synthesis. Thyroid hormone in the bloodstream is 
bound to thyroid hormone binding protein (THBP) remaining inactive. On the other hand the 
unbound –free thyroid hormone forms a negative feedback loop with TSH and TRH synthesis.  
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Circulating thyroid hormones (TH) bind with high affinity to thyroid receptors (TR) which have 
predominantly nuclear localisation. The thyroid receptors are in turn binding to thyroid 
response elements (TREs) in gene promoters, altering the transcriptional activity in a range of 
different genes involved in insulin signalling, cell proliferation, apoptosis and lipogenesis. In 
the absence of TH, basal transcription is repressed by TRs in a process known as 
transcriptional silencing (Sinha et al. 2012).  
 
1.16.10 Thyroid Dysfunction 
Dysfunctions of the thyroid gland are often caused by excess or limited levels of thyroid 
hormones known as hyper and hypo-thyroidism respectively. Thyroid dysfunction 
predominantly affects greatly women with a female: male ratio of about 4:1 (Truter 2011). 
 
1.16.10.1 Hyperthyroidism 
Hyperthyroidism also known as thyrotoxicosis, is excess circulating thyroid hormone levels 
due to hyperactivity of the thyroid gland. Subsequent symptoms include increased blood 
pressure, anxiety and weight loss. Hyperthyroidism is most commonly caused (up to 80%) by 
the autoimmune condition Graves’ disease (GD). In (GD) thyroid stimulating antibodies (TsAb) 
are produced which bind the TSH receptor mimicking the activity of TSH and leading to an 
excess of thyroid hormone production (Amballi 2007) and goitre. Hyperthyroidism often occurs 
following an infection. Inflammation can occur after a viral infection resulting in excess thyroid 
hormone generation and temporary hyperthyroidism which can last even months. Also 
postpartum thyroiditis has been found to affect up to 10% of females where following 
pregnancy exhibit increased levels of thyroid antibodies (Truter 2011). Excess iodine intake 
from diet and some more rare tumours have also been associated with the cause of 
hyperthyroidism. 
 
1.16.10. 2 Hypothyroidism 
Hypothyroidism also known as myxoedema is caused by the down regulation of thyroid 
hormone production. This leads to an increase of body mass due to disruption of metabolism; 
hypothyroidism also results in cold intolerance and dull facial expressions. Hypothyroidism 
similarly to hyperthyroidism can be caused by thyroiditis and unbalanced iodine intake from 
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diet (Truter 2011). Hashimoto’s syndrome is also a common cause of hypothyroidism, this 
autoimmune disease causes the apoptosis of thyroid cells due to the increased expression of 
cytokines which activate apoptotic and other cell death pathways (Hiromatsu et al. 2013). 
Congenital hypothyroidism which occurs in 1 in 2000 new-borns, is responsible for the poor 
development or function of the thyroid gland which consequently lead to hypothyroidism and 
can potentially impair the new-born’s growth and promote mental retardation (Rastogi and 
LaFranchi 2010; Truter 2011).  
 
1.16.11 Thyroid nodules and goitres 
TSH has been also associated with thyroid growth and nodule formation. A prolonged 
increased TSH can lead to thyrocyte proliferation and the formation of diffuse goitre (Ock et 
al. 2013). Thyroid disease has a particularly increased prevalence in iodine deficient regions 
and can be classified as solitary nodular and multinodular thyroid disease. Nodules result from 
dysregulated growth of a single thyroid cell whereas diffuse goitre is often enlargement of all 
follicular cells. Nodules can be characterised histologically as true adenomas and 
adenomatous nodules which have encapsulated lesions and no lesions respectively. 
Morphologically they can be subdivided into cold nodules which illustrate decreased 
radioactive iodine uptake, normal and hot nodules which illustrate increased uptake. In the 
vast majority nodules are cold in a proportion of about 85%, 10% of nodules appear normal 
and only 5% hot. Hot nodules are usually caused by activating mutations in the TSHR or Gsq 
(Krohn et al. 2005).  
Enlarged thyroid entities with normal thyroid function are known as euthyroid goitres and are 
classified into diffuse goitre, multinodular goitre (MNG) and solitary thyroid nodule (Adriana 
2015). Multinodular goitre is a thyroid containing a large number of enlarged thyroid nodules.  
In iodine deficient areas multinodular goitre can be endemic and the enlarged thyroid gland is 
considered to be due to the lack of thyroid hormones which in turn cause the generation of 
excess TSH which stimulates thyroid growth. The thyroid gland in order to respond to such 
changes increases its volume. Multinodular goitres can often cause dyspnoea, dysphagia and 
orthopnoea and in about 10% can lead to malignancies (Nada et al. 2011). Initial hypotheses 
regarding the formation of multinodular goitres suggested that thyroid goes through 2 distinct 
phases, a phase of hyperplasia and a resting phase. Iodine deficiency with its consequent rise 
of TSH will result in a hyperplasia phase. The theory suggests that a potential decrease in 
requirement for thyroid hormone will eventually lead to a resting phase where storage of colloid 
takes place. A potential repetition of these two cycles has been suggested to cause the 
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formation of non- toxic multinodular goitre which could possibly explain the histological colloid 
goitre (Moulick 2008). Also, three main thyroid specific transcription factors are considered 
vital for thyroid development and function, NKX2-1, PAX-8 and FOXE-1. NKX2-1 has a key 
role in C-cells and thyroid follicular cells proliferation and survival, PAX-8 in proliferation of 
thyroid follicular cells and FOXE-1 regulates the differentiation of the thyroid. Studies in mice 
have revealed that these transcription factors are essential for thyroid development as NKX-2 
and FOXE1 null mice have illustrated thyroid agenesis and PAX-8 null mice were born with 
severe hypothyroidism (Kimura 2011). Another important regulator of thyrocyte proliferation 
and nodule formation is insulin-like growth factor 1 (IGF-1). IGFs have been found to be 
involved in a range of different diseases such as breast cancer.  A number of studies have 
shown that overexpression of IGF-1 is associated with increased thyroid volume and 
supressed TSH, indicating the interaction between IGF-1 and TSH (Ock et al. 2013). Also, 
investigation of IGF-1 levels on follicular adenoma, goitre and papillary thyroid cancer patients 
has revealed that both IGF-1 and IGF-1R had a significantly increased transcript levels 
compared to healthy patients (Liu et al. 2013).   
 
1.16.11.1 Risk factors 
Iodine deficiency is considered the major factor for nodular thyroid disease causing endemic 
goitre. Studies have shown that the prevalence of endemic goitre in areas with iodine 
deficiency was approximately 30% in males and 40% in females (Knudsen et al. 2002). In 
addition to this another important factor appears to be age as the prevalence increases up to 
3 fold in older populations. Smoking is considered another risk factor which can potentially 
decrease iodine availability and organification due to the elevated levels of thiocyanate 
(Knudsen et al. 2002; Krohn et al. 2005). As with all thyroid conditions, there is a higher 
prevalence of diffuse goitre in women compared to men (ratio 4:1) and a role for oestrogens 
in goitre formation has been proposed (Manole et al. 2001; Vanderpump 2011).   
The prevalence of thyroid malignancy has been estimated to vary according to different area 
from 0.9% to 13%. In the past MNG was considered as a relatively low risk factor for thyroid 
malignancy however, recent studies have estimated a prevalence ranging from 7 to 17%. The 
aetiology for MNG formation is not well established yet, with various factors such as iodine 
deficiency, decrease in thyroid hormone synthesis and reduction of circulating iodide due to 
increased iodine clearance from the kidneys are some potential reasons responsible for the 
disease (Hanumanthappa 2012). The number of thyroid cancer cases has been increased up 
to 5 fold in the last 6 decades constituting approximately 2% of all cancer. (Hanumanthappa 
2012; Cossu et al. 2013; Xing 2013).  
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1.16.12 Thyroid cancer 
Thyroid cancer has a varied cellular origin and histological classification. The majority of 
thyroid cancers derive from follicular cells such as papillary thyroid cancer (PTC), follicular 
thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid 
cancer (ATC). On the other hand, medullary thyroid cancer (MTC) originates from 
parafollicular C cells and has a relatively low prevalence (Xing 2013). PTC accounts for 80% 
of thyroid cancers with a survival rate of approximately 90% (Brown et al. 2011; Tufano et al. 
2012). Papillary thyroid cancer along with follicular thyroid cancer (FTC) the second most 
frequent type of thyroid cancer with prevalence up to 11% are often referred together as 
differentiated thyroid cancer (DTC) (Schneider and Chen 2013). The least aggressive and 
lethal thyroid cancer is considered to be the DTC with a 90% 10 year survival rate and 
excellent prognosis (Table 1.2). On the other hand, anaplastic thyroid cancer (ATC) with 
prevalence up to 2% is one of the most dangerous lethal and rapidly developing cancers. ATC 
is thought to be derived either from de-differentiated DTC cells or to arise de novo (Brown et 
al. 2011; Schneider and Chen 2013).  
 
Table 1.2 Different types of thyroid cancer: their prevalence, patient target group and 
lethality. Adapted from (Kondo et al. 2006). 
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1.16.13 Aetiology 
1.16.13.1 Sporadic cancer 
Aetiology of thyroid cancer can be either environmental and/or genetic causes. Exposure of 
the head and neck region of the body to radiation in the past for the treatment of tonsillitis and 
acne and nowadays for treatment of Hodgkin disease can lead to potential PTC occurrence. 
Also following the Chernobyl nuclear accident an increased prevalence of thyroid cancer had 
been recorded in children aged 12 or less at the time of the I131 release. Diet is also another 
important factor as papillary thyroid cancer and follicular thyroid cancer can be caused in areas 
with high iodine content and iodine deficiency respectively. Consequently, the level of TSH 
has a key role in thyroid malignancy as increased TSH has been linked with increased 
prevalence of DTC (Schneider and Chen 2013). 
 
1.16.13.2 Familial cancer   
Genetic causes are also considered to have a key role in DTC occurrence. Familial non-
medullary thyroid cancer accounts for the approximately 9% of the DTC cases. Linkage 
analysis in different families has identified three different loci MNG1 (Neumann et al. 1999), 
MNG2 (Capon et al. 2000) and MNG3 (Takahashi et al. 2001) associated with recurrent 
euthyroid goitre, an X- linked loci with increased prevalence of MNG in females and euthyroid 
MNG with elevated serum TSH respectively. Also a recent study has revealed another form 
of familial MNG exhibiting high risk of PTC progression (Bakhsh et al. 2006). Thyroid cancer 
can be inherited in patients suffering from Cowden, Gardner and Werner syndromes. Also a 
number of molecular biomarkers have been identified to be directly related with DTC 
pathogenesis and development.  
 
1.16.13.3 Proto-oncogenes and growth factors 
Rearranged during transfection (Ret) proto-oncogene is expressed solely in parafollicular C 
cells. Although in some papillary carcinomas receptor tyroisine kinase (RTK) was found to be 
expressed which is encoded by ret. Chromosomal rearrangements lead to activation of ret 
gene in these carcinomas. The ret rearrangements produce a fusion of the tyrosine kinase 
domain of ret with gene regions expressed in thyroid follicular cells resulting in expression 
ret/PTCs proteins. The consequent ret/PTCs are in turn causing ligand independent 
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expression of ret tyrosine kinase activity in thyroid follicular cells leading to PTC. Also, it is 
noteworthy that 70% of the cancers caused by the Chernobyl nuclear accident found to carry 
the ret/PTC rearrangement (Moretti et al. 2009; Schneider and Chen 2013).  
V-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is another molecular 
biomarker found in approximately 45% of the PTC patients.  T1799A transversion mutation is 
the most common BRAF mutation accounting for 80% of the mutations in BRAF. The T1799A 
leads to an amino acid substitution V600E and in turn MAP kinase /ERK pathway activation. 
The amino acid substitution is believed to disrupt the ATP binding P loop responsible for the 
inactivity of BRAF, leading to a catalytically active form. BRAF is the most potent among the 
Raf kinases and overactivation of the MAP kinase/ERK pathway is known to be responsible 
for cell proliferation and tumour formation (Xing et al. 2005; Schneider and Chen 2013).   
Chromosomal translocation between PAX8 and PPARγ have been found to affect 36% of 
FTC, 11% of FA and 13% of follicular variant of PTC. PAX8 is a thyroid specific transcription 
factor, vital for follicular cells genesis and has been reported to be present in benign thyroid 
neoplasias (Moretti et al. 2009). PPARγ it is a nuclear hormone receptor and transcription 
factor with tumour suppressor activity. The fusion of these two genes leads to the formation of 
PPFP protein. Studies have suggested that expression of PPFP interrupts PAX8 activity 
leading to the downregulation of thyroid genes such as Thyroglobulin (Tg), TPO and NIS. In 
addition, PPFP has been suggested to have also oncogenic activity as it was found to abolish 
PPARγ activity leading to cell proliferation and decrease of apoptotic cells (Placzkowski et al. 
2008; Braunstein 2012). 
FOXE-1 is forkhead transcription factor, with nuclear localisation and expression and as 
mentioned above it is an essential thyroid transcription factor for thyroid function. It regulates 
thyroid differentiation and gene expression of thyroglobulin (TG) and thyroperoxidase (TPO). 
Studies have illustrated that SNPs within and near FOXE-1 are associated with increased 
susceptibility to thyroid cancer. Studies have shown that SNPs near the FOXE-1 gene are 
linked with increased risk up to 7 fold of developing thyroid cancer (Gudmundsson et al. 2009). 
Also, SNPs within the 11-22 polyalanine tract in the DNA-binding domain of the gene have 
confirmed the association of that domain with PTC (Bullock et al. 2012). 
 
 
 
39 
 
1.17Thesis Aims 
Phospholipases C enzymes have been investigated for their role in health and diseases. The 
first two chapters of this thesis were dedicated to PLCζ and its potential role in assisted 
reproduction. The aim of Chapter 2 was the design of 24 different plasmid constructs of 
recombinant human PLCζ for optimisation of protein expression in a range of different bacterial 
cells. In Chapter 3, recombinant human PLCζ was purified with the use of affinity 
chromatography and microinjected into mouse eggs for in-vivo activity assessment.  
In Chapter 4, 5 and 6 the role of PLCβ1 InDel in patients suffering from MNG who are likely to 
develop PTC was investigated. In chapter 4, a qPCR based genotyping tool was designed for 
estimation of the prevalence of the InDel in different group of patients. Also the presence of 
an active ERα promoter within the InDel using a luciferase reporter assay was investigated. 
In Chapter 5, we investigated the effect of altered PLCβ1 transcript levels on thyrocyte 
proliferation. In Chapter 6, the region of Chr.20 with high LOD score was investigated by next 
generation sequencing for the potential presence of SNPs that may be responsible for the 
disease.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 2. Expression of Recombinant 
hPLCζ for Biomedical Application  
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2.1 Introduction 
2.1.1 Biomedical applications 
hPLCζ is a sperm specific protein with the unique function of activating the oocyte following 
sperm - egg fusion (Saunders et al. 2002). The egg activation occurs due to the PLCζ ability 
to trigger Ca2+ release from the intracellular calcium stores in the form of Ca2+ oscillations. 
hPLCζ is also considered to be linked with certain forms of male infertility (Nomikos et al. 
2011a). Experiments using mutant hPLCζ (H398P) identified in a patient who failed 
intracytoplasmic sperm injection (ICSI), revealed that the mutant sperm was unable to 
hydrolyse PIP2 and activate the egg. This signifies the central role of PLCζ in fertility and its 
potential biomedical therapeutic application in similar clinical cases (Nomikos et al. 2011a). 
Another potential biomedical application of hPLCζ could be in globozoospermia which is 
estimated to affect approximately 0.1% of the population, and it is characterised by the 
rounded head of the spermatozoa (Dam et al. 2007). Studies have shown that round-headed 
spermatozoa that have low levels or absence of hPLCζ, resulted in failure of egg activation 
following ICSI. Current applications such as calcium ionophore A23187 are not causing 
physiological oscillations as in natural fertilisation as they trigger a single Ca2+ spike instead 
of multiple. The role of PLCζ in the fertilization process as sperm factor that mimics 
physiological fertilisation can have a great potential in therapeutic application in the future 
(Yoon et al. 2008). 
 
2.1.2 Bacterial Expression system 
The bacterial expression system is currently the most popular protein expression system, 
because it is inexpensive and can produce particularly high yields of recombinant protein. 
However, eukaryotic proteins expressed in bacterial cells are often insoluble or non- functional 
due to the lack of post translational modification machinery. It can often jeopardise protein 
solubility producing inclusion bodies, promoting disulphide bond formation, incorrect protein 
folding and mismatch of the use of codons between the bacterial cell and the eukaryotic 
protein (Costa et al. 2014). The most common problem encountered is the codon usage 
between the host cell and expressed eukaryotic protein. The lack of necessary number of 
tRNA pools can lead to serious problems such as premature termination of translation and 
amino acid frameshift (Terpe 2006; Makino et al. 2011).  Therefore, genetically modified E.Coli 
strains are often used to increase protein expression and solubility allowing co expression of 
tRNAs for rare codons (Table 2.1).  
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Table 2.1 Different bacterial strains that are commonly used to enhance expression and 
solubility of eukaryotic proteins.  
 
Bacterial 
Strains 
Key Features 
Rosetta De3 Designed to enhance the expression of eukaryotic proteins that contain 
codons rarely used in E. coli. 
BL21 DE3 This strain is deficient of lon and omp-t proteases and is therefore 
suitable for expression of non-toxic genes. 
Rosetta pLysS In Rosetta (DE3) pLysS the rare tRNA genes are present on the same 
plasmids that carry the T7 lysozyme. 
BL21 pLysS The pLysS plasmid produces T7 lysozyme to reduce basal level 
expression of the gene of interest. Thus it is suitable for expression of 
toxic genes. 
Rosetta gami Rosetta-gami host strains are Origami derivatives that combine the 
enhanced disulphide bond formation with enhanced expression of 
eukaryotic proteins that contain codons rarely used in E. coli. 
 
  
2.1.3 Protein solubility tags  
The use of recombinant proteins with the incorporation of peptide fusion partners for protein 
purification is becoming increasingly popular. Such partners known as affinity tags can be 
either small peptide tags or large peptides and proteins. The choice of the ideal protein 
solubility tag is dependent on the type of the protein of interest and the application that the 
purified protein is destined for (Terpe 2003).  
The small peptides are a popular choice of affinity tags as they may not be immunogenic and 
in some biomedical applications, removal of the tag may not be necessary. On the other hand, 
large peptides or proteins offer the advantage of increasing the solubility of the recombinant 
protein. Although, removal of the solubility partner often is required for number of applications 
such as crystallography or biomedical applications (Terpe 2003).  
The most commonly used solubility tags in E.Coli expression systems are the Maltose binding 
protein (MBP) and the Glutathione-S-Transferase (GST). They offer the unique advantage of 
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binding to amylose and glutathione resin respectively, providing an extra purification choice. 
MBP is considered as the most efficient solubility tag achieving high solubility in recombinant 
proteins when fused at the N terminal of the protein of interest. MBP promotes protein solubility 
as it exhibits intrinsic chaperone activity enhancing the correct protein folding of the 
recombinant protein (Costa et al. 2014). Thioredoxin (Trx) and NusA even though they don’t 
offer a particular purification option, have been shown to enhance solubility (Esposito and 
Chatterjee 2006). NusA increases protein solubility as it delays translation at transcriptional 
pauses allowing the correct folding of the target protein. Similarly Trx prevents inclusion bodies 
formation due to its oxidoreductase activity which in turn reduces disulphide bond formation 
(Costa et al. 2014).  
 
2.1.4 Human Thioredoxin as a solubility tag 
Thioredoxin is classified as a redox active protein with a size of 12kDa. The protein was initially 
discovered (Laurent et al. 1964) in E.Coli and it was identified to be important cofactor of 
ribonucleotide reductase which in turn is known to form the deoxyribonucleotide precursors of 
DNA (Holmgren 1985). Although, further studies have revealed that Thioredoxin protein has 
an important role in a wide range of biological phenomena such as cell growth (Gasdaska et 
al. 1995), apoptosis (Matsui et al. 1996), immune response (Rosen et al. 1995), virology, 
cancer cellular responses to oxidative stress and many others (Holmgren 1985). Thioredoxin 
is also present naturally in the oocyte (Lopata et al. 2001). Recent studies have shown that 
overexpression of Thioredoxin can potentially promote foetal growth (Umekawa et al. 2008). 
Therefore , this protein which is naturally present in the oocyte environment and the same 
time can serve as a solubility tag, was chosen to be sub-cloned along with hPLCζ and retain 
its solubility when the other bacterial solubility partners have been removed. The use of human 
Thioredoxin as solubility tag has given a great potential for hPLCζ in future biomedical 
applications due to its human origin and its solubility retaining abilities (Figure 2.1).  
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Figure 2.1 The principle of using hTrx retaining protein solubility following removal of 
bacterial solubility tags.  
 
2.1.5 Bacterial lysis 
Bacterial lysis is vital for the recovery of the protein of interest in soluble form. In the current 
study bacteria have been lysed by either Ultrasonication or High pressure homogenisation. In 
both cases lysis was enhanced by enzymatic lysis with the use of lysosome. Ultrasonication 
is the current gold standard method for bacterial lysis, it uses sonic waves of high frequency 
(>16 kHz) to disrupt the cell walls due to the thousands of atmosphere pressure caused by 
the shock waves of the sonication process. On the other hand, the high pressure homogenizer 
uses high pressure for passing the bacterial culture through a narrow orifice valve followed by 
an instant release into a nozzle outlet. The fluctuation of the high pressure in the orifice valve 
and the instant release into the nozzle outlet result in cell wall disruption (Ho 2008).  The 
choice of cell lysis method was dependent on the volume of the bacterial culture as 
Ultrasonication could lyse cultures up to 100ml where the same time high pressure 
homogenization could lyse bacterial cultures up to 2L. In addition, hPLCζ is a very sensitive 
protein to temperature, sonication often generates heat thus it could potentially contribute to 
the protein degradation and low yield.  
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2.1.6 Aims of the project 
 
The aim of this project was the identification of the optimum bacterial cell line and PLCζ protein 
construct for successful expression and solubility. To optimize protein expression and 
solubility hPLCζ was sub- cloned into the pETMM series of plasmids which contain various 
protein solubility tags (Table 2.2). Protein expression and solubility was assessed using a 
range of different E. Coli strains for the identification of the most competent protein construct. 
The identified optimal protein construct was used in Chapter 3 for purification and in-vivo 
enzymatic activity assessment (Figure 2.2).   
 
 
Figure 2.2 Aims of the chapter. The selection for the optimum condition and protein construct 
of hPLCζ. The first strategy included the sub cloning of hPLCζ into the pETMM series vectors 
which in turn included a range of different solubility tags to retain protein solubility and 
45 
 
providing different purification options. The second strategy included that subcloning of hTrx 
as a solubility tag of human origin at the N-terminal of hPLCζ and the cloning of the hTrx-
hPLCζ into the pETMM series vectors as previously described. In the third strategy hTrx was 
cloned at the C terminus of hPLCζ following its cloning into the pETMM series vectors. The 
plasmid constructs were then assessed for protein expression and solubility with the use of 5 
different bacterial strains. Activity was assessed following protein microinjection into mouse 
oocytes.  
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2.2 Materials and Methods 
2.2.1 Cloning strategy  
Three different cloning strategies were used to improve protein expression and solubility and 
then compared to determine the optimum conditions for in vivo assays and later biomedical 
applications of hPLCζ (Figure 2.3). 
In the first strategy hPLCζ was cloned into the pETMM series of vectors which contained a 
range of different protein solubility tags that not only increase both protein expression and 
solubility but also provide additional options for protein purification.  
The second strategy was to clone hTrx, a protein which is naturally present in the embryonic 
environment into the pETMM-hPLCζ vectors to improve and potentially retain protein solubility 
following cleavage of the bacterial solubility partners.  
The third strategy included the cloning of the previously mentioned hTrx into the C-Terminus 
of the hPLCζ in pETMM-hPLCζ vectors. 
 
Figure 2.3 The cloning strategies included in this project. 1) Cloning of hPLCζ into the 
pETMM series vectors. 2) Cloning of hTrx at the hPLCζ pETMM series vectors. 3) Cloning of 
hTrx at the C terminus of hPLCζ in hPLCζ pETMM series vectors.  
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2.2.2 Molecular sub-cloning  
2.2.2.1 PetMM series with hPLCζ 
A pair of primers was designed using Primer 3 online analysis tool 
(http://bioinfo.ut.ee/primer3/), including a SalI (5’ G/TCGAC 3’) and NotI (5’ GC/GGCCGC 3’) 
restriction enzyme recognition site (Table 2.2). The restriction enzymes have been selected 
following screening for naturally occurring restriction sites within the gene with the use of NEB 
cutter software (http://nc2.neb.com/NEBcutter2/). The designed primers were also screened 
by BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure that there are no other 
unrelated significant homology sequences. Target DNA (coding sequence of hPLCζ) was 
amplified from the original cDNA clone (GenBank accession number AF435950) using 
phusion DNA proofreading polymerase (New England Biolabs). Amplification was performed 
with the addition of the following reagents into a 500 μl reaction tube: 2.5μl of 2x phusion 
master mix (NEB), 0.5μM forward primer, 0.5 μM reverse primer, 1μl of template DNA and 
nuclease-free water (Fisher Scientific) up to 50μl total reaction volume (Table 2.3). 
Amplification took place at PE Applied Biosystems 9700 thermocycler. 
 
Table 2.2 Primers designed for hPLCζ amplification  
Primer Name Tm Sequence Tm 
 
F(hPLCζ)/R(hPLCζ) 
 
60 
 
CCTAGTCGACATGGAAATGAGATGGTTTTTGTC / 
CTAAGCGGCCGCTCATCTGACGTACCAAACATAAA
C 
 
65 
 
Table 2.3 PCR amplification reaction  
 Temperature 
ᵒC 
Time 
 98 30 
seconds 
 
30 
cycles 
 
98 30 
seconds 
55 1 minute 
72 2 minutes 
 72 7 minutes 
 4 ∞ 
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2.2.2.2 Purification of PCR products 
The amplification product was separated with an 0.8% agarose gel (1.6g of Agarose (Sigma 
Aldrich UK) and 200ml 1xTAE (40 mM Tris-acetate, 1mM EDTA) and 1µg/ml ethidium 
bromide. 100 bp DNA Ladder (NEB) was prepared and run in parallel to the samples) via gel 
electrophoresis (90V for 40minutes) and then was gel extracted using the QIAquick Gel 
Purification Kit (QIAGEN. Crawley, UK).  According to the manufacturer’s protocol, the DNA 
visualised in 0.8% agarose gel was extracted with the use of a clean scalpel and placed into 
a 1.5ml Eppendorf tube. The gel slice was weighted and 100μl QC buffer per 100mg of gel 
were added. The mix was then heated at 50 ᵒC for 10 minutes to dissolve the gel. Isopropanol 
was then added 100μl per 100mg of gel and the mixture was transferred into a QIAquick spin 
column. The column was centrifuged for 1 minute at 13,000rpm with flow through being 
discarded. Additional 500μl QC buffer was added to the QIAquick column and centrifuged for 
1 minute at 13,000rpm. Washing steps included addition of 750μl of washing buffer PE 
followed by centrifugation for 1 minute at 13,000rpm. The column was then centrifuged for an 
additional minute followed by addition of 40μl of nuclease free water (Fisher Scientific) at the 
centre of the membrane and incubated for 5 minutes. The column was then centrifuged for 1 
minute at 13,000rpm and eluate was collected.  Quantification of the DNA was performed with 
the use of Nanodrop Lite spectrophotometer (Thermo Scientific). 
Purification of the fragment was followed, by restriction digestion of both vectors and insert 
with NotI and SalI restriction enzymes at 37 ᵒC water bath for 4 hours (Figure 2.4).  The vector 
was then linearized at 80 ᵒC for 20 minutes and then dephosphorylated with alkaline 
phosphatase calf- intestinal (CIP) 10U/μl for 1 hour (New England Biolabs, Herts, UK). 
 
Figure 2.4 Restriction digestion reaction.  
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2.2.2.3 Purification of digested DNA 
Insert and vector DNA were then purified using the PCR purification kit (QIAGEN, Crawley, 
UK). According to the manufacturer’s protocol, the DNA was mixed with 5 volumes of PB 
buffer to 1 DNA sample volume and then placed into a QIAquick column followed by 
centrifugation for 1 minute at 13,000rpm. The flow through was discarded and 750μl of PE 
washing buffer were added followed by centrifugation for 1 minute at 13,000 rpm. The 
QIAquick column was transferred into a clean 1.5ml Eppendorf tube. Elution step included 
addition of nuclease water (Fisher Scientific) and incubation at room temperature for 5 minutes 
followed by centrifugation for 1 minute at 13,000rpm. Quantification of the DNA was performed 
with the use of Nanodrop Lite spectrophotometer (Thermo Scientific). 
 
2.2.2.4 Ligation and transformation 
The insert was then ligated into the vector using T4 DNA ligase (New England Biolabs, Herts, 
UK) (Table 2.4). The ligated DNA was transformed into competent E.Coli TOP10 One-shot 
cells (Invitrogen, Paisley, UK). A vial of competent cells from -80 ᵒC was thawed on ice for 1 
minute. Then 3μl of ligated vector were added to the competent cells followed by incubation 
on ice for 30 minutes. The cells were then heat shocked at 42 ᵒC for 30 seconds and the 
immediately on ice for 5 minutes. Then 300μl of pre-warmed Luria Broth (LB) medium (Sigma-
Aldrich Company Ltd, Dorset, UK) was added to the cells followed by incubation at 37 ᵒC for 
1 hour at 225 rpm in an orbital shaker incubator. LB/agar plates with 50μg/ml Kanamycin were 
prepared and 100μl of cells were spread onto the plate and incubated overnight at 37 ᵒC. The 
following day plasmid DNA was isolated for successful cloning confirmation.  
 
Table 2.4 Ligation reaction with T4 Ligase 
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2.2.2.5 Miniprep DNA purification 
LB medium (Sigma Aldrich) was prepared containing 25mg/ml Kanamycin and 5ml were 
added to falcon tubes (Corning). Then 20 colonies were selected from the agar plate and a 
single colony was added to each falcon tube. The culture was incubated at 225 rpm, 37 ᵒC in 
an orbital shaker incubator for 14 hours. DNA was purified with the Wizard plus SV miniprep 
kit (Promega, Southampton, UK). According to the manufacturer’s protocol, the bacterial 
cultures were centrifuged for 30 minutes at 3000 rpm and the pellet was resuspended in 250μl 
cell resuspension solution followed by the addition of 250μl of cell lysis solution to each 
sample. Then 10μl of alkaline protease solution was added and the mix was incubated for 5 
minutes at room temperature. Incubation was followed by addition of 350μl of neutralisation 
solution and centrifugation at 13,000rpm for 10 minutes at room temperature. The cleared 
lysate was then transferred into a spin column and centrifuged for 1 minute at 13,000rpm at 
room temperature. Then 750μl of wash solution was added and centrifuged at 1 minute at 
13,000rpm. The washing step was repeated with the addition of 250μl of wash solution and 
centrifugation at 13,000rpm for 2 minutes. The spin column was transferred into a clean 1.5ml 
Eppendorf tube and 100μl of nuclease free water (Fisher Scientific) was added. The DNA was 
eluted by centrifugation at 13,000rpm for 1 minute. Quantification of the DNA was performed 
with the use of Nanodrop Lite spectrophotometer (Thermo Scientific). 
2.2.2.6 Confirmation of successful cloning 
The correct insert was confirmed using PCR with the designed primers described above, 
restriction digestion with the restriction enzymes that have been used for the cloning of the 
different construct and DNA Sanger sequencing. The latter required initial PCR amplification 
with primers that flank the sequence of interest. The amplified DNA was then purified using 
the PCR purification kit (Qiagen) and quantified by nanodrop Lite spectrophotometer (Thermo 
Scientific). Then 50ng of the target DNA were used for 3.1 BigDye sequencing reaction 
performed using a PE Applied Biosystems 9700 thermocycler) (Table 2.5). The constructs 
with the correct insert were transformed into E.coli Rosetta (DE3) cells as described above to 
assess protein expression (Figure 2.5).  
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Table 2.5 Sanger sequencing. a) 3.1 Big Dye sequencing reaction mix, b) 3.1 Big Dye 
sequencing reaction 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
 
Figure 2.5 The cloning of hPLCζ into pETMM vectors. The cloning of hPLCζ into pETMM 
vectors resulted in 8 different vector constructs with different solubility tags. All vector 
constructs but pETMM70 included a 6xHistidine tag for protein purification with affinity 
chromatography.  
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Table 2.6 The size of the various bacterial tags included in the vectors of the pET-MM 
series and the size of the total protein after introduction of hPLCζ as illustrated in (Figure 
2.5).  
 
 
2.2.3 Thioredoxin 
Thioredoxin has been shown by Lopata et al. 2001 Umekawa et al. 2008 to occur naturally in 
the egg and that overexpression of hTrx can potentially promote foetal growth. Therefore, hTrx 
was subcloned into the following constructs as potential solubility partner which could stabilize 
hPLCζ and be used in biomedical applications.   
 
2.2.3.1 Cloning of hTrx into hPLCζ-pETMM series vectors 
A pair of primers was designed as described above, including with a BamH1 and EcoR1 
restriction enzyme recognition site. The cloning process was performed as described above 
and expression procedure was applied as described below followed by SDS-PAGE gel and 
western blot confirmation. 
 
2.2.3.2 Cloning of hTrx at the C terminus of hPLCζ-pETMM series vectors 
Two pairs of primers were designed using Primer 3 online analysis tools, the first for hTrx and 
the second for hPLCζ. The forward hTrx primers included a SalI and NotI restriction enzyme 
recognition site and the hPLCζ primers a KpnI and a SalI restriction site (Table 2.7). Target 
DNA (hPLCζ) and (hTrx) were amplified using phusion DNA polymerase. The amplification 
product was separated using a 0.8% agarose gel and gel electrophoresis and gel extracted 
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using the QIAquick Gel Purification Kit (QIAGEN. Crawley, UK). The cloning process was 
completed as previously described. 
Table 2.7 Primers designed for the amplification of hTrx and hPLCζ 
Primer Name Tm Sequence Tm Gene 
 
F(hPLCζ)/R(hPLCζ) 
 
63 
 
CAGCGGTACCGATGGAAATGAGATGGTTTTTGTC / 
TTGGGTCGACTCTGACGTACCAAACATAAAC 
 
61 
 
hPLCζ 
F(hTrx-N)/R(hTrx-N)  
65 
 
ATCGGATCCGATGGTGAAGCAGATCGAGAGC/ 
TTGGAATTCGGGACTAATTCATTAATGGTGGCTTCAAG 
 
62 
 
hTrx 
F(hTrx-C)/R(hTrx-C)  
65 
 
GGTTGTCGACATGGTGAAGCAGATCGAGAGC/ 
TTAAGCGGCCGCTCAGACTAATTCATTAATGGTGGC 
 
65 
 
hTrx 
 
 
2.2.3.3 Bicinchoninic Acid (BCA) protein assay kit 
The BCA protein assay kit was performed according to the manufacturer’s protocol. Initially a 
set of protein standards and working reagent were prepared (Table 2.8). To prepare the 
working reagent 50 parts of BCA reagent A were mixed with 1 part of BCA reagent B. Then 
260μl of working reagent was added to each well of a 96 well microplate (Thermo Scientific) 
and 9μl of the protein standards and target protein were added to the appropriate wells. The 
plate was incubated at 37 ᵒC for 30 minutes followed by absorbance measurement at 595nm 
by EnsPire Perkin Elmer plate reader. 
 
Table 2.8 The preparation of BCA protein standards for BCA protein Assay kit (Adapted 
from Thermo Scientific)  
Vial Diluent 
Volume (μl) 
BSA Source and 
Volume (μl) 
Concentration 
(μg/ml) 
A 0 200 of stock 2,000 
B 66 200 of stock 1,500 
C 100 100 of vial A 1,000 
D 100 100 of vial B 750 
E 100 100 of vial C 500 
F 100 100 of vial E 250 
G 100 100 of vial F 125 
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2.2.4 Bacterial culture and protein expression  
The plasmids of interest were transformed into the various bacterial cells used in this study as 
described above. Cells were cultured in LB medium (Sigma Aldrich) containing the appropriate 
antibiotic (Table 2.9). All flasks contained 25mg/ml Kanamycin as pETMM vectors contain a 
Kanamycin resistance gene the cells were grown at 37 ᵒC at 180rpm in an orbital shaker until 
OD600 is approximately 0.6. Then 1ml culture was collected for uninduced protein expression 
assay and 100μM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Life Technologies) was 
added to bacterial culture. The cells were grown at 16 ᵒC in an orbital shaker at 180 rpm 
overnight and harvested by centrifugation at 3,400rpm for 15 minutes at 4 ᵒC. The samples 
collected prior and post induction, were centrifuged at 10,000rpm for 1 minute and were lysed 
using 5x SDS loading buffer (0.3M Tris-HCl, pH 6.8, 10% w/v SDS, 50% glycerol, 0.25% w/v 
bromomethol, 5% β- mercaptoethanol) followed by heating for 5 minutes at 100 ᵒC. The lysate 
was then analysed on by 7% SDS-PAGE polyacrylamide gel electrophoresis with protein 
stained with Coomassie brilliant blue (1g Coomassie, 480ml Methanol, 420ml H2O and 100ml 
Acetic Acid) and destained with destain buffer (450ml Methanol, 450ml H2O and 100 Acetic 
Acid). 
 
Table 2.9 The various bacterial cell lines used in this study.  
Bacterial cell line Antibiotic resistance 
Rosetta De3 Chloraphenicol 34mg/ml  
BL21 De3 - 
Rosetta gami Chloraphenicol 34mg/ml 
Rosetta pLysS Chloraphenicol 34mg/ml 
BL21 pLysS Chloraphenicol 
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2.2.5 Western Blotting 
Soluble fractions of the bacterial lysates were quantified with Pierce BCA Protein Assay Kit 
(Thermo Scientific) and data were acquired with the use of the EnsPire Perkin Elmer plate 
reader. Approximately 10μg of protein were loaded into a 7% SDS-PAGE gel. The protein 
prior to the loading was mixed with 5x sample buffer (0.3M Tris-HCl, pH 6.8, 10% w/v SDS, 
50% glycerol, 0.25% w/v bromomethol, 5% β- mercaptoethanol). The protein was then 
denatured at 100 ᵒC for 3 minutes and loaded onto the 7% SDS –PAGE gel (Separating gel 
(5ml): (1.5M Tris, pH 8.8, 0.4% sodium dodecyl sulphate (SDS), 40% polyacrylamide, 10% 
ammonium persulfate (APS), 2.55ml H2O, 5μl TEMED. Stacking gel (4ml): 0.5M Tris, pH 6.8, 
0.4% SDS, 40% polyacrylamide, 10% ammonium persulfate (APS), 5μl TEMED, 2.55ml H20). 
The gel run in 1x running buffer (15g/L Tris, 72g/L glycine, 5g/L SDS) for 1 hour at 150 mV). 
It was then transferred onto a HybondTM-P polyvinylidene fluoride (PVDF) membrane (GE 
Healthcare) with the use of Trans-blot SD Semi-Dry Transfer Cell (Bio-Rad) soaked in transfer 
buffer (190mM of Glycine, 25mM of Tris, pH of 9.2, 20% Methanol). The protein gel transfer 
onto the membrane was performed at 12V for 1 hour and then the membrane was transferred 
into blocking buffer 1xTBST (0.2M Tris, 1.37M NaCl, pH 7.5, 0.1% Tween 20 and 10% milk 
powder (Marvel). The membrane incubated for 1 hour in blocking buffer and then incubated 
with primary antibody at 1x TBST with 10% milk powder (Marvel) for 1 hour. The membrane 
was then washed three times for 10 minutes with 1x TBST and then the membrane incubated 
with the secondary antibody for 1 hour (Table 2.10). The incubation was followed by 3 washes 
of 10 minutes in 10x TBST. The washes were followed by 1 minute incubation with Amersham 
ECL Plus western blotting detection system (GE Healthcare). The acquisition of the picture 
was performed with the use of GE Healthcare Amersham Hyperfilm. 
 
Table 2.10 List of antibodies used in this project for protein confirmation by Western 
Blotting  
Primary Antibody Concentration Secondary 
Antibody 
Concentration 
Anti-hPLCζ 
(Monoclonal)(National Centre 
For Scientific Research – 
Demokritos) 
 
1:100 
 
Anti-Rabbit 
 
1:10,000 
 
Anti-hTrx (Monoclonal)(Origene) 
 
1:10,000 
 
Anti-Rabbit 
 
1:10,000 
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2.2.6 Protein solubility assay 
The constructs with the best expression were further analysed for solubility. The frozen pellets 
of the bacterial cultures were thawed at 4◦C and the cells were lysed with the addition of lysis 
buffer (50Mm Na2PO4 and 500Mm NaCl, Ph:8, 100mg of lysozyme, 3 tablets of protease 
inhibitors (Roche Life Sciences) and 1mM Dithiothreitol (DTT)) and sonication. Sonication was 
performed on ice in three 15 second bursts following 2 minutes incubation on ice.  Cell lysis 
was followed by centrifugation of the crude lysate at 18,000RPM for 30 minutes at 4°C. 
Supernatant was collected and soluble fractions were assayed using denaturing 7% 
polyacrylamide gel SDS-PAGE with proteins being stained with Coomassie brilliant blue 
staining. Protein solubility was also confirmed by western blot. 
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2.3 Results 
 
2.3.1 hPLCζ cloned into the pETMM series vectors 
2.3.2 Confirmation of successful cloning  
The hPLCζ gene was amplified with hzF/hzR primers generating a 1.8 kbp product. The DNA 
fragment was digested with SalI and NotI restriction enzymes and cloned successfully into 
pETMM series vectors. Successful cloning of hPLCζ gene was confirmed by restriction 
digestion of the cloned plasmid DNA with SalI/NotI enzymes which successfully digested the 
1.8kbp DNA insert for hPLCζ (Figure 2.6). Successful cloning was also confirmed by Sanger 
sequencing.  
 
Figure 2.6 Confirmation of successful cloning with restriction digest with SalI and NotI 
enzymes for human PLCζ gene (1.8 kbp) into the pETMM series vectors.  
 
2.3.3 Protein expression and solubility assessment of hPLCζ  
The confirmed pETMM-hPLCζ constructs were transfected into 5 different bacterial strains 
(described in Table 2.1) and assessed for its protein expression and solubility (Figure 2.7). 
The protein expression was evaluated with the comparison of bacterial lysates prior and post 
protein expression induction with IPTG. The protein solubility was evaluated following bacterial 
lysis and centrifugation. Supernatant was then collected and quantified by BCA protein assay 
(Promega) and equal volumes were loaded into each well for direct protein solubility 
comparison (Figure 2.8).  
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Figure 2.7 Assessment of protein expression and solubility of hPLCζ-pETMM protein 
constructs in a range of different bacterial cells. Expression was assessed by direct 
comparison between induced (In) and uninduced (Un) protein expression of bacterial culture 
lysates using Coommassie blue stained gels. Protein solubility of soluble fractions of bacterial 
culture lysates was evaluated by western blotting using anti-hPLCζ monoclonal antibody.  
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Figure 2.8 Evaluation of protein expression and solubility of hPLCζ-pETMM proteins. 
Expression and solubility as illustrated in (Figure 2.7).  
 
2.3.4 hTrx is cloned into hPLCζ-pETMM series vectors 
2.3.4.1 Confirmation of successful cloning  
The successful cloning of hTrx into hPLCζ-pETMM vectors was confirmed by double 
restriction digestion. Restriction digestion with SalI/NotI and BamHI/ EcoRI enzymes 
confirmed cloning of hPLCζ (1.8kbp) and hTrx (300bp) respectively (Figure 2.9). The 
incorporation of hTrx aimed to serve as a solubility partner for hPLCζ as it is present in human 
oocyte eliminating potential ethical issues in biomedical applications. 
 
Figure 2.9 Confirmation of successful cloning with restriction digest with SalI/NotI and 
BamHI /EcoRI restriction enzymes for human PLCζ gene (1.8 kbp) and hTrx (300bp) into 
the pETMM series vectors respectively. 
 
61 
 
2.3.4.2 Protein expression and solubility assessment of hTrx-hPLCζ-pETMM constructs 
Protein expression of the 8 different constructs was assessed by gel electrophoresis with SDS 
PAGE gel and Coommassie blue staining and protein solubility with western blot confirmation 
using anti-hPLCζ and anti-hTrx antibodies (Figure 2.10, 2.11). 
 
Figure 2.10 Assessment of protein expression and solubility of hTrx-hPLCζ-pETMM 
protein constructs in a range of different bacterial cells. Expression was assessed by 
direct comparison between induced (In) and uninduced (Un) protein expression of bacterial 
culture lysates using Coommassie blue stained gels. Protein solubility of soluble fractions of 
bacterial lysates was evaluated by western blotting using anti hPLCζ monoclonal antibody 
(left) and anti-hTrx antibody (right).  
‘ 
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Figure 2.11 Evaluation of protein expression and solubility of hPLCζ-pETMM proteins 
Expression and solubility as illustrated in (Figure 2.10). 
 
2.3.5 Cloning of hTrx at the C terminus of hPLCζ-pETMM series vectors 
2.3.5.1Confirmation of successful cloning  
The cloning of hTrx at the C terminus of hPLCζ-pETMM vectors aimed to alter the stability and 
folding of the protein and potentially increase its solubility. The successful cloning was 
confirmed by double restriction digestion (Figure 2.12) and protein expression and solubility 
was evaluated using 5 different bacterial cells (Figure 2.13, 2.14). 
 
Figure 2.12 Cloning of hTrx at the C terminus of hPLCζ-pETMM series vectors. hTrx was 
cloned upstream the C- terminus of hPLCζ and sucessful cloning was confirmed by double 
restriction digest with KpnI/SalI for hPLCζ and SalI/NotI for hTrx at 1800 and 300bp 
respectively. 
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Figure 2.13 Assessment of protein expression and solubility of hPLCζ- hTrx pETMM 
protein constructs in a range of different bacterial cells. Expression was assessed by 
direct comparison between induced (In) and uninduced (Un) protein expression of bacterial 
culture lysates using Coommassie blue stained gels. Protein solubility of soluble fractions was 
evaluated by western blotting using anti hPLCζ monoclonal antibody (left) and anti-hTrx 
antibody (right). 
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Figure 2.14 Evaluation of protein expression and solubility of hPLCζ-pETMM proteins. 
Expression and solubility as illustrated in (Figure 2.13). 
 
2.3.6 Evaluation and selection of the bacterial cell line  
Expression and solubility has been assessed by the direct comparison between protein 
constructs. The optimal bacterial cell line for each protein construct has been selected by the 
direct comparison of the solubility in different bacterial cells for each protein construct (Figure 
2.15, 2.16). The cells were grown at equal volumes and lysed by sonication. The supernatant 
following centrifugation was loaded at equal volumes for protein solubility assessment. The 
protein constructs with the highest expression and solubility assessed in experiments 
described above (Figure 2.10, 2.13) were selected for the bacterial cell line optimisation assay.   
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Figure 2.15  The optimal bacterial cell line for the solubility of each protein construct 
(hTrx-hPLCζ).The solubility was assessed by western blotting with anti-hPLCζ monoclonal 
antibody (left) and anti-hTrx (right). 
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Figure 2.16 The optimal bacterial cell for the solubility of each protein construct (hPLCζ-
hTrx C-terminus). The solubility was assessed by western blotting with anti-hPLCζ 
monoclonal antibody (left) and anti-hTrx (right). 
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2.4 Discussion 
 
2.4.1 PLCζ constructs  
The aim of the experiments performed was to express the protein in high yield retaining 
solubility and eventually activity and then find the constructs which will be subsequently used 
for cloning of hTrx-hPLCζ. hPLCζ it is a highly sensitive protein in both temperature and 
concentration which degrades almost immediately following protein purification. The cloning 
of hPLCζ in pETMM vectors which contain series of different solubility tags, was to first 
increase protein expression and second and most important to retain protein solubility as the 
majority of the pETMM tags included were chaperones and heat shock proteins. The results 
illustrated that soluble and active form of hPLCζ has been created using a range of different 
solubility tags. Also, a range of different bacterial cells were used to achieve optimum 
expression and solubility. The results indicate that Rosetta De3 and BL21 De3 cells express 
the highest amount of protein retaining solubility. The expression of hPLCζ with a range of 
protein solubility tags has shown that nTrx, MBP, NusA and CBP express hPLCζ with relatively 
high protein solubility (Figure 2.17). The assays have been performed with the use of soluble 
fractions of bacterial lysates. Investigation of the protein present in the insoluble fractions 
indicated that only approximately 20 – 30% of the total protein expressed was soluble 
therefore maximizing and retaining the remaining soluble protein was the key for future 
investigations. The method that was used in this project was not quantitative and therefore 
accurate conclusion regarding the proportion of protein solubility and expression cannot be 
drawn. However, it has provided information regarding the different protein expression and 
solubility potential of the various construct and could give clear indication which bacteria and 
protein constructs are more likely to retain protein solubility.  
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Figure 2.17 Summary of the results obtained by the assessment of various protein 
constructs and bacterial cell lines for protein expression and solubility optimization. 
Optimisation strategies as described at Figure 2.2, revealed that 4 of the plasmid 
constructs exhibited better protein expression and solubility when expressed in 
Rosetta (DE3) and BL21 (DE3) bacterial strains.  
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Activity Assessment of 
Purified Recombinant hPLCζ 
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3.1 Introduction 
 
3.1.1 In-vivo PLC activity assay 
In vivo assessment of human PLCζ was performed in mouse eggs (Figure 3.1). Mouse is an 
ideal animal model for the study of mammalian egg activation and assessment of human PLCζ 
activity as multiple Ca2+ oscillation that trigger egg activation are similar to those occurring in 
the human oocyte. Ca2+ oscillations are required for egg activation in both mammalian and 
non-mammalian species however, non-mammalian eggs are generating only a single 
transient. In mammals, Ca2+oscillations exhibit different multiple oscillation patterns with 
mouse eggs being similar to the human. Also, mouse as an animal model is generally very 
popular due to its low maintenance cost and the short generation time providing sufficient 
number of eggs.  
 
 
Figure 3.1 Calcium oscillations observed in mouse eggs. a) cRNA hPLCζ-Luc injection 
into mouse eggs leading to multiple Ca2+ oscillations and egg activation. Red line illustrates 
luciferase emission upon hPLCζ expression. b) Increase in Ca2+ concentration was monitored 
with the use of Ca2+ fluorophores. Adapted from (Theodoridou et al. 2013). 
 
3.1.2 PLC in-vitro activity assay 
The PLC activity assay in vitro utilises the ability of PLCs to hydrolyse PtdIns(4,5)P2 generating 
IP3.  In PLC activity assays, radiolabelled PtdIns(4,5)P2 is used for the measurement of the 
released radioactive phosphates following PtdIns(4,5)P2 hydrolysis by PLCs (Huang et al. 
2013). Although this assay can provide quantitative results of PLC activity it cannot illustrate 
hydrolysis in physiological cell conditions and often can be technically challenging (Rusten 
and Stenmark 2006; Huang et al. 2011).   
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3.1.3 Calcium Fluorescent dyes 
The forefathers of modern calcium imaging were bioluminescent calcium binding 
photoproteins. The most well-known is aequorin. This calcium indicator has a relatively low 
calcium sensitivity and a rapid signal decay. The breakthrough in calcium imaging occurred in 
1980 by (Tsien 1980). The first generation of fluorescent calcium dyes were more sensitive 
and versatile. The group of first generation fluorescent dyes included quin-2, fura-2, indo-1 
and fluo-3 dyes. The first among them to be developed and applied in vivo experiments was 
quin-2 with ultraviolet light excitation (339nm). However its requirement for high intracellular 
dye concentrations due to low brightness led to the development of fura-2 which is excited at 
350 or 380 nm and is more sensitive to calcium changes than quin-2 allowing its use in greater 
range of biological experiment (Grienberger and Konnerth 2012). The third generation of 
fluorescent dyes have a wider excitation spectra such as Oregon Green BAPTA and Fluo-4 
fluorescent dyes (Table 3.1) (Grienberger and Konnerth 2012).  Oregon Green BAPTA which 
was the fluorescent dye of choice in this project offers the advantage of application with lower 
dye concentration preventing phototoxic effects and relatively high sensitivity allowing 
detection of small changes in calcium concentration close to resting levels (Paredes et al. 
2008). 
 
Table 3.1. Characteristics of the various Ca2+ indicators. Kd for Ca2+ illustrate the binding 
affinity to Ca2+. Adapted from (Paredes et al. 2008). 
Indicators Kd  for Ca2+ Excitation nm, Emission nm 
Fura-2 145 363/335 ex, 512 em 
Fluo-3 325 506 ex, 526 em 
Fluo-4 345 494 ex, 516 em 
Indo-1 230 488 ex, 405/486 em 
Oregon Green 488 BAPTA-1 170 488 ex, 520 em 
 
 
3.1.4 Intracytoplasmic sperm injection (ICSI) 
Intracytoplasmic sperm injection is the current gold standard for treatment of male infertility. 
ICSI is performed in patients where spermatozoa are unable to fertilise the egg due to lack of 
mobility or increased percentage of abnormal spermatozoa present in the semen. Then a 
single spermatozoa is injected into the ooplasm. The process of ICSI is operated with the use 
of a micromanipulator equipped with a microscope with x20 and x40 objectives. Microinjection 
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of the spermatozoa into the oocyte it is an invasive method which has to be operated with 
caution. The polar body of the oocyte has to be either at 6’ or 12 o’clock position to avoid 
disruption of the meiotic spindle which can lead to chromosomal aneuploidy and cell death 
(Figure 3.2). ICSI has approximately 70% success rates but as an invasive technique it can 
potentially damage the oocyte and a possible selection of an abnormal spermatozoa can lead 
to chromosomal abnormalities or fertilisation failure (Coward and Wells 2013).  
 
Figure 3.2 Microinjection of a single spermatozoa into the oocytes. a) The 
micromanipulator with which the microinjection takes place (Adapted from 
http://www.origio.com/). b) Single sperm injection (ICSI) of a spermatozoa into the oocyte, the 
polar body has to be at 6 or 12 o’ clock to avoid damage of meiotic spindle (Adapted from 
http://www.nuffieldhealth.com/). 
 
3.1.5 Cleavage of protein solubility tag 
Solubility tags have the ability to overexpress soluble recombinant protein. However, often 
they have to be removed so the protein of interest can be used in various applications such 
as crystallography and in vivo assays. Thus, a cleavage site for binding of a protease is usually 
designed between the protein tag and the protein of interest so that the purified protein can 
be removed from its solubility tag (Esposito and Chatterjee 2006). The most popular proteases 
for solubility tag removal are the Thrombin and the Tobacco etch virus protease (TEV), with 
the latter being the selected protease in this project. TEV protease has a recognition site E-N-
L-Y-F-Q-S, cleaving between glutamine and serine (Terpe 2003) (Figure 3.3). The major 
drawback of proteolytic cleavage of solubility tags is the rapid degradation of the purified 
protein following tag removal. There is yet no perfect solution to prevent protein degradation, 
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although addition of detergents or chaperones are considered to prevent protein degradation 
(Esposito and Chatterjee 2006).  
 
Figure 3.3 The cleavage site of TEV protease removing the solubility tag from the target 
protein 
 
3.1.6 Affinity chromatography 
The principle of affinity chromatography is based on the ability of the protein of interest to bind 
to a ligand on the chromatography matrix. The binding is regulated either via antibody or an 
Immobilized metal-affinity chromatography (IMAC) (Costa 2014). The IMAC technique which 
has been used in this project can employ tags solely for affinity chromatography such as the 
polyhistidine tag or proteins which can act as solubility tags such as MBP and GST and the 
same time can bind to amylose and glutathione resin respectively. Elution of the target protein 
can be achieved by either alteration of pH or with addition of a competitive ligand such as free 
Imidazole (Bornhorst and Falke 2011).   
The use of polyhistidine tag is the most popular method for protein purification utilizing the 
ability of histidine to bind strongly to immobilised metal ion matrices such as (Ni2+ Co2+, Cu2+ 
and Zn2+). The interaction takes place as electron donation from the imidazole rings on the 
histidine molecules interacting with the immobilized metal. The purification method using 
histidine tag is known as Immobilized metal-affinity chromatography (IMAC) (Terpe 2003). The 
current gold standard of Ni2+ purification is with nitrilotriacetic acid (NTA). Nickel ion (Ni2+) has 
6 ligand binding sites four of which are occupied by NTA and the remaining two by the His6 
sequence (Khan et al. 2006) (Figure 3.4). The drawback of the Ni-NTA purification is the low 
binding affinity thus often a double His6 cloning strategy is preferred.  
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Figure 3.4 The binding of Ni-NTA resin to His6. The His6 binds to Ni2+ -NTA with two binding 
sites.  Adapted from (Bornhorst and Falke 2011). 
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3.1.7 AIMS 
The aim of the chapter was the assessment of purification and PLCζ activity of the constructs 
found to exhibit the highest protein expression and solubility in Chapter 2. The recombinant 
proteins were expressed in Rosetta De3 cells in large culture volumes and were purified by 
affinity chromatography. The purified protein of the selected constructs was microinjected into 
mouse oocytes along with Ca2+ fluorophores and PLCζ activity was monitored. The second 
aim was the removal of the bacterial solubility tags from the recombinant protein maintaining 
protein solubility. Thus recombinant MBP-hTrx-hPLCζ was selected as hTrx can potentially 
retain hPLCζ solubility following the removal of MBP. The natural presence of hTrx in human 
oocytes could potentially allow biomedical applications of purified hPLCζ (Figure 3.5).  
 
 
 
Figure 3.5 Aims of the chapter. The chapter assessed hPLCζ constructs in-vivo activity and 
protein solubility of hPLCζ following bacterial solubility tag removal, an essential requirement 
for biomedical applications.  
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3.2 Material and Methods 
3.2.1 Purification of hPLCζ with His6 tag 
The cells (Rosetta De3) were cultured as described in chapter 2, using (4L) of culture for each 
construct. The cells were lysed with the addition of lysis buffer (50Mm Na2PO4 and 500Mm 
NaCl, pH:8, 100mg of lysozyme, 3 tablets of protease inhibitors-EDTA free (Roche Life 
Sciences) and 1mM Dithiothreitol (DTT)). Sonication was performed in three sets of 15 
seconds with each set followed by 2 minutes incubation on ice. Crude lysate was centrifuged 
at 18,000RPM for 30 minutes at 4°C. The supernatant was collected and incubated with Ni-
NTA Agarose beads (QIAGEN) for 1 hour. Prior to the purification step a Bradford assay 
(described below) was prepared for the quantification of the washed and eluted protein in each 
purification stage. The lysate was passed through a gravity column where a series of washings 
took place with phosphate buffer (50Mm Na2PO4 and 500Mm NaCl, pH:8,) and addition of 
20mM and 35mM of Imidazole for the 2 washings respectively with 75mM and 250mM 
Imidazole for protein elution. Purified protein was assayed using denaturing SDS-PAGE gel 
as described in chapter 2. The protein was then concentrated with the use of 3K Amicon tubes 
(AMD Millipore) as described below and buffer exchanged with HEPES buffer following its 
microinjection into mouse eggs, where Ca2+ oscillations were monitored as described below.  
 
3.2.2 Bradford Assay 
A quick and straight forward method was used to measure protein levels during washing and 
elution steps. Bradford reagent (Bio-Rad) was diluted 4 fold, 2.5ml Bradford (Bio-Rad) and 
7.5ml nuclease-free water (Fisher- Scientific) were mixed and 200μl were placed into each 
well of 96 well-plate. Protein presence was detected by visual detection of colour change 
without spectrophotometry assay. 
 
3.2.3 Purification of hPLCζ with MBP solubility tag 
Bacterial cells were lysed with lysis buffer (20Mm Tris/HCl, 200Mm NaCl, 1Mm EDTA, 1Mm 
DTT, pH: 7.5, 3 tablets of protease inhibitors-EDTA free (Roche Life Sciences) and 1mg/ml 
lysozyme. The cells were sonicated and the soluble fraction was collected as described above. 
The soluble fraction was incubated with amylose resin (NEB) 1.5ml per 30ml of supernatant 
and incubated for 1 hour at 4 ᵒ C on a mechanical shaker. The mix was then applied to a gravity 
column and washed with washing buffer (20mM Tris/HCl, 200mM NaCl, 1mM EDTA, 1mM 
DTT, pH: 7.5) until there was colour change in Bradford assay indicating absence of protein. 
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Flow through fraction of 25μl were tested every minute by Bradford assay. Once the washing 
flow through was almost protein-free the protein was eluted with the addition of elution buffer 
(20mM Tris/HCl, 200mM NaCl, 1mM EDTA, 1mM DTT, 10mM Maltose). Then 3 ml elution 
flow through was collected and assessed by SDS-Page gel electrophoresis.  
 
3.2.4 Tev protease expression, purification and storage 
The Tev protease construct kindly provided by Dr. Nomikos (Cardiff University) was expressed 
using 1L of bacterial culture (BL21 De3) which was grown at 37◦C and induced at O.D.=0.6 
with 100μM IPTG overnight at 16 ◦C. The cells were lysed with 25ml of lysis buffer 20mM Tris 
pH-7.5, 200Mm NaCl, 1mM EDTA, 1mM DTT) and sonication as described above. Once lysed 
and centrifuged at 18,000RPM for 30 minutes, the supernatant was allowed to bind to 1.5ml 
of Ni-NTA beads for 1 hour. The protein was washed with 20 and 40mM of Imidazole and 
eluted with 70 and 250 mM of Imidazole. The protein was then quantified with bicinchoninic 
acid assay (BCA) assay 3μg/μl, aliquoted in 50% glycerol and stored in -80◦C. 
 
3.2.5 TEV cleavage of MBP-hTrx-hPLCζ 
1.5L of MBP-hTrx –PLCζ was expressed as described above and lysed with 20ml of lysis 
buffer (20mM Tris PH-7.5, 200Mm NaCl, 1mM EDTA, 1mM DTT) containing protease inhibitor 
mixture (EDTA-free, Roche) and 1mg/ml lysozyme). The cells were centrifuged at 18,000RPM 
for 30minutes. The protein was then allowed to bind to amylose beads for 1hour. It was then 
applied to a gravity column and washed with (20Mm Tris pH 7.5, 200mM NaCl, 1mM EDTA, 
1mM DTT). The protein was then eluted with (20Mm Tris pH-7.5, 200mM NaCl, 1mM EDTA, 
1mM DTT and 10Mm Maltose). The eluted protein was then dialyzed in 4L of dialysis buffer 
(5mM DTT, 1mM EDTA, and 50mM Tris pH-7.5) with Tev protease in ratio of 1:100 overnight 
at 4◦C. The following day the cleaved protein was buffer exchanged with (50mM Na2PO4, and 
500mM NaCl, pH-8) and incubated with 200μl of Ni-NTA beads for 1 hour. The protein was 
then centrifuged at 600RPM for 5 minutes and the supernatant was collected. A second 
extraction was then applied by exchanging the buffer of the protein with (20Mm Tris pH 7.5, 
200Mm NaCl, 1mM EDTA, 1mM DTT) and the protein was then incubated with 200μl of 
amylose beads for 1 hour. Following incubation the protein sample was centrifuged at 600rpm 
for 5 minutes and the supernatant was collected. The purity of the protein was assessed by 
western blot with 2 different antibodies (Anti-EF hand-hPLCζ and Anti- 6x Histidine) (Table 
3.2). 
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Table 3.2. List of antibodies used in this project for protein confirmation by Western 
Blotting  
Primary Antibody Concentration Secondary Antibody Concentration 
Anti-hPLCζ(Monoclonal) 1:100 Anti-Rabbit 1:10,000 
Anti-hTrx (Monoclonal) 1:10,000 Anti-Rabbit 1:10,000 
Anti-His6 1:5000 Anti-Mouse 1:10,000 
Anti-MBP 1:25,000 Anti-Mouse 1:10,000 
 
 
3.2.6 Purified protein concentration and buffer exchange 
Purified protein eluted in approximately 2ml of elution buffer (250mM Imidazole) was loaded 
into a 3K Amicon tube (AMD Millipore) to reduce the volume of the eluate to 50μl. The 
concentrated purified protein was then buffer exchanged in 3k Amicon tubes (AMD Millipore) 
with microinjection buffer (120mM KCL, 20mM Hepes, pH 7.4) to reduce Imidazole 
concentration from 250mM to 2mM and eliminate potential cytotoxic effects on oocytes. Equal 
volumes of microinjection buffer to the concentrated eluate were added to the 3K Amicon tube 
followed by centrifugation at 14,000g for 15minutes until final Imidazole concentration reached 
2mM. To recover the protein from the filter the 3K Amicon tube was inverted and placed in a 
clean collection tube and centrifuged at 5000g for 5 minutes. Concentrated purified and buffer 
exchanged protein was quantified with Pierce BCA protein assay kit (Thermo Scientific).  
 
3.2.7 Microinjection and Calcium imaging 
Mouse eggs were initially washed in M2 media (Sigma) and were microinjected with the 
purified PLCζ protein mixed with an equal volume of 1mM Oregon Green BAPTA dextran 
(Molecular Probes) in the injection buffer. Calcium oscillations were recorded using a Zeiss 
Axiovert 100 microscope equipped with a cooled intensified CCD camera (Photek Ltd, UK). 
Recording of Ca2+ oscillations was performed for 1 hour post injection with measuring intervals 
of 20 seconds. Microinjection and Ca2+ imaging experiments were performed by Dr. Yu. 
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3.3 Results 
3.3.1 In-vivo activity assessment of nTrx-hPLCζ 
Expression levels of nTrx-hPLCζ as illustrated in Chapter 2, were encouraging, therefore, the 
expression, solubility, purity and activity were further evaluated. This protein has the 
advantage of containing bacterial thioredoxin (nTrx) which is a solubility tag with size 
approximately 12 kDa and a His6 region which allows purification with affinity chromatography 
using Ni-NTA beads. The purified and concentrated protein was buffer exchanged following 
microinjection into mice oocytes along with calcium fluorescent dye for the monitoring of 
calcium oscillations. Each calcium oscillation line represents activity in different mouse 
oocytes. The Ca2+ oscillations varied among different egg as each of them has different 
development and survival potential and due to the potential variability of the amount of 
microinjected hPLCζ. The construct displayed good protein expression and solubility but 
following protein purification the eluate was found to contain multiple products, possibly due 
to protein degradation (Figure 3.6).  
 
 
79 
 
 
Figure 3.6 Evaluation of expression, solubility and activity of isolated recombinant 
nTRx-hPLCζ a) nTrx-hPLCζ has shown to have good expression Un:Uninduced, In:Induced 
and solubility p:pellet, s:soluble franction, F/T: flow through mM:Imidazole concentration. 
Although in the final 250mM elution multiple products found to be present. b) The presence of 
nTrx-hPLCζ was confirmed with Western blot using two different antibodies. c) nTrx-hPLCζ 
was concentrated using 3K Amicon centrifuge tubes. The coomassie blue stained gel illustrate 
the concentrated flow through at 60mM 75mM and 275mM Imidazole. The presence of the 
protein was confirmed with Western Blot and quantified with BCA protein assay illustrating the 
optimum concentration of Imidazole for protein elution. The elution was dialysed in HEPES 
buffer and injected to a number of mouse eggs resulting in calcium oscillations and therefore 
egg activation. Each Ca2+ oscillation trait represent oscillations in different mouse egg. Activity 
assay was performed injecting hPLCζ from the 275mM elution fraction. The microinjection 
experiments have been performed by Dr. Yuansong Yu.  
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3.3.2 Activity assessment in vivo of MBP-hPLCζ 
MBP-hPLCζ has the advantage of containing MBP which is a protein solubility tag of size 
approximately 45kDa. In addition, this solubility partner allows the protein to be purified with 
amylose beads offering more purification options. In chapter 2 the expression and solubility 
have shown to be encouraging therefore it was further assessed for purity and activity. Activity 
assay following injection of purified MBP-hPLCζ illustrated multiple oscillations and active 
PLCζ protein (Figure 3.7).  
 
Figure 3.7 Evaluation of expression, solubility and activity of MBP-hPLCζ a) MBP-hPLCζ 
has been shown to be expressed well and with high solubility Un: Uninduced, In: Induced, Lys: 
bacterial lysate, Sup: Supernatant (soluble fraction). Although, multiple products were present 
in the 250mM elution indicating degradation during the purification and cell lysis, F/T: flow- 
through, Sup: supernatant-soluble fraction, mM: Concentration of Imidazole. b) MBP-hPLCζ 
was concentrated and dialysed with HEPES buffer and injected to a number of mouse eggs 
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resulting in calcium oscillations and therefore egg activation. Each Ca2+ oscillation trait 
represent oscillations in different mouse egg. Activity assay was performed injecting hPLCζ 
from the 275mM elution fraction. The microinjection experiments have been performed by Dr. 
Yuansong Yu.  
 
3.3.3 Activity assessment in vivo of hTrx-hPLCζ 
hTrx was sub-cloned into pET-MM11 which contains only the 6xhistidine tag for protein 
purification. hTrx is used to serve a bilateral purpose, initially a protein solubility tag but most 
importantly for its potential use to biomedical applications as hTrx is present naturally in the 
oocytes (Lopata et al. 2001). The protein was expressed using Rosetta De3 cells and purified 
with Ni-NTA affinity chromatography. The purified protein was concentrated and buffer 
exchanged following injection along with Fluo-3 calcium imaging dye into mouse oocytes.  The 
protein was active exhibiting calcium oscillation for over an hour (Figure 3.8).  
 
Figure 3.8 Evaluation of expression, solubility and activity of hTrx-hPLCζ. a) hTrx-hPLCζ 
was shown to have good expression, however the solubility was found to be poor Un: 
Uninduced, In: Induced, Sup: Supernatant (soluble fraction), F/T: flow- through, mM: 
Concentration of Imidazole. c) The presence of hTrx-hPLCζ was confirmed by Western blot 
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and microinjection of the protein in a number of mouse eggs, indicated its activity. Each Ca2+ 
oscillation trait represent oscillations in different mouse egg. Activity assay was performed 
injecting hPLCζ from the 250mM elution fraction. The microinjection experiments have been 
performed by Dr. Yuansong Yu.  
 
3.3.4 Activity assessment in vivo of nTrx-hTrx-hPLCζ 
The protein derived from the sub-cloning of hTrx into the His6-hPLCζ vector was shown to 
have limited solubility. Therefore, hTrx was sub-cloned into nTrx-hPLCζ which contains both 
6xHistidine tag and nTrx solubility tag, to combine the advantage of hTrx as a solubility tag 
that could potentially have a use in biomedical applications and the expression and solubility 
benefits of nTrx. The protein was purified, however a number of proteins appeared to be 
present possibly due to protein degradation as the bands appear to be recognised by both 
anti-Trx (N-Terminal of hPLCζ) and anti-hPLCζ (EF-hands) antibodies. Activity assay has 
illustrated multiple oscillation in a number of mouse oocytes injected with the protein (Figure 
3.9). 
 
Figure 3.9 Evaluation of expression, solubility and activity of nTrx-hTrx-hPLCζ a) The 
protein is shown to be expressed in soluble form although at the 250mM Imidazole elution, 
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multiple products are present indicating degradation during purification p:pellet , s:soluble 
franction, F/T: flow through mM:Imidazole concentration. b) The presence of nTrx-hTrx-hPLCζ 
was confirmed with the use of two different antibodies the western blot was assessing for 
supernatant (soluble protein), pellet (insoluble protein) and 40mM and 250mM of Imidazole 
elution. c) The sample was concentrated, dialyzed in HEPES buffer and injected into mouse 
eggs resulting in calcium oscillations. Each Ca2+ oscillation trait represent oscillations in 
different mouse egg. Activity assay was performed injecting hPLCζ from the 275mM elution 
fraction. The microinjection experiments have been performed by Dr. Yuansong Yu.  
 
3.3.5 Purification and TEV cleavage of MBP-hTrx-hPLCζ  
The experiments illustrated above have shown that active soluble protein has been 
successfully expressed. The next step was to maximize the purity of the protein. Thus, hTrx 
was sub-cloned into MBP-hPLCζ vector which contains the MBP solubility tag. The presence 
of MBP allows the protein to be purified with more than one affinity chromatography strategy. 
The purified protein appears to have multiple products due to protein degradation (Figure 
3.10). Although full length protein was still able to retain its solubility and structure.    
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Figure 3.10 Purification and TEV cleavage of MBP-hTrx-hPLCζ a) The MBP solubility tag 
seemed to enhance expression and to offer a second purification option with amylose beads 
Un: Uninduced, In: Induced, S: Soluble fraction, P: Pellet. MBP-hTrx-hPLCζ was purified using 
amylose beads. b) The presence of MBP-hTrx-hPLCζ was confirmed with the use of 2 different 
antibodies S: Soluble fraction, P:Pellet. 
 
3.3.6 TEV cleavage 
TEV protease was expressed, purified and used for removal of the solubility tag that was 
attached to the protein. The protein after the cleavage seemed to remain soluble, with purity 
to be the last challenge before the protein could be potentially suitable for biomedical 
applications (Figure 3.11). The hTrx solubility partner has retained solubility following the 
removal of MBP and has been purified by Ni-NTA and Amylose beads which bind to His6 and 
MBP respectively removing them from the elution as they have been cleaved from hPLCζ. 
The second 58kDa product that appears to be present is suggested to be bacterial protein 
possibly bound at the XY linker region.    
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Figure 3.11 Removal of bacterial protein solubility tags a) TEV protease cleaves at the 
designed cleaving site of the protein removing the bacterial solubility partners from hPLCζ, 
resulting in a final construct of hTrx with hPLCζ. b) Protein was purified with amylose beads 
and then cleaved using TEV protease. The remaining hTrx-hPLCζ protein was then extracted 
using Ni-NTA beads and further extracted in order to maximize purity with amylose beads to 
remove any MBP related contaminants.  
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3.4 Discussion 
In severe male factor causes of infertility intracytoplasmic sperm injection is performed with 
great results with over 70% success rates. However, about 30% of failing cases seem to be 
associated with absence of egg activation (Miao et al. 2012). hPLCζ is a protein that is solely 
present in spermatozoa and capable of triggering a series of calcium oscillations following its 
introduction into the egg (Saunders et al. 2002). Studies with calcium ionophores and IP3 
revealed that they activate the egg by causing a single calcium peak and therefore fail to mimic 
physiological fertilisation (multiple oscillations), rising questions regarding the embryonic 
development and survival. Recombinant hPLCζ has been shown to trigger calcium oscillations 
similar to those of fertilisation and therefore mimic physiological conditions (Yoon et al. 2008). 
However, the drawback of recombinant hPLCζ was the presence of solubility tags of non-
human protein origin. Eukaryotic protein expressed in bacterial cells often lose their 
functionality and solubility due to the lack of post translational modification machinery. 
Therefore, the presence of a solubility partner is inevitable. The presence of such bacterial 
solubility partners prohibit its use in fertility applications due to ethical issues.  
 
3.4.1 Thioredoxin and TEV cleavage 
The strategy of expressing hPLCζ with human Thioredoxin aimed to maximize protein 
expression and solubility without the necessity of removing protein solubility tags. Also, an 
expression of soluble hPLCζ with human Thioredoxin could potentially be ethically approved 
for biomedical applications, as Thioredoxin is naturally present in the human oocyte. The 
successful removal of the bacterial solubility partners and the increased solubility of the 
remaining hTrx-hPLCζ protein gives hPLCζ a great potential for future use in biomedical 
applications. Although, the construct was shown to express soluble protein, multiple products 
were found to be present following affinity chromatography protein purification. The causes 
could be potential degradation of the protein during expression and purification or the binding 
of a bacterial protein to the XY linker region. Possible solutions for achieving better purity could 
be further optimization of the purification process by using multiple purification steps such as 
Ni-NTA (6x His –tag) and Amylose (MBP-tag) or gel filtration in order to isolate the protein of 
interest. 
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3.4.2 Ca2+ oscillations  
Physiological egg activation following sperm-egg fusion is characterised by multiple Ca2+ 
oscillations. The proteins successfully expressed and purified in this study were assessed for 
their activity in-vivo following microinjection of the purified protein into mouse oocytes. Activity 
assay has confirmed the active recombinant hPLCζ generating multiple oscillations similar to 
the physiological condition of egg activation. The concentration of recombinant purified protein 
microinjected was normalised however due to the purification impurities and contaminants, 
accurate target protein quantity measurement was impossible to be estimated. Thus Ca2+ 
oscillation patterns differ in each protein construct. The different pattern could be due to the 
different protein concentration injected or due to the different stability and folding of the protein 
with each solubility tag. In most of the constructs a characteristic loop has been observed 
approximately 15 minutes following the first spike which is hypothesised to be due to the 
sensitisation of InsP3R.  As the Ca2+ concentration it is increased is hypothesised that this may 
lead to an increase of InsP3R sensitivity to Ca2+ leading to a further increase of Ca2+ release 
via InsP3R (Hirose et al. 1999; Swann and Lai 2013) therefore the increased Ca2+ release may 
cause Ca2+ oscillations of increased frequency illustrated as a characteristic loop (Figure 3.12). 
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Figure 3.12 The different Ca2+ oscillation patterns observed in different protein 
construct of hPLCζ. Each oscillation line illustrates different oocyte. Microinjection 
experiments were performed by Dr. Yuansong Yu.   
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4.1 Introduction 
 
4.1.1 PLCβ1 deletion 
A novel InDel in the 3rd large intron of the PLCβ1 gene on chromosome 20 (Chr20) was 
identified by Genome Wide Linkage Analysis (GWLA) followed by haplotyping and analysis of 
copy number variations plus DNA sequencing of a large kindred (described below) by Dr. 
Bakhsh. The InDel is present in a region on chr 20 which yielded a LOD score of 3.01 
(described in chapter 6) in the GWLA. The deletion has a size of 1076bp and it is an InDel 
with an ATAA insertion at the junction (Figure 4.1). It is hypothesized that the insertion of the 
ATAA is a ‘’cut and paste’’ event as an outcome of the transposable element activity. It has 
been found that there is an 11kb transposon cluster immediately upstream of the region of 
interest (Consortium 2012).   
 
 Figure 4.1 The InDel was identified at the 3rd large intron of PLCβ1 at Chr 20 with a 
1076bp deleted region and an ATAA insertion at the junction.  
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4.1.2 Family History 
The InDel was found to be present in a family with a strong history of Multinodular Goiters 
(MNG) (Figure 4.2) several members with MNG have subsequently developed papillary 
thyroid cancer (PTC). The mother of six children, III-2 suffered from MNG and has undergone 
partial thyroidectomy at the age of 17, followed by complete thyroidectomy for PTC at the age 
of 28. At the age of 41 she was diagnosed with breast carcinoma. Her son IV-1 was diagnosed 
with 9 hyperechoic cysts, fine needle aspiration (FNA) has suggested the development of 
papillary thyroid cancer thus a complete thyroidectomy was performed. He was also 
diagnosed with polycycstic kidney disease in infancy. His sister IV-2 was diagnosed with 
multiple hyperechoic thyroid nodules with FNA examination revealing the presence of multiple 
papilloid adenomata. Histopathological examination following total thyroidectomy has shown 
the presence of papillary hyperplasia. Her sister IV-5 was diagnosed with MNG but thyroid 
scan examination has shown small hypoechoic cysts and thus she was not referred for 
thyroidectomy. Her sister IV-6 was diagnosed with multiple hyper echoic nodules with FNA 
examination showing the presence of multiple papilloid adenomata. The presence of a large 
goitre, the multiple papilloid adenomata and the strong family history of thyroid cancer has led 
to a complete thyroidectomy at the age of 17. The sister IV-3 has undergone thyroidectomy 
for Graves’ disease and her brother IV-4 had no thyroid malignancies or kidney lesions. The 
three relatives, I-1, II-2 and III-5 had undergone thyroidectomy for presumed benign thyroid 
disease with no further detail regarding their medical history or thyroid histology (Figure 4.2).   
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Figure 4.2 Family tree of the family identified with the PLCβ1 InDel. The patients with 
coloured background carried the InDel and were the same time affected by thyroid disease. 
Patients with a diagonal pattern carried the InDel but were not affected. The blue colour 
indicate males and the red females.  
 
4.1.3 Prevalence studies 
Previous study on the prevalence of the InDel by Dr. Bakhsh with standard PCR and in silico 
analysis has identified that the InDel was present in approximately 1% in the Caucasian 
population (3/285) (1/105 was identified following standard PCR genotyping and 2/180 by in 
silico analyses from databases for genomic variants) and in 5% of patients suffering with MNG 
(4/81) (Table 4.1). Of interest the InDel was not present in 70 patients having a solitary nodule 
that was subsequently diagnosed as papillary thyroid cancer. 
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Table 4.1. Prevalence studies performed on PLCβ1 InDel with PCR genotyping.  
 
Group of Patients 
 
Number of Patients 
Number of patients 
found with the 
deletion 
 
Prevalence (%) 
Papillary thyroid 
cancer (PTC) 
 
 
70 
 
0 
 
0 
Caucasian – 
General Population 
 
 
105 
 
1 
 
0.95 
Multinodular Goiter 
(MNG) 
81 4 4.94 
 
4.1.4 Techniques to Measure Copy Number Variation (CNV) 
There is a range of different techniques for detection and assessment of CNVs. The main 
methods include arrays, RFLP followed by Southern blot, qPCR, pyrosequencing, ligation 
detection reaction and the invader assay (Lee and Jeon 2008).  
Microarray technology is widely used for CNV detection the use of which is either array-based 
comparative genomic hybridization or SNP-based microarrays (Lee and Jeon 2008). These 
two methods have been found to be ideal for detection of low level mosaicism being more 
accurate than cytogenetic tests. Although able to identify CNVs, microarrays seem to have a 
limited clinical application as they are less able to identify pathogenic duplications compared 
with their capacity to detect pathogenic deletions. In addition, microarrays cannot detect 
genomic alterations resulting in unchanged genomic material such as inversions and balanced 
translocations (Lee and Jeon 2008; Coughlin et al. 2012).  
RFLP followed by Southern Blot analysis is considered the most traditional technique for 
screening CNVs ranging from 5 to 500kb. Even though it is a good method for detecting large 
CNVs within the duplication, it is an expensive, laborious and time consuming technique 
requiring more than a week for completion (Lee and Jeon 2008).  
Pyrosequencing is another popular method for CNV screening. It has been developed by 
(Ronaghi et al. 1998) and its principle is based on the detection of the pyrophosphates (PPi) 
which are released following the binding of the dNTPs corresponding to the initial template 
located at the 3’ end of the newly synthesized strand (Lee and Jeon 2008). The limitations of 
this technique include its dependence on quality of the template DNA and the fact that it is an 
end point analysis and not a real time analysis with the consequent PCR requiring a thorough 
optimization (Lee and Jeon 2008).  
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Real time PCR on the other hand, is ideal for CNV detection as it is cost and time effective 
with high impact. The privilege of using an apparatus that combines a thermal cycle with the 
real time monitoring of spectral fluorescence, offers the unique advantages of assessing the 
PCR kinetics in real time without requiring further post – PCR analysis (Lee and Jeon 2008; 
D'haene et al. 2010) and so I opted to use this method. 
 
4.1.5 Does the InDel have promoter activity? Reporter gene assay  
In silico analysis of the PLCβ1 intronic InDel has found that there is an oestrogen receptor 
(ERα) α binding site within the deletion (Dunham et al 2012). The identification of the ERα 
binding site in combination with the increased prevalence of thyroid diseases, including MNG 
and PTC in the female population (Vanderpump et al. 1995) and the increased prevalence of 
the InDel in the female members of the family suggested a potential role for oestrogen in 
thyroid disease. These findings lead to a hypothesis that an ERα binding site could indicate 
the presence of silencer elements which can repress promoter activity and could either affect 
PLCβ1 transcript levels or regulate another transcript ‘hidden’ within the large intron. Also, an 
important finding that supports the hypothesis for the potential intrinsic role of ERα, was the 
discovery that 5% of the identified ERα binding sites (>1000) in the human genome are 
present within promoters in introns (Lin et al. 2007). 
 
The reporter gene assay is the gold standard for this type of investigation. The principle of the 
technique is very simple and involves the cloning of the putative promoter sequence into an 
expression vector upstream of a reporter, for example the firefly luciferase gene. The vector 
is in turn transfected into cells so that on addition of the appropriate substrate, firefly luciferase 
can be directly detected indicating the presence of an active promoter. It is a very sensitive 
technique which can be used in a wide range of applications providing a quantitative luciferase 
signal (Allard 2008) (Figure 4.6).  
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4.1.6 MCF7 
The cells selected for this study were the MCF7 breast cancer cell line. MCF7 were ideal for 
this study as they have the ability to respond to oestrogen in the form of estradiol, due to 
oestrogen receptors present in their nucleus. MCF7 breast cancer cell line originated from a 
69 year old female from the Detroit area with metastatic breast cancer (Levenson and Jordan 
1997). Characterisation studies with tamoxifen a drug with oestrogen competing activity has 
proved that MCF7 cells are hormone responsive and thus they provide a suitable cell line to 
study endocrine therapy in correlation with tumour response and the biological activity of 
oestrogen binding (Levenson and Jordan 1997).    
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4.1.7 AIMS 
The aim of the project was first the generation of a qPCR based genotyping tool for the 
identification of the PLCβ1 InDel in large cohort of patients. Prevalence studies, along with the 
clinical information regarding the family affected by the deletion, suggested that it may cause 
benign proliferation and could potentially be used as a biomarker for MNG patients likely to 
develop PTC. However to confirm this it is necessary to analyse additional cohorts to provide 
a more accurate measurement of the prevalence of the InDel in healthy and diseased 
populations (Figure 4.3). 
The second aim of this chapter was to investigate the putative promoter activity of the InDel 
and whether it can be modified by oestrogen. It has been identified that there is an oestrogen 
receptor α (ERα) binding site within the deletion, the increased transcript levels upon the 
deletion of that sequence suggested the potential presence of silencer elements of oestrogen 
receptor promoter, and thus promoter activity was investigated by luciferase assay (Figure 
4.3). 
 
 
 
Figure 4.3 Aims of the chapter. The generation of a qPCR genotyping tool for the PLCβ1 
InDel screening in patients and the identification of an active promoter within the InDel were 
the two aims of the chapter.  
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4.2 Materials and Methods 
 
4.2.1 The design of a qPCR based genotyping tool 
The necessity for a fast, cost effective and accurate tool for screening large cohorts of patients 
led to the optimisation and development of a qPCR based genotyping tool (Figure 4.4).  
 
 
Figure 4.4 Flow chart of the genotyping of patients for the identification of the PLCβ1 
InDel.  
 
4.2.2 Extraction of Genomic DNA from blood 
DNA was purified from whole blood with the use of QIAamp blood Midi Kit (Qiaqen) according 
to the manufacturer’s protocol. Initially 100μl of Qiagen protease was placed in a 15ml 
centrifuge tube followed by 1ml of blood. Blood was mixed thoroughly for a minute and placed 
at 70 ᵒC for 10 minutes. Then 1ml of 100% ethanol was added to the tube and mixed by 
inverting the tube 10 times. The mix was carefully transferred into the QIAamp Midi column 
and centrifuged at 3000rpm for 3 minutes. The QIAamp Midi column was removed and the 
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filtrate was discarded. The QIAamp Midi column was placed back in the 15ml centrifuge tube 
2ml of Buffer AW1 was added and centrifuged at 5000rpm for 1 minute. Without moistening 
the rim, 2ml of AW2 buffer was added to the QIAamp Midi column and centrifuged at 5000 
rpm for 15 minutes. The QIAamp Midi column was placed in a clean 15ml centrifuge tube and 
DNA was eluted by adding 200μl of distilled water and incubating for 5 minutes at room 
temperature. The filter was centrifuged at 5000 rpm for two minutes. The eluate was placed 
back in the column, incubated for another 5 minutes and centrifuged at 5000rm for two minutes 
to maximize DNA concentration. 
 
4.2.3 Primer design and evaluation  
Four pairs of primers were designed with the assistance of ‘’Primer 3’’ online primer design 
tool (http://bioinfo.ut.ee/primer3/), where two pairs of primers were designed within and two 
flanking the deletion (Table 4.3) and (Figure 4.5). The designed primers were also screened 
by BLAST search (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure that there are no other 
unrelated significant homology sequences. Then a PCR amplification was performed (Table 
4.2) on genomic DNA from family members with and without the deletion to evaluate the 
amplification efficiency. PCR amplification was performed according to (NEB) manufacturer’s 
protocol (2.5μl 10x ThermoPol reaction buffer, 0.5μl of 10mM dNTPs, 10mM forward primer, 
10Mm reverse primer, 0.125μl of 5U/μg Taq DNA polymerase (NEB) and 0.1-1μg of genomic 
DNA template in a total reaction volume of 25μ) (Table 4.5). The amplified DNA products were 
evaluated following 1% agarose gel electrophoresis (Chapter 2). The DNA bands were 
extracted with the use of a gel extraction kit (Qiagen) and confirmed by Sanger sequencing 
as described in (Chapter 2). 
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Table 4.2 PCR amplification reaction 
 Temperature 
ᵒC 
Time 
 95 30 seconds 
 
30 
cycles 
 
95 30 seconds 
60 45 seconds 
72 1 minute 
 72 5 minutes 
 4 ∞ 
 
 
  
Figure 4.5 The design of the qPCR based genotyping tool. The four sets of primers were 
initially designed 2 within and 2 flanking the deletion, due to the heterozygosity of the deletion 
the primers flanking the deletion amplified two products as only one allele carries the deletion.  
 
Table 4.3 List of primers designed for development of the qPCR based genotyping tool.  
Primer 
Name 
Tm Sequence Tm 
F1/R1 60.5 GTGGATTGGGACCTGCAATT/TTGTTCTGATCATGCTCCTCA 57.8 
F2/R2 55.7 ACACTGTGACTGGGTGTGAA/CTGTCCCCTAGGTCTTCGTG 58.18 
F3/R3 59.5 TTTCAGTGCCATTGGTAGCC/AGACTTGCATTCTCAGCCAT 55.9 
F4/R4 55.2 ACTACACCTTCCTGCCAGTC/CAGGCAAGAACCATGGTACC 58.9 
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4.2.4 qPCR optimization 
The concentration for each primer pair, was optimized with the use of a primer matrix where 
9 combinations of 3 different forward and reverse primer concentrations were assessed (Table 
4.4). Each of the cDNA samples was quantified with Nanodrop (Nanodrop-Lite Thermo- 
Scientific) and 100ng were loaded in each well of a 96 well PCR plate (Agilent Technologies) 
for the qPCR reaction. The qPCR reaction mix was added to appropriate well of the 96 well 
plate with the genomic DNA and then, placed into the MX3000P® thermocycler for qPCR 
amplification (Table 4.5).  
 
Table 4.4 Primer matrix with 9 different primer concentration combinations. 
 
 
 
Table 4.5 qPCR amplification conditions a) qPCR reaction mix b) Amplification programme  
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4.2.5 Anonymised test 
The ability of the tool to identify the deletion in random patients was evaluated by performing 
an anonymised test. The test included six DNA samples from the affected family, three of 
which were known to harbour the deletion. The test was performed after anonymisation of 
each sample and performing qPCR amplification see (Table 4.5). The reaction contained 
100ng of gDNA and both primers within and flanking the deletion were assessed for their 
ability to identify the InDel.  
 
4.2.6 Additional cohorts 
The genotyping tool was used for the screening of 208 subclinical hypothyroid patients the 
genomic DNA of which was provided by Dr. Anna de Lloyd and were screened for the 
presence of the 1076bp intronic deletion. The primer pair that was selected for its accuracy 
from previous optimisation experiments was the pair within the deletion. The cohort was 
screened twice with these primers, however due to the high number of positives, another two 
screenings were performed with primers flanking the deletion for the identification of potential 
false negative samples. Samples found to harbour the InDel by qPCR were confirmed by 
Sanger sequencing as described in (Chapter 2). 
The previously optimized qPCR tool with primers flanking the deletion was used for the 
screening of additional cohorts comprised of a total of 36 patients. Genomic DNA from this 
group of patients was provided by Dr. Dagmar Fuhrer (Table 4.9).  
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4.2.7 Reporter Gene Assay 
In Silico analysis of the deletion has identified an Oestrogen receptor α (ERα) binding site 
within the deletion. Therefore, a luciferase assay was designed to assess whether an active 
promoter is present within the InDel region (Figure 4.6). 
 
 
Figure 4.6 Flow chart of the reporter gene assay in MCF7 cells. Molecular cloning of the 
deletion region into the PGL3 basic vector and transfection of the plasmid into MCF7 cells was 
followed by Oestrogen treatment and Luciferase detection.  
 
4.2.8 Molecular Cloning 
The primers flanking the deletion F4/R4 (Table 4.2), amplifying a 1551bp product were used 
for the cloning of the PLCb1 deletion region into the PGL3 basic vector (Promega). 
Investigation with NEBcutter software (http://nc2.neb.com/NEBcutter2/) of the region of 
interest has found naturally occurring restriction sites for KpnI and XhoI, therefore both PGL3 
basic vector and amplified DNA were digested with KpnI and XhoI enzymes (Figure 4.7). 
Initially, the region of interest was amplified with the addition of the following reagents into a 
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500 μl reaction tube: 2.5μl of 2x phusion master mix (NEB), 0.5μM forward primer, 0.5 μM 
forward primer, 1μl of template DNA and nuclease-free water (Fisher Scientific) up to 50μl 
total reaction volume (Table 4.2). Amplified products were then purified with the PCR 
purification kit (Qiagen). Molecular cloning was performed as described in (Chapter 2). 
Conditions for PCR amplification and Ligation are illustrated in (Table 4.6 and 4.7).  Successful 
cloning was confirmed by Sanger sequencing. Successful incorporation of target sequence 
and the presence of Firefly Luciferase gene were confirmed by PCR amplification (similar 
conditions as described above) (Table 4.2). Firefly Luciferase primers (Table 4.8) were kindly 
provided by Dr. Martyn Bullock.  
 
Figure 4.7 Sequential restriction digestion of the PLCβ1with KpnI and Xhol enzymes.  
 
Table 4.6 PCR amplification programme  
 Temperature 
ᵒC 
Time 
 98 30 seconds 
 
30 
cycles 
 
98 30 seconds 
55 1 minute 
72 2 minutes 
 72 7 minutes 
 4 ∞ 
 
Table 4.7 Ligation conditions for cloning of the region of interest into PGL3 basic 
vector. 
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Table 4.8. Firefly Luciferase primers  
Primer 
Name 
 
Tm 
 
Sequence 
 
Tm 
LucF/LucR 62 GTGTTGGGCGCGTTATTTAT/CATCGACTGAAATCCCTGGT 63 
 
 
4.2.9 Cell Culture 
4.2.9.1 MCF7 cells 
The cells were kindly provided by Dr. Illaria Muller (Cardiff University, UK). The cells were 
grown in 75 cm2 NuclonTM delta surface flasks (Nunc, UK) in 12 ml culture medium (DMEM -
4.5g/L glucose, L- glutamine without sodium pyruvate, 100U/ml potassium penicillin, 100μg/ml 
streptomycin sulphate, 1mM sodium pyruvate, 10μg/ml bovine insulin and 10% heat-
inactivated foetal calf serum (FCS) (EU approved). The reagents were all acquired from 
(Lonza UK). The cells were incubated at 37 ᵒC and 5% CO2 incubator.  
 
4.2.9.2 Trypsinisation 
The cells were passaged at 80% confluency. Culture medium was removed and cells were 
washed with 10ml sterile PBS. Then 3ml of trypsin (Lonza UK) was added and cells were 
incubated at 37 ᵒC for 10 minutes and cells were released following tapping of the flask. Then 
5ml of culture medium (described above) was added and cells were placed into a 50ml falcon 
tube and centrifuged at 1000rpm for 5 minutes at room temperature. Supernatant was 
discarded and pellet was resuspended with 1ml of culture medium. In a new flask 20% of the 
cells were reseeded in 12ml of culture medium (described above) and incubated at 37 ᵒC and 
5% CO2 incubator.  
 
4.2.9.3 Cryopreservation of cells 
The cells were trypsinised as described above and cell pellet was resuspended with 1ml of 
freezing media (60% basal media, 20% FCS, 20% DMSO). The cells were aliquoted in 2ml 
cryotube vials (Thermo Scientific) which in turn were placed in insulating polystyrene freezing 
container with isopropanol (NALGENE). The freezing container was placed at -80 ᵒC where 
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cells were frozen at a cooling rate of 1 ᵒC/min. The cells following overnight freezing were 
transferred to liquid nitrogen in -190 ᵒC.   
 
4.2.9.4 Transfection 
48 hours prior to transfection, MCF7 cells were transferred and maintained in phenol red free 
Dulbecco’s modified Eagle’s medium F12 containing 5% charcoal stripped foetal bovine 
serum (Lonza UK) and 2% (100U/ml potassium penicillin, 100μg/ml streptomycin sulphate). 
The cells 24h prior to transfection were trypsinised, counted, about 20,000 cells which is about 
70% confluency were plated in the 96 well plate (Thermo Scientific) and incubated at 37 ᵒC 
and 5% CO2 incubator.  For each transfection 150ng of PGL3-basic vector, 3ng of pRL vector 
(Promega) (Firefly Luciferase: Renilla Luciferase – 50:1) (Figure 4.8) and TransfastTM reagent 
(Promega) with ratio (Transfast reagent: DNA – 3:1) were mixed with 50μl phenol red-free 
antibiotic-free and serum free QIBCO® Dulbecco’s Modified Eagle Medium: Nutrient 
Mixture:DMEM/F-12 (Life Technologies). The mix was incubated at 15 minutes at room 
temperature. Culture medium was removed from cells following by washing with PBS. Then 
transfection mix was added on top of the cells drop-wise followed by incubation at 37 ᵒC and 
5% CO2 incubator for 1 hour. Each well was then topped up with 150μl of phenol red-free 
QIBCO® Dulbecco’s Modified Eagle Medium: Nutrient Mixture:DMEM/F-12 (Life 
Technologies) with 10% charcoal stripped fetal bovine serum (Life Technologies) (EU 
approved) and incubated at 37 ᵒC and 5% CO2 incubator overnight.  
 
105 
 
 
Figure 4.8 List of plasmids that have been used in reporter gene assay 
 
4.2.9.5 Luciferase Assay 
The cells were incubated at 37ᵒC for 48h following medium change and treatment with β-
Estradiol (Invitrogen) at 15, 30 and 60 pM. Estradiol was initially dissolved in absolute ethanol 
1.83μM stock and sequentially diluted in Dulbecco’s modified Eagle’s F12 phenol red free 
medium. Treated cells were incubated at 37ᵒC for 24h, then the medium was replaced by 1x 
Passive Lysis Buffer (Promega) and stored at -80ᵒC overnight. The lysed cells were defrosted 
at room temperature with gently shaking with 50μl of cell lysate to be used for Dual Luciferase 
Reporter Assay System with the use of Promega Glomax multi detection system according to 
the manufacturer’s protocol.  
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4.3 Results 
 
4.3.1 The design of a qPCR based genotyping tool 
A novel InDel (1076 bp deletion with ATAA insertion at junction) has been identified in the 
large 3rd intron of the PLCβ1 gene on chromosome 20 using GWLA in a large kindred. The 
deletion has been shown to have a prevalence of about 1% in Caucasian population and 
approximately 5% in patients with euthroid multi-nodular goiter (MNG). Nodular thyroid 
disease is common and a risk factor for thyroid cancer. We hypothesize that this deletion could 
potentially be a marker for patients with MNG most likely to develop papillary thyroid cancer 
(PTC).  
 
4.3.2 Primer pair Evaluation  
A genotyping technique using qPCR was designed and optimized in order to screen a large 
number of patients and identify the prevalence among MNG & PTC patients and the general 
population.  Four sets of different primers were designed; 2 within and 2 flanking the deletion. 
The qPCR was optimized using a primer matrix with 9 different primer concentration 
combinations. The expected amplification product size for the primers within the deletion was 
211 (F1/R1) and 184 (F2/R2) base pairs and for the primers flanking the deletion was 1159 
(F3/R3) and 1551 (F4/R4) (Figure 4.9).  
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Figure 4.9 Assessment of designed primers. a) DNA from patients carrying the deletion 
(P), patients without the deletion (N) and (-) negative PCR control without DNA template. The 
primer pairs flanking the deletion amplified two products due to the heterozygosity of the 
deletion.  b) The expected sizes of the PCR amplified products. F: Forward primer and R: 
Reverse primer.  
 
4.3.3 qPCR optimisation 
The technique was then optimised using a primer matrix as described above using patients 
known to carry the deletion and patients without the deletion. The result was positive with all 
the true positives identified by the technique. It was found that the primers within the deletion 
produced a Ct value difference of 1 between subjects with and without the deletion. The 
optimal combination selected for F1/R1 primers were F1:500nM/R1:100nM. On the other 
hand, the primers flanking the deletion had a difference in Ct value of ~10 (Figure 4.10).   
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Figure 4.10 qPCR optimisation. A) Primer matrix with F2/R2 primers within the deletion. B) 
Evaluation of the primer concentration due to Ct value difference and quality of the dissociation 
curve. C) Example of the ideal dissociation curve for a primer pair.  
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4.3.4 Anonymised Test 
The efficiency of the technique was then assessed using 6 anonymised samples, 3 with and 
3 without the deletion. The samples carrying the deletion were successfully identified with only 
one outlier due to the old age of the blood samples (Figure 4.11). The primer set (F1/R1) within 
the deletion were then chosen to screen a large cohort of 208 subclinical patients.  
 
Figure 4.11 Evaluation of the anonymised test. a) Anonymised test with primers within the 
deletion F1/R1 and flanking the deletion F3/R3 in 6 patients 3 of whom were positive for the 
deletion. b) The Ct value illustration for primers within (F1/R1 and F2/R2) and flanking (F3/R3, 
F4/R4) the deletion.  
 
4.3.5 Screening of 208 subclinical hypothyroid patients 
Two hundred and eight patients with subclinical hypothyroidism (SH) were genotyped using 
primers F1/R1 within the deletion. This identified 15 subjects having a difference of 1 Ct and 
who were presumed to be positive for the InDel. The 15 positives were screened with the 
primers (F4/R4) which flank the InDel, in order to confirm the true positives; only 2 out of 15 
were confirmed. Consequently, the entire SH cohort was screened again using (F4/R4) 
primers which flank the InDel, for the identification of any potential false negative patient (Table 
4.9). The screening identified one false positive, making the flanking the deletion primers ideal 
for screening large cohort of patients. The patients found carrying the deletion were 2 males 
and one female with one having a history of goitre and thyroid cancer in the family. The 
presence of the deletion was confirmed by Sanger sequencing as described in Chapter 2.   
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4.3.6 Additional Cohorts 
Additional cohorts comprised 36 patients but subdivided into 4 groups, 17 with colloid nodules, 
5 with follicular adenomas, 8 with papillary thyroid carcinoma, 6 with hot nodules were 
screened for the presence of the PLCβ1 InDel. The genotyping identified one patient with 
follicular adenoma carrying the deletion (Table 4.9). Previous studies by Dr. Grennan Jones, 
revealed that the deletion increased PLCβ1 transcript levels therefore, is hypothesized that 
the deletion may have an impact on the cell proliferation (benign) and this will be further 
investigated in chapter 5. 
 
Table 4.9. The different cohort of patients genotyped by the qPCR based tool.  
 
 
 
 
 
 
Group of Patients Total number of patients Number of patients 
found with the deletion 
Number of Subclinical  
hypothyroid patients 
208 3 
Number of patients with 
colloid nodules 
17 0 
Number of patients with 
Follicular adenoma 
5 1 
 Number of patients with 
papillary thyroid 
carcinoma 
8 0 
Number of patients with 
hot nodules 
6 0 
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4.3.7 Reporter gene assay 
4.3.7.1 Cloning of PLCβ1 deletion into PGL3 basic vector 
The PLCβ1 deletion region was amplified with F4/R4 flanking the deletion primers generating 
a 1551bp product. The DNA fragment was digested with KpnI and XhoI restriction enzymes 
and cloned successfully into PGL3 basic vector (Figure 4.7). The region of interest was also 
confirmed by PCR using flanking the deletion primers F3/R3 generating an 1159bp product. 
Quality control of the plasmids used for luciferase assay included assessment of the presence 
of Luciferase gene by primers generating a 200bp product (Figure 4.12).  
 
 
Figure 4.12 Cloning of PLCβ1 deletion into PGL3 basic vector. a) Confirmation of 
successful cloning of the deletion region into the PGL3 basic vector by restriction digestion 
with KpnI and XhoI. b) Confirmation of successful cloning and intact Luciferase gene by PCR 
amplification using F3/R3 PLCβ1 flanking the deletion and Luciferase primers respectively.  
 
4.3.7.2 Luciferase assay  
MCF7 cells which are known to be Oestrogen receptor alpha positive breast cancer cells, were 
co-transfected with PGL3 basic vector containing the deletion region and pRenilla for 
transfection efficiency positive control. Renilla Luciferase, αGCU-Luciferase which contains a 
glycoprotein hormone alpha subunit proximal promoter (Chatterjee et al. 1991) and PGL3 
basic vector were used as positive controls for transfection efficiency. The significant 
luciferase emission from these positive control vectors confirmed the successful transfection 
(Figure 4.12). However, the results from the various treatments indicated either the absence 
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of an active promoter or the presence of silencer elements within the deletion region. 
Oestrogen was used in a dose dependent manner however the results confirmed that there is 
no significant light emission compared to PGL3 basic empty vector or the untreated cells 
suggesting the absence of an active promoter or the presence of silencer elements within the 
region (Figure 4.13).  
 
Figure 4.13 Luciferase assay for identification a potential promoter. a) Luciferase assay 
in 5 different single experiments under the same conditions on MCF7 cells indicating the 
absence of active promoter or the presence of silencer elements within the deletion. b) Renilla 
luciferase emission for the 5 same experiments illustrated at a) confirming the successful 
plasmid transfection into MCF7 cells. 
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4.4 Discussion 
 
4.4.1 The design of a qPCR based genotyping tool 
The development and optimisation of a qPCR based genotyping tool for the successful 
screening of large cohorts of patients has given the opportunity for the investigation of the 
deletion in a fast, cost-effective and efficient manner. It was hypothesized that the primers 
within the deletion, which during the anonymised steps had successfully identified patients 
carrying the deletion with a Ct value difference of 1, would be ideal for the screening of large 
cohorts of patients. Initially, the 208 subclinical hypothyroid patients were screened with the 
primers within the deletion resulting in 15 false positives. The screening of the 15 positive for 
the deletion patients with flanking the deletion primers confirmed that 2 were true positives. 
Therefore, screening of the total 208 patients was repeated with the use of flanking the 
deletion primers for the identification of potential false negatives. The investigation identified 
a false negative confirming that flanking the deletion primers were ideal for the screening of 
large cohorts of patients.  
Screening of additional cohorts with flanking the deletion primers of a total number of 36 
patients from 4 different groups identified and confirmed one more patient heterozygote for 
the deletion. In total, four patients carried the InDel 3 men aged 37 to 39 years old and 1 
woman aged 47 years old. One of the male had follicular adenoma, the second male was 
noted with goitre and the woman had a family history of cancer. The 3 SH patients were 
contacted for a thyroid scan with the female patients arranging an appointment however she 
did not attend the appointed meeting.  
Previous investigation by Dr. Bakhsh (unpublished data) about the prevalence of the InDel 
has revealed that none of the 70 papillary thyroid cancer patients harboured the deletion, it 
was present in approximately 1% of the Caucasian population 1 out of 105 patients and about 
5% in patients with Multinodular Goiters (MNG) 4 out of 81. In the current study the prevalence 
of the InDel in the subclinical hypothyroid patient cohort which was similar to 1% previously 
found in the Caucasian population. On the other hand, 1 out of 5 patients with follicular 
adenoma found to harbour the deletion which is supporting our hypothesis that the InDel is 
promoting benign proliferation.  Previous studies by Dr. Grennan Jones and Dr. Bakhsh 
confirmed that the patients carrying the PLCβ1 InDel exhibited significantly increased PLCβ1 
transcript levels. Taking into account the role of PLCβ1 in cell cycle signalling and its effect on 
the BRAF and MEK/ERK pathway and the fact that it is present in patients with follicular 
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adenoma and MNG plus the original family it suggested that it could potentially have a role in 
benign cell proliferation.  
 
4.4.2 Reporter gene assay 
In silico analysis of the deletion region revealed that there is an Oestrogen receptor α (ERα) 
binding site within the deletion. Therefore, the deletion region was cloned into PGL3 basic 
vector, ideal for luciferase assays as it contains a luciferase gene. The cells used for the 
luciferase assay were MCF7 breast cancer cell line known to be Oestrogen receptor positive.  
The results even though they were quite variable have confirmed that there is either no active 
promoter or the presence of silencer elements within the deletion region. Luciferase excitation 
was not induced following Oestrogen treatment with the signal being equivalent to the 
background luciferase signal. All positive controls for Firefly Luciferase emitted light and PCR 
amplification of the plasmids transfected into MCF7 cells with luciferase primers confirmed the 
presence of functional Firefly luciferase. In addition, Renilla Luciferase also emitted light 
confirming the transfection efficiency of the assay, as it is was co-transfected along with the 
luciferase assay plasmids. The deletion of the sequence has been reported to be correlated 
with elevated thyroid PLCβ1 transcript levels. These results in combination with the lack of 
oestrogen response in the reporter assays has suggested the potential presence of silencer 
elements within the deletion which may act as repressors of PLCβ1 expression.
  
 
 
 
 
 
 
 
 
 
 
Chapter 5.The Effect of PLCβ1 On Cell 
Proliferation 
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5.1 Introduction 
 
5.1.2 The presence of PLCβ1 in human cancer 
A number of studies have shown that PLCβ1 has a major role in a range of different cancers 
such as prostate, colon, breast, leukaemia and ovarian cancer. Increased PLC activity was 
also found in neoplastic thyroid membrane (Kobayashi et al. 1993). Also, it has both nuclear 
and cytoplasmic locations with its signalling cascade being involved in cell cycle progression. 
In this study, the impact of potential alterations of PLCβ1 transcript levels on cell proliferation 
will be assessed characterising its potential contribution in goitre and thyroid cancer 
(Friederichs et al. 2000; Kristiansen et al. 2002; Follo et al. 2009; Molinari et al. 2012; Ribeiro 
et al. 2012; Jia et al. 2013).  
 
5.1.3 The effect of PLCβ1 InDel on the PLCβ1 gene, mRNA expression.  
Unpublished work by Drs. Bakhsh, Zhang and Grennan Jones in our group identified that 
patients who carried the PLCβ1 InDel exhibited increased thyroid PLCβ1 transcript levels. 
More specifically, tissue extracted from thyroid tissue following thyroidectomy has shown that 
PLCβ1 transcript levels were significantly elevated in those affected with the PLCβ1 InDel. 
The increased PLCβ1 transcripts in patients carrying the InDel was up to 3 fold compared to 
unaffected individuals. In this study we have used the Fisher rat thyroid cell line (FRTL-5) to 
assess the impact of alteration in the PLCβ1 transcript levels on cell cycle progression and 
cell doubling time. As will be described below I have used techniques to reduce (siRNA) and 
over-express (lentiviral vectors) PLCβ1 transcripts. 
 
5.1.4 FRTL-5 cell line  
The target cell line was the FRTL-5 cell line which is thyroid stimulating hormone (TSH) 
dependent for cell growth and shares characteristics with thyroid epithelial cells, therefore 
considered an ideal cell model for thyroid cell studies (Iitaka et al. 2001). The FRTL-5 cell line 
was derived from epithelial follicular cells from the thyroid of Fisher rat. The cells are diploid 
and grow as a monolayer, able to express in-vitro a range of thyroid differentiation markers. It 
is a TSH growth dependent cell line with a morphology similar to primary epithelial cells. They 
demonstrate the ability to accumulate iodine in-vitro and generate thyroglobulin, although are 
unable to synthesize thyroid hormones (Stiblar-Martincic et al. 2002).  
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5.1.5 RNA interference (RNAi)  
RNAi technology was discovered by (Fire et al. 1998) and since then it has become a popular 
tool for the evaluation of gene function by regulation of gene expression. The technology is 
based on the mechanism of naturally occurring endogenous siRNAs which derive from 
dsRNAs and have a regulatory role in gene expression (Watanabe et al. 2008). RNAi 
technology uses small interfering RNA sequences (SiRNAs), approximately 21bp double 
stranded RNA (dsRNAs), to interfere with gene expression. RNA interference operates at two 
distinct phases, the initiation phase and the effector phase. During the initiation phase long 
double stranded RNA is fragmented by RNAseIII endonuclease Dicer enzyme into RNA 
duplexes of approximately 21 nucleotides. The fragmented double stranded RNA has a 
dinucleotide overhang at the 3’ end and a monophosphate group at the 5’ end both having 
essential roles in recognition during integration of the RNA induced silencing complex (RISC).  
Dicer along with the human immunodeficiency trans-activating response RNA-binding protein 
(TRBP) load the RNA onto Argonaute (AGO2) to form RISC. Following the formation of RISC, 
double stranded RNA is separated as AGO2 selects the ‘’guide’’ strand and cleaves the 
‘’passenger strand’’. The ‘’guide’’ strand whilst bound with AGO2 is paired with mRNA with the 
rule of complementation. AGO2 then cleaves the bound mRNA resulting in depletion of a 
specific gene (Figure 5.1). (Carmell et al. 2002; Aagaard and Rossi 2007; Shreve and Carter 
2009) 
The main advantage of RNAi technology is the simplicity with which loss of function of a 
particular target protein can be induced. Also, even in comparison with other anti-sense 
techniques, RNAi has the ability to bind to mRNA and lead to its fragmentation with higher 
efficiency even at lower concentrations (Aagaard and Rossi 2007). 
RNAi despite its wide application has a number of limitations such as the off target effect which 
may lead to depletion of other genes. Also, it is cleared very quickly from cells which makes it 
ideal only for short-lasting experiments. In addition, siRNAs are susceptible to enzymatic 
degradation having a short half-life and therefore can be very unstable in physiological 
conditions in vivo. (Sledz and Williams 2005; Aagaard and Rossi 2007).  
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Figure 5.1 The principles of siRNA knockdown. Dicer protein binds to long double stranded 
RNA and cleaves RNA into 21bp fragments which along with trans activating response RNA-
binding protein (TRBP) are loaded onto Argonaute 2 (AGO2) forming the RNA- binding protein 
complex (RISC). AGO2 cleaves the siRNA and selects the guide strand which eventually will 
bind to the target mRNA and AGO2 then cleaves bound mRNA leading to depletion of the 
specific gene.  
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5.1.6 Lentiviral vectors 
The generation of viral vectors and their use for alteration of gene transcript levels offers 
unique advantages in research and gene therapy. The use of lentivruses allows the 
transduction of both dividing and non-dividing cells, without expression of viral proteins 
eliminating immunogenic responses. Also, a great advantage of using viral vectors compared 
to siRNAs is the long term transgene expression allowing long term experiments without 
clearance of the effect. On the other hand, their disadvantages include the possibility of low 
titres and the possible random insertion in the host genome which can potentially trigger 
tumorigenic or tumour suppressor activity.  
5.1.4.7 Lentivirus generation  
The lentivirus that is widely used is the human immunodeficiency virus type1 (HIV-1). The 
generation of a lentiviral vector requires three plasmids, the first contains the viral genes in 
trans such as Gag-Pol and rev which encode regulatory proteins required for packaging, 
replication and transduction. The second plasmid is called the envelop plasmid and contains 
pseudotyped viral particles, the Vesicular Stomatitis Virus (VSV-G) envelope gene, encoding 
for the glycoprotein VSV-G an envelope protein which is incorporated into the viral membrane 
and allows transduction in a plethora of different cells. The third plasmid is known as the 
transfer plasmid and contains the gene of interest aimed for packaging, reverse transcription 
and integration. Transfer vector also contains a rev responsive element (RRE) which 
increases the viral titre as it enhances the nuclear export of unspliced viral genomic RNA. The 
plasmids should be co-transfected in a pseudoviral particle producer cell line for increased 
titre of pseudoviral particles such as HEK293T cells which express SV40 large antigen and 
increases the protein expression from plasmids containing SV40 as replication origin (Figure 
5.2) (Zufferey et al. 1999; Stone et al. 2000; Zennou et al. 2000; Kay et al. 2001).  
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Figure 5.2 The principles of lentiviral generation and infection. Packaging, envelope and 
transfer plasmids are required for the generation of an active lentivirus on cell lines, such as 
HEK293T, capable of producing high titre pseudoviral particles.  
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5.1.8 ΑΙΜ 
PLCβ1 protein has been found to be involved in numerous cancers and is capable of altering 
the cell cycle progression. In this study, patients carrying the PLCβ1 InDel had increased 
PLCβ1 transcript levels with a high prevalence of transition from Multinodular Goiters to 
papillary thyroid cancer. Therefore the impact of alterations of PLCβ1 transcript levels on cell 
proliferation were investigated with the use of siRNA and lentiviral vectors for knockdown and 
overexpression respectively (Figure 5.3).  
 
 
 
Figure 5.3 Aims of the chapter. The aim of this project was to characterise the role of PLCβ1 
in cell proliferation. Initially, doubling time in TSH growth dependent FRTL-5 cells was 
estimated and then again following PLCβ1 knockdown with siRNA. Overexpression of PLCβ1 
was attempted with the generation of active lentiviral vectors.  
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5.2 Materials and Methods 
5.2.1 Cell culture of FRTL5 
FRTL5 rat thyroid cells were kindly provided by Prof. Wynford- Thomas. The glycerol stocks 
were defrosted following 2 minutes incubation at 37 ᵒC and mixed with 7ml of preheated 
HAMF’S F12 (Lonza Uk). Cells were then centrifuged at 1000rpm for 5 minutes and 
supernatant was discarded. Pelleted cells were resuspended with 7ml of 5 hormone (5H) 
medium (HAM’S F12(Lonza UK) with 5% bovine calf serum (BCS)(EU approved), 100U/ml 
potassium penicillin, 100μg/ml streptomycin sulphate (Lonza UK), 10mu/ml bovine TSH, 10nM 
Hydrocortisone, 10μg/ml Insulin, 5g/ml Transferrin and 45μg/ml Ascorbic acid)(Sigma–Aldrich 
UK). Cells grown at 37 ᵒC and 5% CO2 incubator.  
 
5.2.2 Trypsinisation and Cryopreservation. 
The passaging and cryopreservation of FRTL-5 cells was performed as described in (Chapter 
4). The medium requirements for cell growth for FRTL-5 is the 5H culture medium which was 
described above.  
 
5.2.3 Doubling Time estimation 
Assessment of the doubling time was performed using FRTL5 cells grown in 5H and 4H (no 
bovine TSH). More specifically 10,000 cells were plated in duplicates in a 24 well plate 
(Thermo Scientific UK) and cultured in 5H and 4H medium for 9 days. Cell counting was 
performed on days 3, 5, 7, and 9 using an automated cell counter (Nexcelom Bioscience 
Cellometer Auto T4) (described in 5.2.5).  
 
5.2.4 SiRNA knockdown 
24h prior to transfection, FRTL-5 cells were trypsinised as described in (Chapter 4). FRTL5 
cells were counted with the use of an automated cell counter (Nexcelom Bioscience 
Cellometer Auto T4) and 60,000 cells were plated in each well of a 12 well plate (Thermo 
Scientific UK).  The cells were grown at 37 ᵒC and 5%CO2 incubator overnight. The following 
day the cells were transfected with 40nM of SiRNA or scrambled SiRNA (Santa Cruz) (Table 
5.1). The SiRNAs were mixed with 50 μl of serum and antibiotic free medium HAM’S F12 
122 
 
(Lonza UK) (Figure 5.4). The Viafect (Promega UK) transfection reagent was mixed with 100μl 
of serum and antibiotic free medium for each of the SiRNA samples with ratio (Viafect reagent: 
DNA – 3:1). The samples were incubated at room temperature for 5 minutes and then the 50 
μl of siRNA and scrambled siRNA were mixed with a 100μl of transfection reagent mix and 
incubated for 15 minutes at room temperature. The siRNA- transfection reagent complex was 
then added to the cells drop-wise with serum antibiotic free medium up to 250μl for 3 hours at 
37 ᵒC, 5% CO2. 5H medium was added up to 500μl to each well and incubated for 48h at 
37ᵒC, 5% CO2 then it was replaced by 500ml of fresh 5H medium. Cell counting and cell lysis 
were performed at 24h, 48h, and 72h post transfection (Figure 5.4).  The PLCβ1 siRNA 
cleaves PLCβ1 in three different positions (Table 5.1). 
 
Table 5.1 PLCβ1 siRNA is cleaving PLCβ1 mRNA in three different positions.  
 Sense Antisense 
sc-270424A: GAAGAGCCAAUUGUAUUCAtt UGAAUACAAUUGGCUCUUCtt 
sc-270424B: CAGAGAUGAUCCGAUCAUAtt UAUGAUCGGAUCAUCUCUGtt 
sc-270424C: GAACUCCAUCGGACUCUAAtt UUAGAGUCCGAUGGAGUUCtt 
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Figure 5.4 SiRNA treatment for PLCβ1 knockdown. FRTL-5 cells were treated with PLCβ1 
siRNA and cell proliferation was assessed at 24, 48 and 72 hours post transfection.  
 
5.2.5 Cell counting and Cell Lysis 
Following trypsinization cells were centrifuged at 3000 rpm for 1 minute and supernatant was 
discarded. Pellet was resuspended in 100μl of HAMF’S F12 (Lonza UK) and 20μl were loaded 
into the cell counting chamber and cell number was estimated with the use of an automated 
cell counter. The remaining cells from the same well were lysed following the addition of 500μl 
of TRI reagent (Sigma- Aldrich UK) and stored at -80ᵒC.  
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5.2.6 mRNA extraction  
Isolation of the total mRNA was performed according to the manufacturer’s protocol (Sigma –
Aldrich UK). The lysed cells stored at -80 ᵒC were defrosted at room temperature and then, 
0.2ml chloroform per ml of TRI reagent were mixed and incubated at room temperature for 15 
minutes. The samples were then centrifuged at 13,000rpm at 4ᵒC. The top aqueous solution 
was transferred to a fresh 1.5ml Eppendorf tube and mixed with 0.5ml isopropanol (Fisher 
Scientific) per ml of TRI reagent were mixed and incubated at room temperature for 10 
minutes. The mix was centrifuged at 13,000rpm for 10 minutes at 4ᵒC. Supernatant was 
removed and the pellet was washed with 1ml of 75% ethanol per ml of TRI (Sigma) reagent. 
The mix was vortexed and centrifuged at 8,000 rpm for 5 minutes at 4ᵒC. Supernatant was 
discarded and the pellet was briefly air dried and resuspended in 10μl of deionised water. RNA 
was quantified with Nanodrop-Lite (Thermo Scientific). 
 
5.2.7 cDNA synthesis 
A total volume of 6μl was prepared consisting of 1μg of RNA and distilled water up to 6μl. The 
mix was incubated at 60 ᵒ C for 10 minutes following incubation on ice for 5 minutes.  RNA was 
then mixed with 4μl of M-MLV RT 5x buffer, 0.5μg/μl oligo(dT)-15 primer, 1mM of dNTPs 
(10mM each). The mix was vortexed and then mixed with 200units of M-MLV reverse 
transcriptase and 20units of recombinant RNasin®-Ribonuclease inhibitor. The total of 20μl 
reaction was centrifuged and placed into a thermocycler (Techne TC-512) at 37ᵒC for 1 hour, 
at 95 ᵒC for 5 minutes and then hold at 4 ᵒC. All reagents were acquired from (Promega UK). 
 
5.2.8 PLCβ1 primer selection  
A number of primers were designed but failed to amplify the rat PLCβ1 product. Therefore, 
primers cited in peer reviewed journals for either rat or mouse PLCβ1 were used for 
amplification optimisation (Table 5.2); primers for a rat β-actin housekeeping gene (kindly 
provided by Dr. Zhang) were used as a positive control. 
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Table 5.2 List of primers. A number of primers from studies where successful amplification 
of PLCβ1 was achieved in peer reviewed journals were selected and altered accordingly for 
rat PLCβ1 gene.  
Primer 
Reference 
Forward Primer Reverse Primer Product 
Size (bp) 
Exon
s 
Dwivedi et 
al. 2005 
TTTTCGGCAGACCGGAA
GGCA 
TGCTGTTGGGCTCGTAC
TTCT 
315 6-8 
Ballester et 
al. 2004 
CCACGTGAAACCAGGA
CAAC 
ACGCTCTGAATCAGATC
CTCTGT 
149 22-23 
Tvent et al. 
2014 
CAGAAGTAGAGGCGCA
GACC 
CTCGGTGGTTTTCTTGT
GGT 
127 23-24 
Watkins 
and Sinclair 
2014 
TGGATGAGAAGCCCAA
GC 
GGCAGTCTTTTGAACTT
GTC 
67 29-30 
β-actin  TGTCACCAACTGGGAC
GATA 
GGGGTGTTGAAGGTCT
CAAA 
165  
 
 
5.2.9 qPCR and Densitometry analysis 
PLCβ1 transcript levels were quantified by qPCR and also semi-quantitatively following gel 
electrophoresis and densitometry analysis. QPCR reaction included 1μl of cDNA, 12.5μl of 2x 
SyBR Green master qPCR mix (Invitrogen), 10μM primer stock and distilled water up to 25μl. 
Reaction cDNA included SiRNA (Santa Cruz), Scrambled-SiRNA (Santa Cruz), Control 
samples and a standard curve of PLCβ1(1.1x109 , 1.1x108 , 1.1x107 , 1.1x106 , 1.1x105 , 
1.1x104 , 1.1x103 copies) and β-actin (1.4x109 , 1.4x108 , 1.4x107 , 1.4x107 , 1.4x106 , 1.4x105 
, 1.4x104 , 1.4x103 copies). The β-actin housekeeping gene was included in this study as 
internal control for normalisation of the qPCR quantitation as housekeeping genes have the 
same mRNA expression levels in all cells. The PLCβ1 silencing and ablation of PLCβ1 
transcript levels resulted in generation of primer dimers during qPCR amplification due to the 
lack of specific DNA template, thus qPCR quantification could not be performed. Amplified 
samples were then loaded into a 2% agarose gel followed by gel electrophoresis (90V for 
40minutes) as described in Chapter 2 and knockdown of PLCβ1 was confirmed with 
densitometry analysis with AlphaImager HP software.  
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5.2.10 Preparation of Lentivirus 
5.2.10.1 Lentivirus preparation plasmids 
Lentivirus preparation plasmids which included packaging, envelope plasmids and plasmids 
for GFP, PLCβ1a and PLCβ1b expression were kindly provided by Dr. Roberta Fiume from 
the University of Bologna. Also, active GFP lentivirus supernatant and Lentivirus packaging 
system with plasmid expressing GFP has been provided by Dr. Richard Darley from the 
University of Cardiff as a positive control (Table 5.3).  
 
Table 5.3 List of vectors acquired from the collaborators from Cardiff and Bologna 
University 
 
 
5.2.10.2 Generation of Lentivirus 
The cells required for the generation of lentivirus were the HEK293T cells which were grown 
in (DMEM -4.5g/L glucose, L- glutamine without sodium pyruvate, 100U/ml potassium 
penicillin, 100μg/ml streptomycin sulphate, 1mM sodium pyruvate, 10μg/ml bovine insulin and 
10% heat-inactivated foetal calf serum (FCS) (EU approved) (Lonza UK) at 37 ᵒC in 5% CO2 
incubator. The cells were passaged as described in Chapter 4.  
72 hours prior to the start of transfection, HEK293T cells were seeded at 4x 106 cells in 75cm2 
flask (Nunc). Prior to the initiation of the experiment, flasks were coated with 2m of Poly-L-
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lysine and allowed to stand for 30 minutes at temperature following rinsing with PBS. Then 
4x106 HEK cells were added to the 75cm2 flask and incubated overnight at 37ᵒC. The following 
day the medium was replaced with fresh Dulbecco’s Modified Eagle’s Medium (DMEM) with 
4.5g/L Glucose, L-Glutamine without Na Pyruvate with 10% FCS (EU approved) and 100U/ml 
potassium penicillin, 100μg/ml streptomycin sulphate (Lonza UK).  The various components 
required to generate a lentivirus (8μg of envelope plasmid, 15μg of packaging plasmid), 20μg 
of transfer vector, 2.5M of CaCl2, and 350μl of sterile H2O) were mixed in a falcon tube. Then 
450μl of 2x HEPES-buffered saline (HeBs) (12Mm Dextrose, 50Mm HEPES, 10Mm KCl, 
280Mm NaCl, 1.5Mm Na2PO4, pH 7) solution is added to the mix dropwise while bubbling the 
solution with a stripette following brief vortex (supernatant of active GFP lentivirus and 
plasmids and reagents for the generation of active GFP lentivirus were kindly provided from 
Dr. Darley). The precipitate was incubated for 20 minutes at room temperature. Approximately 
5 minutes prior to the transfection 25mM of stock chloroquine was added to the cells. The 
resulting precipitate was then added to cells and incubated at 37ᵒC overnight. The following 
day the medium was changed with fresh DMEM with 10% FCS and 100U/ml potassium 
penicillin, 100μg/ml streptomycin sulphate (Lonza UK) and incubated at 37ᵒC overnight. The 
following day the virus particles were harvested by removing supernatant which was frozen in 
liquid nitrogen and stored at -190 ᵒC. The medium was replaced in cells and incubated at 37ᵒC 
overnight. The following day the viruses were harvested for a final time.   
 
5.2.10.3 Spinoculation  
FRTL-5 cells were trypsinised as described in (Chapter 4) with 1x106 cells being concentred 
in 100μl of medium. Then 900μl of 1:5 diluted virus supernatant was mixed with 100μl of cells 
and 10μl of 0.5mg/ml polybrene (Sigma-Aldrich UK). The mix was loaded into the designated 
well of a 6 well plate (Thermo Scientific UK) and centrifuged at 2200 rpm for 30minutes at 
room temperature. Following the centrifugation each well was filled with 1ml of complete 
medium. The cells were incubated at 37ᵒC and 5% of CO2 overnight. Initial experiments used 
control GFP lentivirus supernatant provided by Dr. Darley.  
Plasmids provided by our collaborators from Bologna along with the plasmids from Cardiff 
were used to generate active GFP lentivirus in HEK293T cells. Generated viruses were 
compared for their efficiency following transduction of FRLT-5 cells and assessment for light 
emission following excitation at 488nm with an Argon laser of Leica SP5 microsystems 
confocal microscope. (The microscope imaging was performed by Prof. Hallett). 
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5.3 Results 
5.3.1 FRTL5 Doubling time estimation  
FRTL-5 cells are TSH growth dependent, therefore the doubling time of this cell line was 
estimated following growth in 4H and 5H culture medium for 9 days. The lack of TSH in the 
culture had a detrimental effect on the cell proliferation as cell number remained almost stable 
(Figure 5.5). On the other hand, TSH seemed to have a dose dependent effect on FRTL5 as 
seen a low dose of 1mu/ml and a high-recommended dose of 10mu/ml were used for cell 
treatment (Figure 5.5). An initial drop in cell number was observed at the first cell counting in 
day 3 post cell plating. Cell death was caused potentially during the plating process and due 
to stressing condition in culture without or low TSH which is essential for FRTL5 cell growth. 
Estimation of the doubling time illustrated that cells in optimal condition require approximately 
72hours to divide. On the other hand, lack or low concentration of TSH resulted in ablation of 
cell growth with cells requiring about 21 days and 12.6 days for division respectively (Figure 
5.5 and 5.6). The cell proliferation and doubling time was estimated as the average of two 
experiments. Also, lack of TSH affected the morphology of the cells as they are unable to form 
monolayers (Figure 5.7). 
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Figure 5.5  Cell proliferation of TSH growth dependent FRTL-5 cells. The cells were grown 
in 4H medium and 5H medium with 2 different TSH concentrations for 9 days. The data 
illustrated are the average of the measurements of two experiments both performed in 
duplicate. Statistical analysis used one way ANOVA comparison. The difference between the 
10mu/ml of TSH and no TSH was significant p<0.05 (* represents p<0.05 and **p<0.001). 
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Figure 5.6 Doubling time estimation of TSH growth dependent FRTL-5 cells. Two 
different bovine TSH concentration were used for FRTL-5 treatment, which are TSH growth 
dependent. Measurements were taken every 3 days during a 9 day assay where cells have 
shown a dose dependent response to TSH. Representative of two experiments. Statistical 
analysis used one way ANOVA comparison. The difference of 10mu/ml compared to no TSH 
was significant P<001 (* represents p<0.05 and **p<0.001). 
 
131 
 
 
Figure 5.7 Lack of TSH abolishes cell proliferation and formation of monolayer.  (a c) 
Cells treated with TSH seemed to be evenly distributed within the plate and display 
characteristic ‘cobblestone’ morphology. (b, d) in contrast with the cells without TSH which 
were found to form clusters and be tightly packed with a characteristic rounding shape. 
 
5.3.2 SiRNA knockdown of PLCβ1 in FRTL-5 cells 
5.3.2.1 Quantitative analysis 
Equal numbers of FRTL-5 cells were plated and treated with PLCβ1, SiRNA, a scrambled 
SiRNA and a control untreated sample. SiRNA knocks down PLCβ1 by cleavage of the mRNA 
in three different positions. The level of PLCβ1 SiRNA silencing was estimated semi-
quantitatively as the complete silencing of the gene caused primer dimer formation due to the 
lack of presence of a primer specific DNA template. Therefore, it was not possible to perform 
an accurate measurement with qPCR-Ct (Figure 5.8). Thus, the qPCR products were loaded 
into an agarose gel and densitometry analysis of amplified products was performed.   
 
b 
c d 
a 
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Figure 5.8 Quantitative analysis with qPCR Ct values could not be performed due to the 
presence of primer dimers. A) qPCR amplified products of SiRNA and Scrambled RNA 
treated cells. b) The qPCR amplification curve illustrating both SiRNA and Scrambled SiRNA 
treated cells with an almost identical Ct value of 29 cycles. c) The dissociation curve from cells 
treated with SIRNA, described in a) and b) illustrate the presence of a primer dimer interfering 
with the Ct value in b. d). The dissociation curve from cells treated with Scrambled SiRNA 
illustrating amplification of PLCβ1 gene.  
 
5.3.2.2 Densitometry analysis  
The successful gene silencing was unable to be quantified with qPCR as explained above 
therefore, qPCR products were evaluated by densitometry analysis. The amplified cDNA 
products confirmed the silencing of PLCβ1 gene as shown in (Figure 5.9).  The estimation of 
PLCβ1 knockdown on cell proliferation revealed that ablation of PLCβ1 gene delayed cell 
proliferation (Figure 5.10). The cells treated with Scrambled SiRNA illustrated some delay in 
cell proliferation compared to untreated cells as transfection reagents are often cytotoxic 
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affecting cell proliferation rate. The highest delay in cell proliferation was observed at 72 hours 
post transfection as FRTL-5 cells in this project have a doubling time of approximately 71 
hours thus, the effect of PLCβ1 knockdown at that time point was more prominent. The 
reduction of cell number following PLCβ1 SiRNA treatment illustrated 11%, 6% and 20% 
reduction at 24 hours, 48hours and 72hours post transfection time points respectively in 
comparison with the scrambled SiRNA control cells (Figure 5.10). The successful knockdown 
of PLCβ1 was confirmed by densitometry assay with levels of PLCβ1 found to be completely 
depleted (Figure 5.9b). 
 
Figure 5.9 Confirmation of PLCβ1 knockdown with densitometry analysis. a) Amplified 
cDNA from cells treated with SiRNA (Si) and Scrambled SiRNA (Scr) using primers for β actin 
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(165bp) and PLCβ1 (127bp) confirmed the knockdown of PLCβ1 transcripts. b) The 
densitometry analysis of the agarose gel a) has provided a semi-quantitative measurement of 
PLCβ1 knockdown. Statistical analysis used one way ANOVA comparison. The difference 
between siRNA PLCβ1 and Scrambled Control was significant P<0.05 (* represents p<0.05). 
 
Figure 5.10 SiRNA knockdown of PLCβ1 and assessment of cell proliferation and 
doubling time. FRTL-5 cells following PLCβ1 knockdown were counted at 24, 48 and 72 
hours post transfection. Cell number of FRTL-5 cells was estimated between 48 and 72 hours 
post transfection. Cell proliferation was decreased from 6% to 20% between 48h to 72h post 
transfection. The data illustrate the average measurement of three experiments performed in 
duplicate. Statistical analysis used one way ANOVA and the difference between 24h siRNA 
knockdown and the 72h scrambled siRNA treated cells was significant P<0.05 (* represents 
p<0.05). 
 
5.3.2.3 Generation of active GFP lentivirus  
Initially, generation of active GFP lentivirus was performed with the lentiviral set from Cardiff 
(Positive GFP virus) to successfully generate the virus in HEK293T cells (Figure 5.11) and 
transduce FRTL-5 cells with characteristic GFP light under the confocal microscope (Figure 
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5.12). On the other hand, the other set of plasmids from Dr. Roberta Fiume (Test GFP 
Lentivirus) (Table 5.3) was unable to generate the virus (Figure 5.11, 5.12). A direct 
transfection of the PLCβ1 expression plasmids into the FRTL-5 cells was attempted without 
success. The plasmids acquired from Dr. Roberta Fiume contained the PLCβ1 expression 
plasmids therefore, due to the inability to generate active lentivirus from the plasmids provided, 
overexpression of PLCβ1 could not be performed. 
 
Figure 5.11 Active lentivirus generation. The lentiviral generation kit provided from (Cardiff 
collaborators) (Positive GFP virus) had successfully generated active GFP lentivirus using 
HEK293T cells. However, the second lentiviral generation kit (Dr. Fiume) (Test GFP virus) 
was unable to generate active lentivirus.  
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Figure 5.12 Infection of active lentivirus expressing GFP on FRTL-5 cells. Active 
lentivirus (Cardiff) (Positive GFP virus) generated from HEK293T cells expressing GFP was 
used for transduction of FRTL-5 cells. On the other hand, the second lentivirus (Dr. Fiume) 
(Test GFP virus) generation kit with was unable to generate active lentivirus. 
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5.4 Discussion  
The ATAA InDel at the 3rd large intron of PLCβ1 gene has been found to affect a family with 
individuals suffering from MNG and with high prevalence of progression to papillary thyroid 
cancer. Following thyroidectomy of the papillary thyroid patients and mRNA extraction from 
their thyroid tissue, it was revealed that PLCβ1 transcript levels were significantly higher (up 
to 3 fold) compared with healthy patients who do not harbour the PLCβ1 InDel.  
FRTL-5 cells are one of the most popular models for thyroid cell study as they share common 
characteristics with thyroid follicular cells. They are growing in monolayers and are relatively 
easy to be transfected. However they illustrate very high doubling time as they divide 
approximately every 3 days which may be a drawback for SiRNA experiments as their effect 
weakens with time.  
In this chapter, in vivo studies have been conducted to investigate the impact of a potential 
alteration of PLCβ1 on cell proliferation. Depletion of PLCβ1 transcript levels led to a 
significant reduction in cell proliferation which agrees with the hypothesis that elevated PLCβ1 
transcript levels due to the PLCβ1 InDel could trigger benign proliferation in affected patients. 
SiRNA technology was used for PLCβ1 knockdown on FRTL-5 cells and cell proliferation was 
assessed every 24h in a 72h treatment study. Complete depletion of PLCβ1 levels were 
confirmed with a considerable reduction on cell proliferation of approximately 11% at 24 hours, 
6% at 48 hours and a 20% reduction at 72hours. The quantitation of PLCβ1 knockdown was 
performed semi-quantitatively using agarose gel electrophoresis and densitometry analysis, 
as qPCR –Ct value quantitation could not be performed due to the presence of primer dimers 
as PLCβ1 transcript levels were depleted. The absence of DNA template allowed the 
generation of primer dimers during the qPCR amplification which in turn interfere with the 
resulting Ct value. Thus a gel electrophoresis of the amplified products has clearly 
demonstrated the knockdown of PLCβ1 transcript levels.  
Previous studies by Dr. Lei Zhang and Dr. Fiona Grennan Jones (unpublished data) have 
shown that overexpression of PLCβ1 causes an overexpression of D3 and cdk4 complex 
which in turn phosphorylates the tumour suppressor, retinoblastoma protein (pRb). The 
phosphorylation of pRb then causes the release of the E2F family proteins which are essential 
for the progression from G1 to S phase. Also, additional evidence indicated that 
overexpression of PLCβ1 prevents cell death due to oxidative stress as it suppresses 
apoptotic genes such as c-fos. That domino effect caused by the alteration of PLCβ1 transcript 
levels indicate its key role in cell proliferation and the possibility that depleted PLCβ1 transcript 
levels may result in cell arrest at G1 phase unable to progress to S phase and eventually 
leading to apoptosis thus explaining the significantly high reduction at the 72h interval.  
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Overexpression of PLCβ1 with the generation of lentiviral expression vector was attempted 
with plasmids for the generation of active lentivirus expressing GFP and PLCβ1 being 
provided from two different collaborators. The GFP lentiviral packaging system was found to 
be functional with active GFP lentivirus being generated.  On the other hand, the plasmid 
system provided from the second collaborator for the generation of GFP and PLCβ1 lentivirus 
was unable to generate active lentivirus (Figure 5.11, 5.12). Direct transfection of FRTL-5 cells 
with the PLCβ1 expression plasmids was also unsuccessfully attempted. Therefore, 
overexpression of PLCβ1 on FRTL-5 cells could not be assessed and is considered as a 
potential future experiment for complete investigation of the role of PLCβ1 on cell proliferation. 
  
 
 
 
 
 
 
 
Chapter 6. In Depth Investigation Of The 
High-LOD Score Chr 20 Region Using 
Next Generation Sequencing. 
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6.1 Introduction  
6.1.1 Next Generation Sequencing 
The first forefathers of next generation sequencing were developed during the 1970s involving 
chain termination and fragmentation protocols. The chain termination which was developed 
by Sanger and colleagues proved to be less laborious in comparison with the fragmentation 
protocol where a number of toxic chemicals and radioisotopes were used, establishing Sanger 
sequencing as the foundation protocol for DNA sequencing until the beginning of 21st century 
(van Dijk et al. 2014).  
 
6.1.1.1 Sanger sequencing 
Sanger sequencing was the first generation sequencing technology with which the sequencing 
of the entire human genome was achieved at the end of 2004 (van Dijk et al. 2014). The 
principle of Sanger sequencing is based on the activity of DNA polymerase to synthesize 
complementary DNA. The reaction requires dNTPS and ddNTPs. Each time a ddNTP has 
been incorporated the synthesis reaction is terminated generating fragments of different sizes. 
The ddNTPs are attached to different fluorescent dyes (originally P32 labelling was used) 
allowing the identification of the individual incorporated base (Morozova and Marra 2008).The 
use of ddNTPs was vital as they contain a 3’H instead of 3’ OH, the lack of a hydroxyl group 
at the 3’ end is responsible for the termination of the further elongation of the chain following 
the incorporation of a ddNTP. The different size fragments generated are identified with the 
use of a high-resolution polyacrylamide gel electrophoresis and laser excitation (Russell 2002; 
Primrose et al. 2003; Shendure and Ji 2008) (Figure 6.1).  
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Figure 6.1 The principles of Sanger sequencing. The Sanger sequencing technology was 
the first sequencing technique achieving read lengths up to 1000bp. Each time a ddNTP is 
incorporated the chain is terminated and the nucleotide is identified by high resolution gel 
electrophoresis and laser excitation.  
 
6.1.1.2 454 Pyrosequencing 
The first among the next generation sequencing techniques was the 454 pyrosequencing, 
released in 2005 by Life Sciences. The technology utilises streptavidin beads bound to primers 
at one end and DNA fragments bound at the other end of the primers. Each streptavidin 
contains a single DNA fragment and thus following emulsion PCR each bead is bound to 
approximately 107 copies of the initial DNA fragment (Morozova and Marra 2008; Zhou et al. 
2010). The enriched beads are then inserted into a picotitre plate where each well contains a 
single bead. The use of the picotitre plate offers the advantage of conducting simultaneous 
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pyrosequencing reactions generating high throughput results relatively fast (Mardis 2008; 
Morozova and Marra 2008). In the pyrosequencing reaction individual dNTPs are added 
sequentially and upon every nucleotide incorporation there is a release of pyrophosphate 
generating detectable light. The release of pyrophosphate is proportional to the amount of 
dNTPs incorporated each time. Following the pyrophosphate release the latter is converted 
into ATP by ATP sulfurylase and in the presence of adenosine 5’ phosphorylase. The release 
of ATP is in turn responsible for the conversion of luciferin to oxyluciferin leading to generation 
of visible light (Shendure and Ji 2008; Ansorge 2009) (Figure 6.2).  The detected light forms 
a pyrogram where the DNA sequence can be determined (Morozova and Marra 2008). The 
technology generates long reads approximately 1kb in less than 24hours, however it is low 
throughput with high error rate in homopolymer-rich regions as excitation of repetition of the 
same base is in general difficult to discriminate. The technology will no longer be supported 
by Life Sciences by the middle of 2016 (van Dijk et al. 2014).  
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Figure 6.2 The principles of 454 pyrosequencing. 454 pyrosequencing is the first next 
generation sequencing technology based on a ‘sequencing by synthesis’ principle utilising 
light excitation detection for identification of incorporated nucleotides. 
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6.1.1.3 Illumina Solexa sequencing 
Illumina Solexa sequencing technology was introduced in 2007 and is also a sequencing by 
synthesis based technology. The DNA fragments are bound at one end onto a solid surface 
which is coated with adapters with which the free end of the DNA fragment binds, due to 
complementarity forming a bridge (van Dijk et al. 2014). Solid phase amplification of these 
DNA fragments and denaturation generates a flow cell where each lane contains primers 
complementary to those on the DNA library (Figure 6.3). The sequencing occurs with the use 
of reversible terminators (Mardis 2008). The reversible terminators are equipped with four 
ddNTPs with cleavable fluorescent dyes. The synthesis is performed a base at a time with the 
detectable light being captured by a charge coupled device. The synthesis cycle is then 
repeated as both the terminator group and fluorescent label are removed (Shendure and Ji 
2008; Ansorge 2009; Zhou et al. 2010; Liu et al. 2012). The technology is the most popular 
current approach for next generation sequencing offering high compatibility, it has the highest 
throughput with read length reaching up to 300bp. On the other hand it is more laborious than 
the other technologies with high error accumulation rate in elongated DNA strands (Zhou et 
al. 2010; van Dijk et al. 2014).  
 
Figure 6.3 The principles of Illumina Solexa sequencing. Illumina Solexa technology is a 
‘sequencing by synthesis’ technology where DNA is bound at one end to a solid surface while 
the other is binding to a complementary adapter forming a bridge. The bridge formation 
initiates the chain synthesis. Figure adapted from (Metzker 2010). 
 
144 
 
6.1.1.4 Supported oligonucleotide ligation and detection (SOLiD) 
Supported oligonucleotide ligation and detection (SOLiD) was developed by Applied 
Biosciences in 2006 and is based on a two base ligation sequencing system. The DNA 
fragments is bound at its 5’ end with an adapter where in turn a universal sequencing primer 
is hybridized. Octamers compete for their ligation to primers (Shendure and Ji 2008; Metzker 
2010). The position one and two are designed to be interrogated and in position five there is 
a cleavage site as nucleotides five and six are bound with phosphorothiolate linkage which is 
cleaved by silver ions. The dinucleotides for the first and second position are labelled with four 
different fluorescent dyes enabling interrogation of 16 dinucleotides with the use of four 
different dyes. The process is repeated 10 times using a primer one base shorter (n-1) each 
time (Figure 6.4). SOLiD technology has the lowest error rate of all current technologies 
exhibiting approximately 99.95% accuracy, but the run is long lasting up to 14 days and the 
read length is relatively short at up to 75 base pairs (Liu et al. 2012; van Dijk et al. 2014). 
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Figure 6.4 The principles of SOLiD sequencing. SOLiD sequencing is based on a two base 
ligation sequencing system. a) Octamers compete for binding next to the primer with the first 
two nucleotides to be designed for investigation. Following incorporation there is a cleavage 
site between position 5 and 6.  b)The process is repeated 10 times each time with a primer 1 
base shorter. Figure adapted from (Metzker 2010). 
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6.1.1.5 Semiconductor sequencing-Ion Torrent 
Ion Torrent technology which is the sequencing method that was used in this chapter, is a 
relatively new advancement in next generation sequencing with the Personal genome 
analyser recently released in 2010. The technology is based on the 454 pyrosequencing 
principle with the innovation of being independent of light detection for the identification of 
incorporated nucleotides (van Dijk et al. 2014). In Ion Torrent sequencing DNA libraries are 
mixed in equal molarity with small beads following emulsion PCR. The beads contain specific 
sequences on their surface which are complementary to specific adapters. The DNA libraries 
are ligated to specific adapters and following the mix, each bead is bound to a different DNA 
library. Enriched beads are primed and placed into an Ion Chip which contains pH detection 
wells (Mardis 2008; Liu et al. 2012). Each bead is deposited into each well and following the 
incorporation of any nucleotide by the polymerase a proton is released causing a change in 
pH which is in turn detected by a sensor in the well (Figure 5). The technology does not require 
light detection and read length can reach up to 400bp in only a few hours. On the other hand, 
it shares the major drawback of 454 pyrosequencing as it is based on the same principle, 
therefore it has a high error rate in detection of homopolymer repeats (Mardis 2008; van Dijk 
et al. 2014).  
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Figure 6.5 Semiconductor sequencing-Ion Torrent a) DNA library generation. Figure 
adapted from (Ion Torrent-Life Technologies), b) Incorporation of a nucleotide causes the 
release of a proton altering the pH. Small changes in pH are detected by sensors based in 
each well Figure adapted from (Rothberg et al. 2011). 
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6.1.1.6.1Ion Torrent platforms  
Personal Genome Machine (PGM) was the first sequencing platform released by Ion Torrent. 
It is a powerful platform generating up to 2Gb output data. It is the cheapest sequencing 
platform available in the market. The PGM chip contains more than 1 million micro-machined 
wells generating more than 5 million reads per run (Figure 6.6). In 2012, Ion Torrent has 
recently released the Ion Proton Sequencer which can generate up to 10Gb of output data. 
The Ion Proton chip is larger than the PGM chip and contains more than 165 million micro-
machined wells generating more than 80 million reads per run (Figure 6.6). Platform 
information was acquired from Ion Torrent, Life Technologies.  
 
 
Figure 6.6 Ion Torrent Chips. Information and Chip images were acquired from Ion Torrent 
Life Technologies. 
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6.1.1.7 Heliscope 
Heliscope is a third generation sequencing technology which uses the same principle as 
illumina sequencing without requirement of DNA amplification. Sheared DNA hybridizes to a 
flow cell surface coated with primers  (Thompson and Steinmann 2010). The primer extension 
and incorporation of labelled nucleotides generates visible light which is detected by a charge 
coupled device. Heliscope is a single molecule sequencing reaction which requires less 
material and doesn’t suffer from GC content and size biases due to amplification but loss of 
synchronicity can lead to error accumulation during DNA synthesis (Figure 6.7) (Shendure 
and Ji 2008; Ansorge 2009; Thompson and Steinmann 2010). 
 
Figure 6.7 The principles of Heliscope sequencing. Heliscope is a third generation 
sequencing technology known as a single molecule sequencing technique. a) Its principle is 
based on Illumina solexa sequencing as a DNA fragment binds to flow surface coated with 
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primers. b) Incorporated nucleotides are detected by a charge coupled device. Adapted from 
(Gupta 2008). 
 
6.1.2 Linkage analysis 
Linkage analysis is a routine approach for the identification of a chromosomal location of 
specific genes associated with certain disease. The analysis is based on the principle that 
genes of the same chromosome which are located close to each other, following meiosis they 
remain linked to each other. The generation of genetic maps based on linkage analysis has 
been the foundation for the mapping of disease related genes (Pulst 1999).  
 
6.1.3 Logarithm of the odds (LOD) score 
The mathematical estimation of the likelihood of linkage is measured by the logarithm of the 
odds (LOD) score. The LOD score is calculated as the probability of two linked loci to the 
probability that the loci are unlinked.  
LOD score=Z= log10 
𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑖𝑓 𝑡ℎ𝑒 𝑙𝑜𝑐𝑖 𝑎𝑟𝑒 𝑙𝑖𝑛𝑘𝑒𝑑 
𝐿𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑖𝑓 𝑡ℎ𝑒 𝑙𝑜𝑐𝑖 𝑎𝑟𝑒 𝑢𝑛𝑙𝑖𝑛𝑘𝑒𝑑
 
Linkage is generally accepted to be significant with LOD score of 3 when the study include 
100 to 300 markers.  LOD score of 3 is translated as 1000:1 ratio in favour of genetic linkage 
a with a p value of 0.05. On the other hand, LOD score less than -2 is be significant against 
genetic linkage (Pulst 1999).  
 
6.1.4 Parametric and Non-Parametric linkage analysis 
Parametric and non-parametric linkage analysis are the two main computational solutions 
providing two different models of analysis. The decision for the selection of the correct tool is 
important. That depend on the genetic model that is decided for the analysis. Parametric 
analysis is more powerful than non-parametric when the genetic model is close to the real 
mode of inheritance of the disease (Kruglyak et al. 1996; Strauch et al. 2000).  Parametric 
linkage analysis is a method based on a genetic model. It requires information such as gene 
frequency and penetrance parameters. However it can be misleading in cases of linkage 
model misspecification.  
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Non-parametric linkage analysis does not require a genetic model to operate and is 
considered essential for analysis of complex traits. It operates by evaluation of shared alleles 
between affected individuals independent from disease models (Liò and Morton 1997; Strauch 
et al. 2000; Dawn Teare and Barrett 2005).  
 
6.1.5 Multipoint and single point linkage analysis 
The most common linkage analysis method for linkage investigation in a small region with 
multiple markers is the multipoint linkage analysis. It is more powerful than the single point 
analysis when the identity by descent (IBD) is ambiguous as it utilises information from 
haplotypes from multiple markers in contrast to the single point analysis (Sullivan et al. 2003). 
However, multipoint analysis is sensitive to misspecification of distances between the markers 
in such small regions (Halpern and Whittemore 1999).  
Single point analysis is uses the locus of a known genetic marker and the locus of an unknown 
disease marker thus is also known as a two point linkage analysis. Every variant is evaluated 
individually reducing the sensitivity due to misspecifications. Therefore, it is often considered 
important that both analyses be performed (Halpern and Whittemore 1999; Strachan and 
Read 2011).  
 
6.1.6 MERLIN genetic linkage analysis software 
The software selected in this chapter for the non-parametric linkage analysis was MERLIN, 
which was devised by the University of Michigan. It is a software that doesn’t require 
knowledge of scripting, performing non parametric linkage analysis faster than any other 
software available on the market. It is considered an ideal solution for analysis of samples with 
large pedigrees due to its unique linear model for linkage analysis (Kong and Cox 1997; 
Dudbridge 2003; Neale et al. 2012).  
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6.1.7 Aim 
Genome wide linkage analysis performed by Dr. Bakhsh (unpublished data) has revealed that 
there is a high LOD score region on chromosome 20 which includes PLCβ1 InDel. The 
analysis in this chapter has focused on the exome of the chromosome 20 high LOD-score 
region using next generation sequencing (NGS). Exome sequencing analysis aimed either to 
identify other potential genetic variants which may be responsible for the disease or to confirm 
that the PLCβ1 InDel is solely responsible for the pathogenesis of the patients (Figure 6.8). 
The initial focus was on the family (18 patients) in which the InDel and its linkage with MNG 
progressing to PTC was first identified. I also investigated other European patients who carry 
the InDel (3 patients identified in chapter 4) and subjects from families having similar 
pathogenesis to the original family. Finally I applied NGS to the cohort of 80 patients with 
Multinodular Goitres, 4 of whom are known to be InDel heterozygotes. PLCβ1 InDel carriers, 
were screened by NGS.  
 
Figure 6.8 Aims of the chapter. Summary of the investigations for the identification of 
potential disease related variants across the high LOD score 10cM region.  
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6.2 Material and Methods 
 
 
Figure 6.9 Summary of the work flow in this chapter. Quality Control (QC control), ISPs 
(Ion Sphere Particles), PGM (Personal Genome Machine), MNG (Multinodular Goitre). Ion 
Torrent platform pictures were acquired from Life Technologies.  
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6.2.1 Primer Design  
The primer pools for the preparation of the DNA libraries were designed with the use of 
Ampliseq 3.0.1 software (https://ampliseq.com/) according to the manufacturer’s protocol. A 
total number of 429 primers were designed generating 100-300bp amplification products. The 
designed primer pools covered the exome sequences (all coding regions, intron/exon 
boundaries, proximal promoters and 3’ untranslated regions) of a region spanning from chr20: 
8113337 to 11907302. A complete list of the primers used for the DNA library generation can 
be found in Appendix. Primer design was performed by Dr. Mantripragada.  
 
6.2.2 Picogreen assay DNA quantitation  
Genomic DNA was extracted from whole blood (as described in Chapter 4) and quantified with 
Quant-iTTM PicoGreen® dsDNA Assay kit (Life Technologies). Genomic DNA was initially 
diluted 1:4 in 1x TE buffer and 2μl were transferred to a 96 well plate and made up to 100ul 
using Picogreen (Invitrogen) diluted (1:200) in 1x TE buffer. In addition to the genomic DNA 
samples, a series of DNA standards (Lambda DNA standard) were prepared for the standard 
curve (Table 6.1).  The plate was then loaded into the Fluoroskan Ascent fluorometer which 
measured absorbance between 485-538nm. Genomic DNA concentration was estimated with 
the use of the standard curve and the following formula (Fluorescence reading-c)/gradient)*Z, 
where c is the y-intercept and *Z the dilution factor.  
 
Table 6.1 Picogreen DNA standard concentrations  
Standard ng/μl 
1 75 
2 50 
3 25 
4 12.5 
5 6.25 
6 3.125 
7 1.5625 
8 0 
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6.2.3 Ion AmliSeq Library preparation  
6.2.3.1 PCR amplification of genomic DNA targets 
Approximately 10ng of the genomic DNA of interest and an AmpliSeq primer pool of 429 
primers were amplified in a 20μl reaction (Table 6.2). 
 
Table 6.2 PCR amplification of genomic DNA targets. a) AmpliSeq (Life Teechnologies) 
reaction mix b) Amplification programme  
 
 
6.2.3.2 Partially digestion of primer sequences and adapter ligation 
The primers of the amplified DNA samples were partially digested by the addition of 2μl of 
FuPa reagent (Life Technologies) and placed in the thermal cycler (Table 6.3a). In the 
meantime barcode/adapter mix was prepared and the partially digested primer DNA samples 
were then ligated with adapters and placed on the thermal cycler for the ligation reaction 
(Table 6.3b, c, and d).  
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Table 6.3. Primer digestion and Adapter ligation. a) Partial digestion of primer sequences, 
b) Adapter ligation mix, c) Barcode adapter mix, d) Adapter ligation reaction  
 
 
6.2.3.3 Purification of unamplified library 
DNA libraries were then purified using Agencourt AMPure XP beads (Beckman Coulter) at 
1.5X sample volume. DNA libraries were initially treated with 45μl of 1.5x Agencourt AMPure 
XP Reagent, they were mixed and incubated for 5 minutes at room temperature. A magnetic 
rack was then placed underneath the DNA library plate and incubated for 2 minutes until 
solution appeared clear as the beads were magnetised by the magnetic rack to the side of the 
tube. Washing steps were then followed by the addition of 150μl of 70% ethanol while the 
plate was on top of the magnetic rack. The beads were allowed to mix by moving the magnet 
side to side and then the supernatant was discarded and washing step was repeated for a 
second time and the samples were then allowed to air-dry for 5 minutes at room temperature. 
The plate was then removed from the magnet and DNA was eluted from the beads with the 
addition of 50μl of Low TE (Life technologies) per samples which were in turn prepared for 
qPCR quantification. A 100-fold dilution was prepared for each of the samples with nuclease 
free water (Life Technologies). Series of dilutions were also prepared from E.coli DH10B 
control library for the generation of a DNA standard curve in qPCR amplification (Table 6.4). 
Reaction mix in a total volume of 10μl was then prepared and loaded into a 96 well plate. All 
samples including DNA standards were in triplicates and loaded on the qPCR thermocycler 
(StepOne Applied Biosystems) for qPCR amplification (Table 6.4c). 
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Table 6.4. Quantification of DNA libraries. a) E.Coli DH10B DNA standard concentrations, 
b) Ion Library TaqMan qPCR mix, c) qPCR amplification programme  
 
6.2.4 Preparation of template-positive Ion PGM Template Ion Sphere particles  
Undiluted Ion AmpliSeq libraries were quantified with qPCR and based on the library 
concentration they were subsequently diluted with Low TE (Life technologies) to a final 
concentration of 100pM. Diluted libraries were then combined together. The library mix was 
then prepared for Emulsion PCR with Ion OneTouch 2 (Life Technologies). The preparation 
of the reaction mix (Table 6.5) was followed by the addition of 100μl of Ion PGM Template 
OT2 200 Ion Sphere particles. The mix was transferred to the Ion OneTouch Reaction tube 
which was filled with 1.5ml of Ion OneTouch Reaction Oil. The tubes were then placed on the 
Ion OneTouch 2 (Life Technologies) and emulsion PCR was performed.  
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Table 6.5 Emulsion PCR. a) Combining Ion AmpliSeq libraries, b) Emulsion PCR reaction 
mix 
 
 
6.2.5 Ion Sphere particles recovery 
The amplified product was collected from the Ion OneTouch and Ion OneTouch Recovery 
solution was removed leaving 50μl to avoid disturbance of the Ion Spheres.  The ISPs were 
then resuspended and following the addition of 1ml of Ion OneTouch wash solution, were 
centrifuged for 2.5 minutes at 15,500xg and all but 100ul of supernatant was discarded. All 
reagents were acquired from Life Technologies. 
 
6.2.6 Enrichment  
The entire template-positive ISP sample (100μl) was transferred to the first well of an 8 well 
strip, 130μl of Dynabeads MyOne Streptavidin C1 beads washed and resuspended according 
to the Ion PGM OT2 200 protocol (Appendix) were added to the second well (Figure 6.11). Ion 
one touch wash solution (300ul) was added to wells 3, 4 and 5. Melt Off solution (300μl) 
(125mM NaOH and 0.1% Tween 20) was added on well 7and wells 6 and 8 remained empty 
(Figure 6.10). The 8 well strip was placed at Ion OneTouch ES which was initialised and run 
according to the Ion PGM OT2 200 protocol. Once enrichment was completed the sample was 
centrifuged at 15,500 x g for 1.5 minutes and then supernatant was removed leaving 10μl of 
solution followed by the addition of 200μl of Ion OneTouch Wash Solution. A total of 10μl were 
transferred in a separate PCR tube for polyclonality assessment by Qubit 2.0 Fluorometry. All 
reagents were acquired from (Life Technologies). 
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Figure 6.10 Loading order of 8 well strip for ISP enrichment  
 
 
 
Figure 6.11 Enrichment of template-positive ISPs. The biotin attached at the end of DNA 
sequences binds to streptavidin on MyOne Beads which in turn are magnetised by a magnet.  
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6.2.7 Qubit 2.0 Fluorimetry 
ISPs were mixed with 19μl of Annealing Buffer, 1μl of Ion Probes and 20μl of Ion Probe Master 
Mix and placed in a thermocycler (Table 6.6). Quality Control Wash Buffer (200μl) was added 
and following a vortex the mix was centrifuged at 15,500 x g for 1.5 minutes. Supernatant was 
then removed leaving 10μl to avoid disturbing the pellet. The washing steps were repeated 
two times and then the pellet was resuspended in a total volume of 200μl of Quality Control 
Wash Buffer. The sample was then inserted into the Qubit fluorimeter for quality assessment. 
Reading were recorded for both Alexa Fluor 488 and 647. All reagents were acquired from 
(Life Technologies) 
 
Table 6.6. Annealing Ion probes programme  
 
 
 
 
6.2.8 Enriched template-positive ISPs preparation for PGM 
Control Ion sphere particles were briefly vortexed and centrifuged for 2 seconds then 5μl were 
added to the, enriched-template positive ISPs. The mix was centrifuged for 2 minutes at 
15,500xg then supernatant was removed leaving 15μl at the bottom of the tube. The pellet 
was resuspended by adding 12μl of sequencing primer. The total 27μl reaction mix was then 
placed in a thermo-cycler for 2 minutes at 95 ᵒC and then 2minutes at 37 ᵒC. 
The ISP reaction mix (27μl) was then transferred at room temperature where a 3μl of Ion PGM 
Sequencing 200 v2 Polymerase to the ISPs. The mix incubated at room temperature for 5 
minutes and then was ready for loading into the PGM Chip. The Ion 318TM Chip kit v2 was 
initialised and loaded as it was described at Ion 318TM Chip kit v2 User Guide, Appendix. 
 
6.2.9 Template-positive Ion PI Ion Sphere Particles for Proton 
Enriched template-positive ISPs were centrifuged at 15,500xg for 5 minutes. The supernatant 
was removed leaving 10μl at the bottom of the tube. The pellet was resuspended by adding 
15μl of Ion PI Annealing Buffer. Also 20μl of Ion PI Sequencing primer was added to mix in a 
 Temperature 
(ᵒC) 
Time 
Hold 50 2 min 
Hold 95 20 sec 
 
Cycle (40 
cycles) 
95 1 sec 
60 20 sec 
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total volume of 45μl. The mix was vortexed and placed in a thermos- cycler at 95ᵒC for 2 
minutes and then at 37ᵒC for 2 minutes. The ISPs were then placed at room temperature 
following the addition of 10μl of Ion PI loading buffer. The Ion PI Chip V2 was initialised and 
loaded as it was described at Ion PI Sequencing 200 kit v3 User Guide, Appendix.  
 
6.2.10 Calibration, Ion PI Chip loading and Sequencing run 
The sequencer was calibrated prior to the chip loading according to the manufacturer’s 
protocol (Appendix). The chip was then loaded, planned run was selected where each barcode 
was annotated for each sample. Once the predefined plan was selected, the sequencing run 
was performed. The sequencing data analysed by Ion Torrent Suite software (4.4.2), using 
the plug-in variant caller (v 4.2.10) and configuration with generic Personal Genome Machine 
(PGM) germ line settings and high stringency analysis mode. The output of the variant caller 
was analysed with Microsoft excel where a summary of each variant can be viewed and 
Integrative Genomics Viewer (IGV) where comprehensive details about the individual variant 
call can be assessed.  
 
6.2.11 Linkage analysis  
Merlin in order to operate requires three types of files a Pedigree, a Map and a Data file. The 
three files were created as it is described below and were converted into text files (tab 
delimited) so it can be uploaded in Merlin software and non-parametric linkage analysis to be 
performed.  
The results from the next generation sequencing of the original family were processed in an 
excel file. A table was prepared with a list of the total number of different SNPs raised from 
the sequencing and the calls for each allele for the different SNPs for each patient. The SNPs 
which were not present for some patients and therefore had no calls were considered to be 
homozygous for the wild type. The PedFile which was required for Merlin software and non-
parametric linkage analysis was prepared based on the excel file with the total list of different 
SNPs comprising the genotype for each patient. The new file included all the relevant 
information for each member of the family such as relation to each other, sex, disease status 
and genotype (Figure 6.12). Also for some patients only maternal SNPs were known as their 
father was not sequenced and therefore a dummy father was created where his genotype was 
illustrated as 0 0 for each SNPs. The genotype was then converted into number such as A, C, 
G, T to be 1, 2, 3, and 4 respectively (Figure 6.12).  
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Figure 6.12 The pedigree file. An example of a Pedigree file where the first 6 columns 
illustrate family ID, individual ID, father ID, mother ID, gender and disease status followed by 
with genotype information for each SNP. The highlighted column illustrates the individual ID 
of the members of the family as seen in the family tree.  
 
The second file that was required for Merlin software was the Map File. This file contained 
three columns including information regarding chromosome number, SNP name, and 
chromosomal position in centimorgan (cM) respectively, (Figure 6.13b).  
The third file is called Data File it contains a list with the total number of SNPs found in 
sequencing. The first row starts with the disease title and the last with Age (Figure 6.13a).  
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Figure 6.13 The data file. a) Data File with first row being the disease title (A) including a list 
of markers (M) and ending with Age (C) title. b) Map File consisted of three columns the first 
is the chromosome ID (chr20), the second SNP ID and the third cM position.  
 
6.2.11. 1 PedCheck anaylsis for Mendelian error identification  
PedCheck software has been used for the identification of potential Mendelian errors within 
the family. The analysis included 4 levels of assessment and revealed 4 inconsistencies 
across 181 SNPs. The inconsistencies were removed and the new file was used for Merlin 
analysis.  
 
6.2.11.2 Graphical Representation of Relationships (GRR) assessment.  
Potential labelling errors were investigated with the use of GRR software. The software 
performed an allele comparison between the individuals to show that relatives share also a 
pattern of alleles.  The pedigree file prepared for Merlin was also used for GRR analysis.  
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6.2.11.3 Non parametric linkage analysis 
The analysis was performed with the use of Merlin software. Merlin was downloaded from the 
University of Michigan centre of statistics. Analysis required three files, a pedigree file, a map 
file and a data file. A comprehensive list of the commands used for merlin can be found in 
Appendix. Merlin performed multipoint and singlepoint non parametric linkage analysis 
providing LOD score for the SNPs across the 10 cM region.  
 
6.2.14 Manual Haplotyping  
A comprehensive overview was performed by manual haplotyping. The process involved 
individual SNPs inheritance assessment from parents to children and identification of the 
disease-risk allele. Haplotyping can reveal chromosomal recombinations and in combination 
with Merlin indicates which part of the sequenced region is a potential disease region. 
 
6.2.15 Identification of potential disease SNPs 
6.2.15.1 Filtering Step  
The filtering steps of the potential disease variants included allele frequency identification with 
the use of University of California Santa Cruz human genome browser, as only rare variants 
less than 2% in the general population could be considered as disease related (Figure 6.14). 
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Figure 6.14 Summary of the variant identification filtering steps 
6.2.11.4 Raw data assessment 
The raw data were also assessed for potential presence of false negative variants. The raw 
data files were downloaded from the Ion Torrent server in IGV format and were viewed with 
use of IGV software a visualisation tool which allowed the comprehensive investigation of 
individual variant read depth in different calls. 
 
6.2.11.5 Sanger sequencing confirmation 
The identification of a single rare variant led to further investigation with Sanger sequencing 
for confirmation of true positives and true negatives from NGS results (as described in chapter 
2). Primers were designed that flank the region of the variant with the use of primer 3 software 
(http://primer3.ut.ee/) (Table 6.7).  
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Table 6.7 Primers designed for the identification of true and false positives.  
Primer 
Name 
Tm Sequence Tm Gene 
 
F1/R1 
 
64 
 
CACACTTAGCTCGCCATCAA/TTTTAAGCCGCCAAGTTTTG 
 
61 
Intron 
SNAP-
25 
 
 
6.11.6 Study of Health in Pomerania (SHIP) 
The Study of Health in Pomerania (SHIP) includes patients from the Pomerania region in East 
Germany which has shown particularly elevated mortality rate compared to West Germany. 
The lack of scientific studies has led to the necessity of the SHIP study. The aim of the study 
was the investigation of the prevalence of common diseases and disorder within this 
population. The first cohort recruited comprised from 4,308 patients the second from 3,300 
and a third cohort is currently being recruited (Völzke et al. 2011).   
The SHIP cohort of 986 patients was genotyped for the presence of ANKRD5 SNP. The cohort 
consisted of patients suffering from nodules and/or goitres and the analysis was kindly 
performed by Prof. Henry Völzke and Dr. Alexander Teumer. 
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6.3 Results 
 
6.3.1 Quality control  
6.3.1.1 TaqMan assay quantitation of Ion Torrent libraries 
Genomic DNA was initially quantified using of PicoGreen which stains only double stranded 
DNA as it is exhibits emission at 530nM excluding readings from single stranded DNA. The 
samples were quantified twice and the average of the two measurements were used for the 
library preparation (Figure 6.15). 
 
Figure 6.15 TaqMan quantitation. a) The concentration of genomic double stranded DNA 
was estimated (ng/μl) with the use of picogreen stain, b) DNA standards were used for 
standard curve and accurate calculation of genomic DNA concentration.  
 
 
 
 
 
 
 
168 
 
6.3.1.2 Amplification confirmation 
Selected DNA samples were then amplified using of Ampliseq amplification kit. Confirmation 
of amplification efficiency was performed with the Bioanalyser. The Bioanalyzer chip has the 
ability to provide accurate measurement of the size and number of amplification products for 
11 samples at the same time (Figure 6.16).  
 
Figure 6.16 Assessment of Amplified genomic DNA. a) Electropherogram of a DNA ladder, 
b) and of a DNA library. c) Electrophoresis run of DNA libraries. 
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6.3.1.3 QPCR quantification of DNA libraries 
Amplified libraries were partially digested and ligated with barcodes following purification. The 
purified libraries were then quantified and the concentration was estimated with the use of a 
standard curve. 
 
6.3.1.4 Polyclonality Assessment  
The pools were pulled together amplified and enriched with ISPs. The level of polyclonality 
which indicated more than one template per ISP was estimated prior to the Chip loading with 
the use of the Qubit 2.0 fluorimeter. Measurements were taken both for Alexa Fluor 488 and 
647 nm with levels of polyclonality between 20 to 30 % which is considered acceptable levels 
for sequencing.  
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6.3.2 Next Generation sequencing data quality assessment  
6.3.2.1 Sequencing with Personal Genome Machine  
The Personal Genome Machine has generated a total of 939Mbp of data, achieving a 99% 
accurately mapped sequences, over 91% of the percentage of target bases covered by at 
least 0.2 times the average base read depth (Figure 6.17). 
 
 
Figure 6.17 Quality assessment of the generated data. a) Chip loading with approximately 
85% occupied wells , b) breakdown of the final number of libraries screened, c) Average raw 
(1x) accuracy across each individual base position in a read, d) Total number of bases aligned 
to the reference sequence, e) Alignment quality (AQ17, mega bases of DNA with one 
mismatch in the first 50 bases relative to the reference strain, AQ20, mega bases of DNA with 
one mismatch in the first 100 bases relative to the reference strain) 
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6.3.3 Next generation sequencing of 25 patients 
The first analysis included 25 patients (Figure 6.19); 18 were the members of the family 
carrying the PLCβ1 InDel, 4 European patients found to carry the InDel (The 22 patients 
mentioned are described in Chapter 4) and 3 patients from a family with similar phenotype to 
Family 1 with the II-2 female found to suffer from MNG, developing PTC. These 3 patients 
were genotyped for the PLCβ1 InDel and found not to be carriers (Figure 6.18). 
 
 
Figure 6.18 Family II. The family which illustrate similar phenotype with Family1 (described 
in Chapter 4). The II-2 female found to suffer with MNG developing PTC.  
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Figure 6.19 Summary of the data assessment from next generation sequencing with 
Personal Genome Machine. The screening included 25 patients 18 of whom were patients 
from the family carrying the PLCβ1 InDel.  
 
6.3.4 Quality Control of files prepared for Merlin 
The list of total different variants from all 25 patients was assessed for labelling and Mendelian 
errors by GRR and Pedcheck software respectively. The GRR software compared the alleles 
of the individuals for assessment of their relationships. The results indicated three different 
clusters in the first cluster, closer relatives such as brothers and sisters seemed to share most 
alleles. The second included parent- child and the third were unrelated individuals (Figure 
6.20). Careful assessment of the relationship between the sequenced patients did not identify 
any labelling error. Also Mendelian error assessment with the use of PedCheck was performed 
at 4 levels and identified 4 inconsistencies across the pedigree file which were excluded from 
the study. The clusters appeared to be in close proximity to each other as the assessed 
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chromosomal region was relatively small with small number of SNPs therefore genetic 
similarities had a profound effect in allele comparison in that small region.  
 
 
Figure 6.20 Summary of allele comparison with graphical representation of 
relationships between the 18 members of the family. Squares illustrate all the possible 
combinations of allele comparison between the chosen kindred. The squares annotated with 
red colour represent sibling-sibling relationship, with yellow parent-child relationship and with 
blue genetically unrelated relationship. Higher IBS mean indicate higher allele similarity with 
value of 2.0 to account for identical twins.  
 
6.3.5 Non parametric linkage analysis 
The variants from next generation sequencing were analysed and prepared for non-parametric 
linkage analysis with Merlin software. The linkage association was illustrated as a LOD score 
across the sequenced region measured in cM. Multipoint analysis has shown that linkage was 
not significant (LOD score >3.0) as LOD score was 2.39  but indicated that there is a major 
recombination right in the middle of the sequenced region which had to be thoroughly 
investigated (Figure 6.21a). In Single point analysis similarly to multipoint illustrated no variant 
with significant LOD score but there was a major cluster of variants present in the first half of 
the examined region that had to be investigated further (Figure 6.21b). 
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Figure 6.21 Non parametric linkage analysis summary. a) Multipoint analysis illustrating a 
linkage with a LOD score of 2.39 b) Singlepoint analysis has shown that none of the individual 
variants illustrated significantly LOD score > 3.0.  
 
6.3.6 SNP Filtering 
6.3.6.1 Manual Haplotyping  
The results from Merlin have suggested a potential major recombination in the middle of the 
sequenced region suggesting that one of the two regions is associated with the disease. 
Therefore, the variants were manually haplotyped for the identification of minor allele or risk 
haplotype. The haplotype was processed by identifying the mode of inheritance from parent 
to the child and isolating the disease allele that has been inherited from one generation to the 
other (Figure 6.22). Manual haplotyping and direct comparison of SNPs between affected and 
unaffected-control patients has revealed the presence of SNPs which were unique for affected 
patients clustering in the first region prior to the recombination point as it was indicated by 
linkage analysis. The identification of these variants suggested that there is a haplotype 
segregating within the family (Figure 6.23) (Figure 6.24).  
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Figure 6.22 Manual haplotyping identifying the disease allele. Manual haplotyping of the 
alleles from parents to children identifying the disease allele, annotated with green.   
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6.3.6.2 Identification of a haplotype segregating within the family 
The Initial step of the identification of the risk haplotype was followed by the alignment of the 
disease related alleles from all the member of the family and with direct comparison between 
the affected and unaffected individuals. The comparison revealed chromosomal crossovers 
shared only among the affected members of the family (Figure 6.23).  
 
Figure 6.23 Manual Haplotyping.  a) Alignment of the risk alleles from all members of the 
family has shown that there is a cluster of variants present only in affected individuals. Each 
base is highlighted with different colour and each column represents the risk allele of each 
patient. The cluster of variants identified and highlighted with red colour illustrated in affected 
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patients different risk alleles compared to healthy individuals. b) A cluster of variants illustrated 
in Figure 6.23a, was found to segregate within the family.  
 
6.3.6.3 Filtering of Identified SNPs 
The variants were then evaluated regarding their allele frequency in the general population. A 
variant is considered as a candidate when it is rare in the general population (<2%). The 
variants were assessed with the use of the University of California Santa Cruz (UCSC) 
Genome Browser. This filtering step has revealed that only 1 variant was rare with 
approximately 1.2% allele frequency (Table 6.8). The presence of the SNP within the family 
was also confirmed by Sanger sequencing as described in (Chapter 2).  
 
Table 6.8. ANRD5 SNP was the only rare SNP present in the segregating variant cluster.  
 
 
 
 
 
Chromosomal 
position 
Chr20:10036484 
Gene ANKRD5 
Gene position 3’ prime UTR 
SNP change T>C 
Allele Frequency T=98.8%, C=1.2% 
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Figure 6.24 Summary of the filtering steps undertaken to identify the candidate ANKRD5 
SNP. 
 
6.3.6.4 Genotyping analysis of SHIP cohort for ANKRD5 SNP 
The SHIP cohort of 986 patients was genotyped for the presence of ANKRD5 SNP. The cohort 
consisted of patients suffering from nodules and/or goitres and the analysis was kindly 
performed by Prof. Henry Völzke and Dr. Alexander Teumer. The genotyping screening has 
revealed that the SNP was not important for the disease as the prevalence in affected 
population (Goitres and Nodules) was lower than in the unaffected population (Table 6.9).  
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Table 6.9 Genotyping analysis of SHIP cohort for ANKRD5 SNP. a) Percentage of Nodules 
and Goitre patients with (affected) and without (unaffected the AKRD5 SNP. b) The total 
number of patients included in the genotyping screening from SHIP cohort 
 
 
6.3.7 Next generation sequencing of 80 MNG patients 
The screening of 25 patients including the 18 family members carrying the PLCβ1 InDel was 
followed by the screening of 80 MNG patients assessing the same region (Figure 6.25).  The 
80 patients were all suffering from MNG and previous genotyping studies by Dr. Bullock and 
Prof. Clifton-Bligh from the University of Sydney revealed that 4 out 80 carried the PLCβ1 
InDel (also described in Chapter 4). The patients were unrelated to each other therefore, non-
parametric linkage analysis could not be performed. Enriched libraries prior to the sequencing 
were assessed for polyclonality with Qubit fluorometer and measurements were taken at both 
Alexa Fluor 488 and 647nm. Levels of polyclonality were between 20 to 30 % which are 
acceptable levels for sequencing. 
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Figure 6.25 Summary of the next generation sequencing of the 80 MNG patients  
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6.3.8 Quality assessment of sequenced data  
6.3.8.1 Sequencing with Ion Torrent Proton Sequencer  
The Proton sequencer has generated a total of 9.9Gbp of data, achieving 98% accurately 
mapped sequences, and over 88% of the percentage of target bases covered by at least 0.2 
times the average base read depth (Figure 6.26).  
 
 
Figure 6.26 Quality assessment of the generated data. a) Chip loading with approximately 
88% occupied wells , b) breakdown of the final number of libraries screened, c) Average raw 
(1x) accuracy across each individual base position in a read, d) Total number of bases aligned 
to the reference sequence, e) Alignment quality (AQ17, mega bases of DNA with one 
mismatch in the first 50 bases relative to the reference strain, AQ20, mega bases of DNA with 
one mismatch in the first 100 bases relative to the reference strain). 
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6.3.9 SNP assessment 
The 80 MNG patients were unrelated to each and therefore, non-parametric linkage analysis 
could not be performed. The results had to be processed by direct comparison between the 
SNPs present in affected and absent in unaffected-control patients (Healthy patients from the 
affected family). Interestingly, 4 out 85 patients carried the PLCβ1 InDel with prevalence of 
5% which is significantly higher compared to 1% in the general population.  A list with the total 
number of SNPs was prepared similar to the pedigree file for non-parametric linkage analysis 
and comparison has been performed individually in each of the 308 different variants. The 
screening has been completed in two different levels, a first selection which were variants 
present in the 4 MNG patients carrying the PLCβ1 InDel and the same time absent in 
unaffected-control patients (Table 6.10). The second selection included variants absent in 
unaffected-control patients but not necessarily present in all 4 MNG patients carrying the 
PLCβ1 InDel. The first selection identified 1 deletion at antisense SNAP 25 gene and second 
selection identified 4 variants (Figure 6.27). 
 
Figure 6.27 Variant comparison was completed in two levels of selection. The first 
selection which were variants present in the 4 MNG patients carrying the PLCβ1 InDel and 
the same time absent in unaffected-control patients identified one deletion highlighted with 
green and the second type of selection 4 variants highlighted with yellow (The second 
selection included variants absent in unaffected-control patients but not necessarily present 
in all 4 MNG patients carrying the PLCβ1 InDel).  
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Table 6.10 Summary of the variant identified by the two types of screening 
Region Variant Gene Prevalence Position 
10006820 AAAC > - Antisense 
SNAP-25 
74/80 Intron 
10023689 G > A ANKRD5 42/80 Intron 
10037105 ATAGATGATAAGATAG > - ANKRD5 51/80 3’prime 
UTR 
10037145 GATA > - ANKRD5 22/80 3’prime 
UTR 
10654331 A >G Jag1 66/80 3’prime 
UTR 
 
6.3.10 Filtering of identified variants  
Alignment and direct comparison of the variants of the different patients has revealed 5 
variants present in affected individuals and the same time absent from the unaffected patients. 
The comparison included two types of selection. The first included variants that are present in 
all four MNG patient with the PLCβ1 InDel and the same time absence in unaffected-control 
patients. On the other hand, the second type included variants that are mostly present but not 
necessarily in all of the four MNG patients with the PLCβ1 InDel and the rest of the MNG 
patients and the same time absent in unaffected-control patients.  
Screening with the first selection found one deletion chr20:10006820-10006824 (AAAC) 
present in 74 out of 80 MNG patients. Screening for this deletion in the originally affected 
family was found in patients but with incompatible mode of inheritance indicating de novo 
mutagenesis. Thus further investigation was conducted for the identification of potential false 
negative patients for the deletion within the family. The results confirmed that the deletion was 
present in patients that appear to be false negative (indicated as absent) including healthy 
individuals and thus it was not important for the disease (Figure 6.28). Further investigation 
for identification of potential false negatives within the investigate family (Chapter 4) was 
performed by assessment of the raw data of 86 different variants indicated as negative-absent. 
The analysis has not found any false negative variant with potential important role in the 
disease.  
Assessment of the raw data for the four variants found by the second selection has revealed 
that the ATAGATGATAGATAG deletion was an artefact of sequencing misalignment, the 
100023689 and 10037145 SNPs were found to be present also in unaffected patients and 
therefore were not important variants. Variant 10654331 was found in 66 out of 80 MNG 
patients however it was absent in family members. The 66 patients were sequenced using Ion 
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Torrent Proton sequencer with the 14 MNG patients and the family members sequenced with 
the Personal Genome Machine. Therefore, investigation for potential presence of the SNP 
within the family was investigated by Sanger sequencing of the family members and of patients 
with the SNP from the Proton sequencing. The results have shown that none of the patients 
was carrying the SNP, indicating that it was an artefact of Proton sequencer (Table 6.11).   
 
 
Figure 6.28 Summary of the false positive patients carrying the deletion found with the 
first type of selection (described above) for screening. a) Patients appeared to carry the 
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AAC deletion in the family indicating the presence of false negatives. b) Raw data analysis 
and Sanger sequencing revealed the presence of false negative for the deletion in the family.  
The blue colour in the family tree represent males and red colour females.  
 
Table 6.11 Summary of the results following raw data analysis and Sanger sequencing.  
Region Variant Gene Prevalence Position Post-raw data 
and Sanger 
Sequencing 
assessment 
10006820 AAAC > - Antisense 
SNAP-25 
74/80 Intron Not Important 
(present in 
Controls) 
10023689 G > A ANKRD5 42/80 Intron Not Important 
(present in 
Controls) 
10037105 ATAGATGATAGATAG 
> - 
ANKRD5 51/80 3’prime 
UTR 
Artefact 
10037145 GATA > - ANKRD5 22/80 3’prime 
UTR 
Not important 
(present in 
Controls) 
10654331 A > G Jag1 66/80 3’prime 
UTR 
Artefact 
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6.4 Discussion 
The PLCβ1 InDel has been identified in a family where many members were suffering from 
MNG and many of them progressed to papillary thyroid cancer (Chapter 4). Also, the PLCβ1 
InDel was identified to have increased prevalence in MNG patients with 5% compared to the 
general population with 1%. Also, genome wide linkage and haplotype analysis of the family 
by Dr. Bakhsh has identified a 10 cM region with high LOD score >3. That region contained 
10 genes (PLCβ1, PLCβ4, LAMP5, PAK7, ANKEF1, SNAP25, MKK5, SLX4IP, JAG1, 
BTBD3), therefore a thorough investigation of that area for the identification of potential SNPs 
that may have role in the disease had to be conducted.  
The exome of family members from this 10cM region was sequenced by Personal Genome 
Machine and semi conducting sequencing technology and primers were designed generating 
approximately 200bp fragments. The quality of sequencing data was satisfactory identifying 
more than 180 different variants. Non parametric linkage analysis was performed to 
investigate potential recombinations within that region that may indicate the presence of 
disease related variants. The analysis has found a recombination at the middle of the region 
indicating that one of the parts was disease related. Interestingly, even though the target 
region was a high LOD score region in Genome Wide Linkage Analysis as it was mentioned 
above, the LOD score following non parametric Linkage analysis was not significant. That was 
possibly due to the reduction of the size of the investigated region (10cM) compared to the 
initial analysis by Dr. Bakhsh where non-parametric analysis was performed in all 
chromosomes and the entire chromosome 20 where the high LOD score (20cM) was found. 
The reduction of the investigated region as only exomic sequences of the high LOD score 
region were included, had subsequently reduced the number of variants in the study thus the 
LOD score could not show significant linkage. Therefore, manual haplotyping had to be 
performed to identify the risk haplotype. Manual haplotyping of all the different variants from 
parent to offspring allowed the identification of the risk allele which is inherited from one 
generation to the other. Isolation of the risk alleles for each variant and direct comparison of 
the affected with unaffected- control patients, revealed that there is a haplotype of 12 variants 
segregating within the family. Filtering steps reduced the region of interest as only 
approximately 500kb from about 3.8Mb were found to be associated with the disease and 
segregated within the family. Filtering of these variants regarding its allele frequency found 
that only one variant was rare <2%. However, genotyping of 986 patients from the SHIP study 
containing nodules  and/or goitres revealed that this SNP was unrelated with the disease as 
the prevalence was lower in affected compared to unaffected-control population.   
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PLCβ1 InDel was found in increased prevalence in MNG population. Therefore 80 MNG 
patients including the 4 found with the PLCβ1 InDel were screened for the same region as the 
family for potential presence of risk variants. The patients were sequenced with the use of 
proton sequencer and PGM with semi conducting sequencing technology. The quality of the 
sequencing data was satisfactory identifying more than 300 different variants across the 80 
patients. A list with the total number of different variants present in all 80 patients was 
generated. The 80 patients were unrelated to each other therefore non parametric linkage 
analysis could not be performed. The variant assessment has to been done manually by direct 
comparison for their presence in affected and unaffected patients. The screening has been 
performed in two types of screening. The first included the presence of the variants in all 4 
patients carrying the PLCβ1 InDel and the same time absent in unaffected-control patients. 
The second screening included the absence of the variant in unaffected patients but not 
necessary present in all 4 InDel carriers. The analysis identified 5 variants which had be 
investigated individually. Assessment included investigation of the raw data for potential 
identification of poor read depth misalignments and false negatives and Sanger sequencing 
for confirmation of presence or absence of the variant of interest.  
Raw data assessment revealed that 2 variants were sequencing artefacts and therefore not 
real, also in 1 variant unaffected patients of the family were found as false negatives and 
therefore, it was not important for the disease. The other two variant were absent in most of 
the family members and only found in unaffected siblings thus were considered as not 
important  
The presence of false negatives and the use of two different sequencing platforms, PGM and 
Proton indicated that a thorough screening of the variants illustrated as negative (absent) in 
the output files had to be performed for the identification of a potential important false negative. 
Therefore the raw data from 86 different variants were screened identifying 3 not important 
false negatives, confirming that there is no other important variant within that high LOD score 
region apart from the PLCβ1 InDel. The data following the sequencing of more than 100 
patients revealed that there was no other disease related variant present with the high LOD 
score region suggesting that PLCβ1 InDel might be the solely responsible genetic cause for 
the disease pathogenesis (Figure 6.29).  
The two platforms that were used in this project are using the power of semi-conducting 
technology for sequencing. Even though they provide robust and high-throughput data, this 
technology can identify only SNPs and very small deletions. Also, it is susceptible false 
positive calls in homopolymer repeat regions. The investigated area included a number of non-
coding regions where great number of microsatellite repeats was identified and further 
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investigation by Sanger sequencing had to be performed as the variant call for these repeats 
was often not very clear. Also, the two platforms PGM, and proton had different sequencing 
potential as Proton uses a larger chip with more than 165 million wells and therefore is more 
sensitive in variant calling generating data with more than 1000 time read depth. Thus, 
comparison between the data acquired from the two different platforms had to be performed 
identifying that PGM illustrated higher false negative rate in variant calls than Proton 
sequencer.  
 
Figure 6.29. A summary of the next generation sequencing experiments.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 7. General Discussion 
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7.1 The role of phospholipase C enzymes in health and disease 
The aim of my thesis was to investigate the role of PLCs in health and disease and more 
specifically the use of PLCζ as a potential therapeutic tool for male infertility and the role of a 
PLCβ1 InDel in patients with MNG likely to develop PTC. 
The PLCβ1 project aims included:  
1. Investigation of the prevalence of PLCβ1 InDel in different groups of patients 
2. Investigate whether a potential ERα promoter binding site within the PLCβ1 InDel is 
an active promoter or contains silencing elements. 
3. Evaluation of the role of PLCβ1 in cell cycle progression and cell proliferation. 
4. Investigate whether the PLCβ1 InDel is solely responsible for the disease.  
The PLCζ project aims included: 
1. Expression and enrichment of recombinant human PLCζ 
2. Activity assessment in vivo of enriched recombinant human PLCζ 
 
In Chapter 4, a genotyping tool was designed for screening large patient cohorts for the 
identification of the PLCβ1 InDel.  The presence of an active ERα promoter or silencing 
elements within the PLCβ1 InDel were also investigated by luciferase reporter gene assay.  
The prevalence of the PLCβ1 InDel within the population varied as described in Chapter 4. 
Patients suffering with MNG illustrated an increased prevalence of 5% compared to 1% in the 
general population. On the other hand none of the PTC patients screened were found to carry 
the InDel. The prevalence of the PLCβ1 InDel has suggested that the InDel is not causing 
PTC but benign proliferation. The family that was found to carry the InDel included many 
patients with MNG developing PTC, suggesting that the increased proliferation in MNG 
patients carrying the InDel make them more susceptible to thyroid cancer. Thus, a qPCR 
based genotyping tool was designed to gain a better insight of the prevalence of the InDel.  
The technique provided a cost effective and fast method for screening simultaneously up to 
40 patients at a time. The qPCR output provided a Ct value based comparison with a clear 
distinction between patients with the InDel and healthy individuals with a difference of 10 
cycles as described in (Figure 4.11b in Chapter 4). The primers that were found to be ideal for 
the genotyping screening were the ones flanking the InDel as Ct difference between affected 
and healthy individuals was approximately 10 Ct values, in contrast primers within the deletion 
the Ct value difference was close to 1 making the distinction extremely difficult.  
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The 208 subclinical hypothyroid patients genotyped, illustrated a PLCβ1 InDel prevalence of 
approximately 1% similar to the prevalence in the general population. This cohort was 
expected to be similar with the general population (euthyroid) as their peripheral thyroid 
hormone levels were normal with only their thyroid stimulating hormone being slightly 
elevated. Their thyroid function is normal with an increased likelihood of becoming 
hypothyroid. The original family affected by the PLCβ1 InDel was euthyroid with an increased 
prevalence of MNG developing to PTC. Also, the 5% prevalence of the PLCβ1 InDel within 
MNG patients suggested that patients with MNG would be the ideal cohort to test. 
Furthermore, none of the 70 PTC patients tested was found to carry the InDel suggesting that 
it is more likely to be present in PTC patients initially suffering from MNG, rather than PTC 
presenting as a single nodule. The patients from the study of health in Pomerania (SHIP) were 
good candidate for genotyping as they had increased prevalence of both thyroid goitres and 
nodules. However, it was not possible to genotype these patients for the InDel as the PLCβ1 
region does not include any SNPs represented in existing genotyping data from the cohort. 
Thus we would have needed to obtain genomic DNA for qPCR genotyping of the InDel and 
such samples were not available to us.  
In silico analysis had identified that within the PLCβ1 InDel there is oestrogen receptor (ERα) 
α binding site. This lead to the hypothesis that the InDel might be an alternative promoter for 
PLCβ1 or for another transcript within the long intron. Patients carrying the InDel had also 
illustrated increased thyroid PLCβ1 transcript levels that could indicate even the presence of 
potential silencing elements within the InDel. It could even exert effects at considerable 
distance, as in the case of the FTO gene (Smemo et al. 2014). To investigate the potential 
promoter activity of the InDel I used a luciferase reporter gene assay in MCF-7 cells which are 
an oestrogen receptor positive cell line. The cells were treated with oestrogen and luciferase 
response would indicate presence of an active promoter. The assay has confirmed that there 
is no active promoter within the InDel as there was no significant luciferase light emission. 
However, even though empty PGL3 basic vector contained a luciferase gene and emitted light 
in luciferase assay as expected, there was a reduction of luciferase emission in cells which 
contained PLCβ1 InDel-PGL3 basic vector which could indicate the presence of silencing 
elements within the InDel. The presence of luciferase in these plasmids was confirmed by 
PCR therefore, luciferase emission of similar levels as the positive control (empty PGL3 basic 
vector) was expected. The successful transfection and validation of a functional assay was 
achieved with the use of positive control plasmids which were co-transfected into cells along 
with the plasmid of interest. Renilla plasmid and α-Luciferase plasmids emitted Renilla 
luciferase and Firefly luciferase respectively confirming the successful cell transfection.  
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In Chapter 5 the role of the PLCβ1 gene in cell proliferation was investigated by knockdown 
and overexpression of PLCβ1 by SiRNA and lentiviral transduction respectively. SiRNA 
knockdown was shown to delay cell proliferation up to 20% in comparison with scrambled 
SiRNA (Control) treated cells. Studies by (Faenza et al. 2000) have shown that overexpression 
of PLCβ1 in mouse erythroleukemia (MEL) cells led to cell cycle progression by affecting the 
MAPK/ERK pathway inducing cell cycle progression from G1 to S phase.  The siRNA 
knockdown on rat thyroid FRTL-5 cells has supported these findings indicating a clear role of 
PLCβ1 in cell proliferation. The FRTL-5 cells provide a suitable cell model for thyroid cell 
studies as they share common characteristics with human thyroid epithelial cells. However, 
the doubling time of these cells is very high requiring approximately 3 days for cell division 
which is a drawback for short lasting experiments such SiRNA treatment as SiRNA clears from 
the cells relatively fast. A human thyroid cancer cell line such as thyroid papillary carcinoma 
(TPC-1) would be the optimal choice for such study however none was available at the time 
of the project. Also, a complete investigation of the effect of PLCβ1 on cell cycle would require 
a flow cytometry assay to confirm the stage of the cell cycle the cells are held in. It is 
hypothesised that PLCβ1 knockdown cells would be held at G1 phase and that there would 
be an increased percentage of apoptotic cells as studies by (Lee et al. 2000) have revealed 
that overexpression of PLCβ1 suppresses apoptotic genes such as c-fos. 
Overexpression, of PLCβ1 was attempted with lentiviral expression vectors for PLCβ1 
provided by a collaborator Dr. Roberta Fiume from the University of Bologna. Supernatant for 
GFP positive control was also provided by Dr. Darley from Cardiff University. Even though 
active GFP lentiviral vector from the (Cardiff) samples was successfully generated. It was not 
possible to generate an active lentiviral vector for GFP or PLCβ1 using the components 
provided by Dr. Fiume, even after several attempts. Direct transfection into HEK293T cells 
and FRTL-5 cells was attempted with no positive result. The patients from the family affected 
by the PLCβ1 InDel were shown to have increased PLCβ1 transcript levels in their thyroid 
tissue. Therefore, it was particularly important to mimic the disease condition by 
overexpression of PLCβ1.  
 
7.1.1 The cell signalling of PLCβ1  
A further insight regarding the molecular pathway of the PLCβ1 reveals its vital role in cell 
proliferation and carcinogenesis. PLCβ1b is activated following the binding of a stimulus (e.g. 
a hormone or light) to its cognate GPCR which releases Gαq making it available to bind to 
PLCβ1, as previously described. However it has also been found to be activated in response 
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to different stimuli such as, interleukin-2, insulin and insulin-like growth factor-1 (Cocco et al. 
2002) which function via tyrosine kinase receptors. Interleukin-2, activates nuclear PLCβ1 in 
human natural killer cells (NK) following treatment for 60 minutes. The activation is thought to 
occur via the ERK/MAPK pathway as IL-2 can activate PI3 kinase via IL-2Rβ chain which in 
turn activates PKC isoforms (Vitale et al. 2001). The second activation stimulus is insulin and 
studies on NIH 3T3 cells treated with insulin, reported enhanced cell proliferation. Following 
insulin treatment, increased DAG quantity was measured and PLC activity assays supported 
the indication that insulin activates nuclear PLCβ1 (Martelli et al. 2000b). A number of studies 
had initially identified the nuclear presence of PLCβ1, however it was not clarified until the 
correlation between IGF-1 treatment and nuclear activity of PLCβ1 was found (Martelli et al. 
1992). A later study (Manzoli et al. 1997) had revealed the mitogenic role of PLCβ1, where 
overexpression of PLCβ1 followed by IGF-I stimulation resulted in significant enhancement of 
DNA synthesis.  However, the missing part of the puzzle was how nuclear PLCβ1 is activated 
as Gαq and Gβγ do not localize to the nucleus. It was found that upon stimulation with IGF-1, 
MAP kinase translocates to the nucleus and phosphorylates PLCβ1 on serine 982 present 
within a MAP kinase consensus sequence pro- ser- ser- pro at its characteristic C terminal 
region. This phosphorylation site is unique for PLCβ1 as it is not present in any other PLCβ 
isoforms (Martelli et al. 1999; Martelli et al. 2001). Mutagenesis of this site by replacing serine 
with alanine or treating the cells with a specific MEK inhibitor PD98059 had the same result in 
failing to activate nuclear PLCβ1. These results were a strong indication that nuclear activation 
is regulated by the MAP kinase translocation in the nucleus(Xu et al. 2001a). In addition to 
this finding another piece of the nuclear PLCΒ1 signalling puzzle was put in place when a 
negative feedback was identified between PKCa and nuclear PLCβ1. Stimulation with IGF-1 
and translocation of MAP- kinase leads to activation of PLCβ1b. The increased concentration 
of DAG by PIP2 hydrolysis within the nucleus attracts the PKCa from the cytoplasm which in 
turn translocates to the nucleus and phosphorylates PLCβ1b at serine 887. The 
phosphorylation of PLCβ1b by PKCa terminates PLCβ1b activity. This hypothesis has been 
supported by the overexpression of mutated PLCβ1b on the PKCa phosphorylated site with 
alanine which resulted in sustained activation of PLCβ1b. Suggesting that PLCβ1a is activated 
by GPCR route and PLCβ1b by Tyrosine kinase receptors (Taniguchi et al. 1995; Martelli et 
al. 2000a; Xu et al. 2001b)(Xu et al. 2001).  
 
7.1.2 Overexpression of PLCβ1 promotes cell cycle progression 
The correlation of PLCβ1 expression and the cell cycle regulation through a PKC mediated 
pathway has also been suggested by a very recent study where a decrease of PKCa following 
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overexpression of PLCβ1 was observed in K562 cells. Further analysis of this finding was 
carried out by silencing PKCa which resulted in upregulation of cyclin D3, similarly with PLCβ1 
effect, indicating that PLCβ1 leads to cell cycle progression by targeting to cyclin D3 via the 
PKCa pathway (Poli et al. 2013). A greater insight regarding the role of nuclear PLCβ1 has 
been given by (Faenza et al. 2000). PLCβ1b has been found to have a key role in cell cycle 
regulation, as its overexpression in mouse erythroleukemia (MEL) cells, lead to 
overexpression of cyclin D3 and cdk4. The complex of D3/cdk4 is known to phosphorylate the 
Retinoblastoma protein (pRb). The phosphorylation of this tumour suppressor resulted in the 
release of proteins from the E2F family which in turn induced the expression of genes that are 
required for cell cycle progression from G1 to S phase (Faenza et al. 2000). The 
overexpression of nuclear PLCβ1 was found to be correlated with the enzymatic activity which 
was 3 fold higher than in wild type cells. It is noteworthy that increased PLC activity has been 
reported in thyroid neoplasms (Kobayashi et al. 1993). Unpublished work by Dr. Lei Zhang 
and Dr. Fiona Grennan Jones by our group has indicated significantly higher transcript levels 
of isoform a in all thyroids tested (p<0.01) but no significant difference in the ratio of PLCβ1-a 
to PLCβ1-b in PLCβ1 InDel-affected and non-affected thyroids. The increased enzymatic 
activity which could follow-on from the higher transcript levels is considered to be vital as IP3 
and DAG are generated, with the latter attracting PKCa into the nucleus and triggering a 
nuclear signalling cascade which leads to cell cycle progression (Faenza et al. 2000). A few 
years later, a study on serum-stimulated HL-60 cells found that there are two waves of PLCβ1b 
activity throughout the cell cycle. The first occurs at 30 minutes in serum stimulated HL 60 
cells during the G1 phase and the second at 11.5 hours. Both PLCβ1 activity peaks were 
associated with serine phosphorylation and they were inhibited following the use of PI-PLC 
and Erk kinase (MEK) inhibitors, such as ET-18-OCH3 and PD98059 respectively. Interestingly 
it has been suggested that the two peaks are equally important for the transition of G1 to S 
phase.  Inhibition of only the second peak resulted in the same mitotic index profile as the cells 
which were initially treated with inhibitors, with both cells failing to enter S phase underlining 
the importance of both PLC activity peaks for cell cycle progression from G1 to S phase 
(Lukinovic-Skudar et al. 2007). Initial evidence regarding the role of nuclear PLCβ1 in 
transition of G2/M phase has been provided by (Lukinovic-Skudar et al. 2005). This suggestion 
was supported by the finding that PLCβ1b is associated with laminB1. The study has revealed 
that both co-localise to the nuclear speckles and that the loss of laminB1 causes structural 
changes to the speckles, suggesting a potential role in RNA splicing as they are rich in pre 
messenger RNA splicing factors. The study has revealed that once JNK is activated by an 
extracellular signal can activate PLCβ1b which in turn leads to generation of DAG. The 
increased concentration of DAG chemo–attracts PKCa from the cytoplasm to the nucleus 
resulting in phosphorylation of laminB1. The depolymerisation of laminB1 caused by its 
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phosphorylation induces the cell cycle progression from G2 to M phase and is considered to 
have a key role in the breakdown of the nuclear envelope (Fiume et al. 2009). Lamins and 
more specifically the B type are present in most somatic cells and are considered to be vital 
for cell survival as they regulate apoptosis, gene expression, and nuclear architecture and are 
often involved in cancer and tumour progression. Alteration of the expression of the B type 
lamins is essential for cell survival as laminB proteins are always present in cancer cells 
(Foster et al. 2010).  Another hypothesis suggests that overexpression of PLCβ1 may prevent 
cell death caused by oxidative stress by suppressing specific apoptotic genes such as c-fos. 
Overexpression of PLCβ1 caused 5 fold increase of PLCβ1 transcript levels in NIH3T3 cells, 
followed by approximately 2 fold increase in the PLCβ1 enzymatic activity (Lee et al. 2000). 
The cellular survival due to overexpression of PLCβ1 is suggested to be followed by cell cycle 
progression to S phase. PLCβ1 was speculated to inhibit via Translin associated factor (TRAX) 
the downregulation of lactate dehydrogenase (LDH) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPD) which are known to be involved in histone synthesis as they are part 
of the octamer-binding factor 1 coactivator (OCA-S) which has a vital role in histone 
expression by binding to H2B promoter in S phase at the time of histone synthesis(Philip et 
al. 2012). Therefore, the overexpression of PLCβ1 is suggested to prevent cell death by 
oxidative stress and by regulating histone synthesis, to promote cell cycle progression (Lee et 
al. 2000; Philip et al. 2012). The key role of PLCβ1 on the cell cycle was supported by another 
study where copy number alteration of PLCβ1 gene was investigated in a number of breast 
cancers. The study identified that the genetic alterations of PLCβ1 had an effect on the mitotic 
index of the cells (Molinari et al. 2012). A summary of the studies described above is illustrated 
in (Figure 7.1).  
 
7.1.3 Downregulation of PLCβ1 
On the other hand, downregulation of the PLCβ1b in patients with myelodysplastic syndrome 
(MDS) has been associated with high risk of developing acute myeloid leukaemia (AML). A 
mono-allelic deletion on PLCβ1 gene has been shown to have more severe clinical outcome 
in high risk MDS patients compared with patients having both alleles. In addition, the high risk 
MDS patients carrying the deletion were found to have decreased expression of PLCβ1b, 
indicating that a potential decrease of the nuclear PLCβ1 could affect the cell cycle in MDS 
pathogenesis (Follo et al. 2009).  Interestingly, PLCβ1 has been found to affect the Akt 
signalling pathway, in MDS patients. A recent study where MDS patients were treated with 
azacitidine revealed that untreated patients had elevated activated Akt in contrast with the 
treated which had elevated levels of PLCβ1 expression and dowregulated activated Akt. The 
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study revealed direct correlation between the PLCβ1 and activated Akt levels, as the PIP2 
levels fluctuated according to the changes of PLCβ1 and activated Akt having an inverse and 
direct relationship respectively (Follo et al. 2008). 
The PLCβ1 transcript levels were also found to be altered in another recent study by 
(Guerrero-Preston et al. 2014) where promoter methylation differences of PLCβ1 were found 
in head and neck squamous cell carcinoma (HNSCC) leading to dowregulation of the gene. 
This important finding suggested that somatic mutations along with promoter methylation may 
be an important factor for the downregulation of tumour suppressor genes in HNSCC.  
 
Figure 7.1 Cell signalling of PLCβ1. Overexpression of PLCβ1 is found to be correlated to 
cell cycle progression and involved in a number of different cancers. PLCβ1b is activated via 
phosphorylation by MAPK (ERK) and promotes cell cycle progression from G1 to S and G2 to 
M phase due to up-regulation of cdk4 and laminB1 respectively.  
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7.1.4 The Correlation of PLCβ1 with the main somatic and germline mutations in human 
cancer 
The studies mentioned above have indicated a number of genes which seem to be directly 
affected by the overexpression of PLCβ1 transcript levels and activity. Databases such as the 
Catalogue of Somatic Mutations In Cancer (COSMIC) and the International Cancer Genome 
Consortium (ICGC) were used to gain a better understanding regarding the importance of 
PLCβ1 and its correlation with the main somatic and germline mutations occurring in the four 
main cancers in which PLCβ1 is involved, (Figure 7.2). The main PLCβ1 signalling cascade, 
contains several downstream components implicated in a range of cancers, e.g. BRAF and 
RB1. RB1 is phosphorylated from cyclin D3 following PLCβ1 overexpression, which disables 
its ability to bind to E2F, allowing the latter to be released and promote cell cycle progression 
from G1 to S phase (Faenza et al. 2000). In addition, BRAF gene is one of the most common 
genes to be altered in PTC which in turn is most frequent type of thyroid cancer. The B-type 
Raf kinase (BRAF V600E) mutation accounts for 90% of the BRAF mutations (Frasca et al. 
2008). Patients carrying the BRAF mutation have illustrated approximately 5 times higher 
mortality rate in comparison with the mutation negative patients, thus it is used as biomarker 
for PTC prognosis (Haq et al. 2013; Xing 2013). 
  
Figure 7.2 Somatic germline mutations in PLCβ1 found in patients with Prostate, Ovary, 
Colorectal and Breast cancer. The data were acquired from Catalogue of Somatic Mutations 
In Cancer (COSMIC) and International cancer genome consortium (ICGC). The genes 
correlating directly and indirectly with the PLCβ1 pathway are underlined. The genes 
underlined are present within PLCβ1 cell signalling cascades.  
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7.1.6 PLCβ1 InDel and goitre formation hypothesis 
The family patients found with the InDel (as described in Chapter 4) have illustrated increased 
levels of PLCβ1 transcripts. Furthermore, Akt in a recent study was found to be associated 
with PLCβ1 in patients with myelodysplastic syndrome (MDS) with high risk of developing 
acute myeloid leukemia (AML) (Follo et al. 2008). The study has shown that PLCβ1 levels 
were correlated with the levels of activated Akt, possibly due to the PIP2 levels as the latter is 
the common substrate for both PLCβ1 and Akt. Phosphoinositide 3-kinase (PI3K) is known to 
generate Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) via dephosphorylation of PIP2. 
Then PIP3 activates Akt following its binding at Akt-PH domain. Activated Akt then 
phosphorylates tuberous sclerosis complex 2 (TSC2) which prevents the TSC1/TSC2 
complex to inhibit Ras homolog enriched in brain (RHEB) activity by GTP hydrolysis. Active 
RHEB-GTP in turn activates mTOR by a mechanism not well understood. It is hypothesized 
that the lack of PIP2 substrate due to the increased PLCβ1 transcript levels in the patients 
carrying the PLCβ1 InDel may downregulate Akt activity and therefore leading to 
dowregulation of mTOR activity (Hay and Sonenberg 2004). A study by (de Souza et al. 2010) 
has illustrated that inhibition of mTOR in TSH-stimulated PCCL3 thyroid cell line has increased 
iodide uptake suggesting that mTOR has a key role in regulating thyroid function. A study from 
(Zimmermann et al. 2005) which has investigated the consequence of a chronic high iodine 
intake in children from Hokkaido Island in Japan has shown that excess Iodine intake is 
associated with goitre formation and increased thyroid volume. Also in a study for chronic 
iodine excess in American workers in West Africa (Pearce et al. 2002) illustrated increased 
goitre prevalence suggesting the goitrogenic effect of excess iodine intake. As described in 
Chapter 1, the iodide imported by NIS is oxidised in the follicular lumen by TPO via the activity 
of H2O2. Studies by (Corvilain et al. 1994; Moreno-Reyes et al. 2007) have supported the 
hypothesis that H2O2 is generated predominantly by PIP2-DAG-Ca2+ cascade. Therefore, the 
excess iodine uptake by the thyroid which may lead to goitre formation and the increased 
PLCβ1 transcript levels found in patients carrying the PLCβ1 InDel leading to overactivation 
of PI-PLC-DAG-Ca2+ could increase H2O2 generation. As described above overexpression of 
PLCβ1 can lead to cell proliferation and cell cycle progression. Thus we suggest that the InDel 
can be goitrogenic due to potential increased iodide uptake, can cause benign proliferation as 
overexpression of PLCβ1 leads to cell cycle progression and the subsequent overactivation 
of the cascade can lead to excess H2O2 generation which in turn can be mutagenic and cause 
oxidative DNA damage and cancer (Song et al. 2007). However, the MNG patients in the 
original family affected by the PLCβ1 InDel were euthyroid. Thus further investigation will be 
required to identify the role of the PLCβ1 InDel in thyroid hormone synthesis and whether it 
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affects iodine uptake with the resulting increased H2O2 generation possibly leading to cancer 
(Figure 7.3).   
 
 
Figure 7.3. The associated cell signalling cascades in the disease pathogenesis. 
Overexpression of PLCβ1 downregulates mTOR cascade causing in turn increased iodide 
uptake which is goitrogenic. The overactivation of the PIP2-DAG-Ca2+ has also been 
suggested to increase the generation of H2O2. 
 
In Chapter 6, the high LOD score region on chromosome 20 identified by Dr. Bakhsh has been 
investigated by next generation sequencing for the potential presence of other variants that 
may be responsible for the disease pathogenesis. Semi conducting sequencing technology 
by Ion Torrent was chosen for the screening of the exomic regions of that Chr.20 20cM. The 
target patients were the member of the family found to carry the InDel (18), the 4 patients 
found to carry the InDel in chapter 4 by the genotyping tool and 80 MNG patients 4 of whom 
were known to carry the InDel. The screening has not identified additional variants that could 
be disease related confirming that PLCβ1 ΙnDel is solely responsible for the disease. The Ion 
Torrent sequencing technology is high throughput generating a vast amount of data. Although 
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it can only detect SNPs and small deletion therefore large deletions or InDels could be missed, 
although previous studies using analysis of copy number variation identified only the InDel on 
Chr 20.  
 
PLCζ and its potential use in biomedical applications 
In Chapter 2, different protein constructs were designed to allow optimal protein expression 
and solubility of recombinant human PLCζ. The protein was expressed in a bacterial 
expression system therefore, the expression of a mammalian protein such as human PLCζ 
was very challenging. Thus a range of different protein solubility partners were used to 
enhance protein solubility.  
Dr. Nomikos had successfully expressed recombinant hPLCζ with NusA solubility tag (NusA-
hPLCζ) (Nomikos et al. 2013). In this study, hPLCζ was subcloned into a plasmid of the petMM 
series and generated NusA- hPLCζ which in turn exhibited a high yield in protein expression 
and solubility. Also the protein without the presence of a solubility tag illustrates rapid 
degradation. Thus NusA and other solubility tags were used to retain protein solubility. The 
major drawback of this strategy is that the protein is destined to be injected into human eggs 
to trigger egg activation in cases of severe male infertility. The bacterial origin of such solubility 
tags would be an impediment for future biomedical applications of hPLCζ in human eggs. Thus 
the human thioredoxin (hTrx), a protein that occurs naturally in human eggs, was employed 
as a potential solubility tag. The bacterial Trx (nTrx) was found to retain hPLCζ solubility thus 
hTrx was subcloned as second solubility tag at the N terminal of hPLCζ in between hPLCζ 
and the bacterial solubility tag.  
In Chapter 3, the protein constructs with the highest yield of soluble recombinant hPLCζ were 
selected and assessed for their in vivo PLCζ activity following recombinant hPLCζ 
microinjection into mouse eggs. The expressed protein was enriched with affinity 
chromatography using the His6 protein tag which binds with high affinity to Ni2+ beads. Activity 
assay illustrated that different active forms of hPLCζ were expressed which could potentially 
be used in biomedical applications. However, the level of purity of the enriched protein was 
low therefore, multiple protein purification steps should be performed.  
PLCζ, in common with many proteins produced in the testis, is temperature sensitive. Bacterial 
cells were lysed using sonication, which unfortunately produces heat, even when performed 
on ice. An alternative would be the use of a French press to break open the bacteria but it can 
be used only for larger volumes of bacterial lysates >300ml. 
200 
 
As mentioned above, hPLCζ has to be partnered with a solubility tag of human origin and the 
same time has to be purified free from bacterial contaminants in order to be ethically approved 
for biomedical applications in human oocytes. Thus hTrx was subcloned at the N-Terminus 
and C -Terminus of hPLCζ. Bacterial solubility tags were removed by proteolytic cleavage and 
hTrx-hPLCζ was shown to be soluble and active in vivo a vital step for the potential use of 
hPLCζ in biomedical applications.  
 
Final Conclusion 
In conclusion, the data from chapters 2 and 3 have illustrated that active recombinant hPLCζ 
was successfully expressed and enriched. However, even though the protein was found to be 
active in vivo a number of bacterial protein contaminants were present in the enriched protein. 
Thus further optimization of protein production and additional purification steps are required 
to generate a product suitable for clinical use. 
1. Assessment of the protein solubility levels was performed by direct comparison of each 
protein construct following western blot. The culture conditions and volumes were 
equal and experiments were conducted at the same time. This technique is not 
quantitative but can provide clear visual indication of the proportion of protein solubility. 
A potential quantitative analysis that could be performed is by enzyme-linked 
immunosorbent assay (ELISA).  
2. Protein contaminant in affinity chromatography elution could be eliminated by 
introducing a double His6 tag in the protein construct to maximize the potential binding 
of the protein to the Ni2+ beads and the same time including more washing steps with 
more stringent washing buffer to remove remaining contaminants. Also, affinity 
chromatography could be combined with either ion exchange chromatography or gel 
filtration to maximize purification levels of hPLCζ.  
3. hPLCζ as described in the general introduction, has a positively charge X-Y linker 
which binds strongly to the negatively charged PIP2. It is hypothesized that these 
proteins are attached to hPLCζ via this positively charged X-Y linker as western blot 
assay with anti-MBP and anti-HIS6 antibodies were unable to detect the protein 
suggesting that is a bacterial origin protein and not a degraded part of recombinant 
hPLCζ. Therefore, the potential use of a buffer with increased salt concentration would 
be likely to prevent the protein interactions and a combination of two chromatography 
methods as mentioned above could achieve higher levels of protein purity.  
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Several conclusions can be drawn from the data presented in chapters 4, 5 & 6. The frequency 
of the PLCβ1 InDel is about 1% in healthy individuals or patients with SH but 5% in those with 
MNG. It could contain silencing elements that could influence PLCβ1 transcript levels. 
Reducing PLCβ1 transcripts (the opposite of the situation in the family) using siRNA also 
decreased proliferation, supporting the idea that it contributes to benign thyroid proliferation 
as occurs in MNG. Finally NGS analysis of the chr 20 high LOD score region did not identify 
other variants which are associated with disease. Thus the PLCβ1 InDel could provide a 
biomarker for MNG and identify patients most likely to develop PTC.   
Future investigations could include: 
1. The genotyping of patient cohorts suffering from MNG developing PTC as it is the 
population more likely to be affected by the PLCβ1 InDel. 
2. Developing assays that can investigate the effect of the overexpression of hPLCβ1 on 
the cell cycle, mimicking the physiological effect of the PLCβ1 InDel in PLCβ1 
transcript levels.  
3. Investigate the correlation of PLCβ1 overexpression with BRAF down regulation and 
goitre formation.  
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(Appendix A) 
(Appendix A1) 
pETMM vector series 
hPLCζ was cloned into the pETMM vector series which contain a range of different protein 
solubility tags. 
 
Figure App 8.1 pETMM 11. Contains a His6 region for protein purification with Ni2+ resin 
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Figure App 8.2 pETMM 20. Contains a His6 and an nTrx region allowing protein purification 
and enhancing protein solubility respectively. 
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Figure App 8.3 pETMM 30. Contains a His6 and a GST region allowing protein purification 
and enhancing protein solubility respectively. 
 
 
 
205 
 
 
Figure App 8.4 Petmm 41. Contains a His6 and a MBP region allowing protein purification 
and enhancing protein solubility respectively. 
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Figure App 8.5 pETMM 50. Includes nDsbA as a solubility tag and a His6 for purification with 
Ni2+ resin. 
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Figure App 8.6 pETMM 60. Includes NusA as a solubility tag and a His6 for purification with 
Ni2+ resin. 
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Figure App 8.7 pETMM 70. Includes only CBP as a solubility tag which allows protein 
purification with Calmodulin resin. 
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Figure App. 8.8 pETMM 80. Includes DsbC as a solubility tag and a His6 for purification with 
Ni2+ resin 
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(Appendix B) 
(Appendix B1) 
Ampliseq primer pools 
Primers were designed with the use of Ampliseq 3.0.1 software (https://ampliseq.com/) 
according to the manufacturer’s protocol. A total number of 429 primers were designed 
generating 100-300bp amplification products.  
 
Table App. 8.1 List of Ampliseq primers 
AmpliSeq_Version=3.0.1 Workflow=DNA" db=hg19  
chr20 8113337 8113476  GENE_ID=PLCB1 
chr20 8130861 8130992  GENE_ID=PLCB1 
chr20 8130992 8131094  GENE_ID=PLCB1 
chr20 8351850 8351982  GENE_ID=PLCB1 
chr20 8351982 8352196  GENE_ID=PLCB1 
chr20 8608886 8609043  GENE_ID=PLCB1 
chr20 8609043 8609185  GENE_ID=PLCB1 
chr20 8626686 8626907  GENE_ID=PLCB1 
chr20 8628444 8628673  GENE_ID=PLCB1 
chr20 8629954 8630163  GENE_ID=PLCB1 
chr20 8637681 8637808  GENE_ID=PLCB1 
chr20 8637808 8637988  GENE_ID=PLCB1 
chr20 8639180 8639401  GENE_ID=PLCB1 
chr20 8665485 8665583  GENE_ID=PLCB1 
chr20 8665583 8665795  GENE_ID=PLCB1 
chr20 8678187 8678395  GENE_ID=PLCB1 
chr20 8678393 8678494  GENE_ID=PLCB1 
chr20 8689158 8689308  GENE_ID=PLCB1 
chr20 8689308 8689479  GENE_ID=PLCB1 
chr20 8696853 8697048  GENE_ID=PLCB1 
chr20 8698233 8698425  GENE_ID=PLCB1 
chr20 8698425 8698576  GENE_ID=PLCB1 
chr20 8702907 8703048  GENE_ID=PLCB1 
chr20 8703048 8703148  GENE_ID=PLCB1 
chr20 8705239 8705461  GENE_ID=PLCB1 
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chr20 8707795 8707961  GENE_ID=PLCB1 
chr20 8707961 8708119  GENE_ID=PLCB1 
chr20 8709583 8709712  GENE_ID=PLCB1 
chr20 8709712 8709897  GENE_ID=PLCB1 
chr20 8713789 8713908  GENE_ID=PLCB1 
chr20 8713908 8714089  GENE_ID=PLCB1 
chr20 8717591 8717744  GENE_ID=PLCB1 
chr20 8717744 8717883  GENE_ID=PLCB1 
chr20 8719831 8719932  GENE_ID=PLCB1 
chr20 8719932 8720103  GENE_ID=PLCB1 
chr20 8720920 8721060  GENE_ID=PLCB1 
chr20 8721060 8721161  GENE_ID=PLCB1 
chr20 8722013 8722124  GENE_ID=PLCB1 
chr20 8722124 8722270  GENE_ID=PLCB1 
chr20 8737642 8737845  GENE_ID=PLCB1 
chr20 8737842 8737943  GENE_ID=PLCB1 
chr20 8740957 8741157  GENE_ID=PLCB1 
chr20 8745697 8745877  GENE_ID=PLCB1 
chr20 8745877 8746074  GENE_ID=PLCB1 
chr20 8755108 8755268  GENE_ID=PLCB1 
chr20 8755268 8755428  GENE_ID=PLCB1 
chr20 8768935 8769066  GENE_ID=PLCB1 
chr20 8769066 8769222  GENE_ID=PLCB1 
chr20 8769212 8769435  GENE_ID=PLCB1 
chr20 8770086 8770295  GENE_ID=PLCB1 
chr20 8770755 8770974  GENE_ID=PLCB1 
chr20 8782570 8782726  GENE_ID=PLCB1 
chr20 8782726 8782899  GENE_ID=PLCB1 
chr20 8862215 8862360  GENE_ID=PLCB1 
chr20 8862360 8862557  GENE_ID=PLCB1 
chr20 8862557 8862774  GENE_ID=PLCB1 
chr20 8862771 8862976  GENE_ID=PLCB1 
chr20 8862976 8863169  GENE_ID=PLCB1 
chr20 8863169 8863380  GENE_ID=PLCB1 
chr20 8863379 8863592  GENE_ID=PLCB1 
chr20 8863592 8863793  GENE_ID=PLCB1 
chr20 8864011 8864115  GENE_ID=PLCB1 
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chr20 8864115 8864298  GENE_ID=PLCB1 
chr20 8864234 8864396  GENE_ID=PLCB1 
chr20 8864396 8864518  GENE_ID=PLCB1 
chr20 8864518 8864684  GENE_ID=PLCB1 
chr20 8864674 8864834  GENE_ID=PLCB1 
chr20 8864832 8864960  GENE_ID=PLCB1 
chr20 8864960 8865068  GENE_ID=PLCB1 
chr20 8865068 8865264  GENE_ID=PLCB1 
chr20 8865264 8865481  GENE_ID=PLCB1 
chr20 8865481 8865610  GENE_ID=PLCB1 
chr20 9049674 9049860  GENE_ID=PLCB4 
chr20 9197970 9198165  GENE_ID=PLCB4 
chr20 9288297 9288473  GENE_ID=PLCB4 
chr20 9288473 9288649  GENE_ID=PLCB4 
chr20 9317638 9317750  GENE_ID=PLCB4 
chr20 9317750 9317903  GENE_ID=PLCB4 
chr20 9318572 9318795  GENE_ID=PLCB4 
chr20 9319483 9319580  GENE_ID=PLCB4 
chr20 9319580 9319781  GENE_ID=PLCB4 
chr20 9343409 9343525  GENE_ID=PLCB4 
chr20 9343525 9343672  GENE_ID=PLCB4 
chr20 9346015 9346231  GENE_ID=PLCB4 
chr20 9351710 9351931  GENE_ID=PLCB4 
chr20 9352836 9352986  GENE_ID=PLCB4 
chr20 9352986 9353139  GENE_ID=PLCB4 
chr20 9353593 9353817  GENE_ID=PLCB4 
chr20 9360563 9360686  GENE_ID=PLCB4 
chr20 9360686 9360879  GENE_ID=PLCB4 
chr20 9364782 9364923  GENE_ID=PLCB4 
chr20 9364923 9365116  GENE_ID=PLCB4 
chr20 9367955 9368138  GENE_ID=PLCB4 
chr20 9368138 9368253  GENE_ID=PLCB4 
chr20 9370428 9370658  GENE_ID=PLCB4 
chr20 9371103 9371321  GENE_ID=PLCB4 
chr20 9374077 9374213  GENE_ID=PLCB4 
chr20 9374213 9374438  GENE_ID=PLCB4 
chr20 9376044 9376191  GENE_ID=PLCB4 
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chr20 9376191 9376417  GENE_ID=PLCB4 
chr20 9382073 9382295  GENE_ID=PLCB4 
chr20 9385834 9386056  GENE_ID=PLCB4 
chr20 9388509 9388610  GENE_ID=PLCB4 
chr20 9388610 9388758  GENE_ID=PLCB4 
chr20 9389220 9389429  GENE_ID=PLCB4 
chr20 9389554 9389765  GENE_ID=PLCB4 
chr20 9389765 9389934  GENE_ID=PLCB4 
chr20 9391604 9391821  GENE_ID=PLCB4 
chr20 9400323 9400460  GENE_ID=PLCB4 
chr20 9400460 9400626  GENE_ID=PLCB4 
chr20 9401863 9401994  GENE_ID=PLCB4 
chr20 9401994 9402158  GENE_ID=PLCB4 
chr20 9404311 9404426  GENE_ID=PLCB4 
chr20 9404426 9404619  GENE_ID=PLCB4 
chr20 9416076 9416240  GENE_ID=PLCB4 
chr20 9416240 9416385  GENE_ID=PLCB4 
chr20 9417554 9417686  GENE_ID=PLCB4 
chr20 9417686 9417881  GENE_ID=PLCB4 
chr20 9424534 9424747  GENE_ID=PLCB4 
chr20 9424755 9424959  GENE_ID=PLCB4 
chr20 9433938 9434166  GENE_ID=PLCB4 
chr20 9438002 9438208  GENE_ID=PLCB4 
chr20 9440199 9440308  GENE_ID=PLCB4 
chr20 9440308 9440507  GENE_ID=PLCB4 
chr20 9449161 9449375  GENE_ID=PLCB4 
chr20 9453356 9453554  GENE_ID=PLCB4 
chr20 9453872 9454083  GENE_ID=PLCB4 
chr20 9457272 9457489  GENE_ID=PLCB4 
chr20 9459480 9459634  GENE_ID=PLCB4 
chr20 9459634 9459833  GENE_ID=PLCB4 
chr20 9459833 9460046  GENE_ID=PLCB4 
chr20 9460046 9460258  GENE_ID=PLCB4 
chr20 9460258 9460460  GENE_ID=PLCB4 
chr20 9460460 9460667  GENE_ID=PLCB4 
chr20 9460658 9460843  GENE_ID=PLCB4 
chr20 9460843 9461016  GENE_ID=PLCB4 
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chr20 9461016 9461237  GENE_ID=PLCB4 
chr20 9461237 9461384  GENE_ID=PLCB4 
chr20 9461384 9461512  GENE_ID=PLCB4 
chr20 9485757 9485917  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9485917 9486016  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9486016 9486232  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9486232 9486416  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9486416 9486639  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9486634 9486779  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9486779 9486996  SUBMITTED_REGION=RP5-1119D9.4_EX1 
chr20 9487522 9487623  SUBMITTED_REGION=RP5-1119D9.4_EX2 
chr20 9487623 9487838  SUBMITTED_REGION=RP5-1119D9.4_EX2 
chr20 9487801 9487907  SUBMITTED_REGION=RP5-1119D9.4_EX2 
chr20 9489497 9489641  SUBMITTED_REGION=RP5-1119D9.4_EX3 
chr20 9489604 9489805  SUBMITTED_REGION=RP5-1119D9.4_EX3 
chr20 9494981 9495119  SUBMITTED_REGION=LAMP5_EX1 
chr20 9495119 9495344  SUBMITTED_REGION=LAMP5_EX1 
chr20 9495242 9495358  SUBMITTED_REGION=LAMP5_EX1 
chr20 9495451 9495651  SUBMITTED_REGION=LAMP5_EX1 
chr20 9496007 9496116  SUBMITTED_REGION=LAMP5_EX2 
chr20 9496116 9496330  SUBMITTED_REGION=LAMP5_EX2 
chr20 9496651 9496764  SUBMITTED_REGION=LAMP5_EX3 
chr20 9496764 9496985  SUBMITTED_REGION=LAMP5_EX4 
chr20 9496985 9497120  SUBMITTED_REGION=LAMP5_EX4 
chr20 9498617 9498758  SUBMITTED_REGION=LAMP5_EX5 
chr20 9498758 9498904  SUBMITTED_REGION=LAMP5_EX5 
chr20 9510300 9510526  SUBMITTED_REGION=LAMP5_EX6 
chr20 9510526 9510754  SUBMITTED_REGION=LAMP5_EX6 
chr20 9510754 9510889  SUBMITTED_REGION=LAMP5_EX6 
chr20 9510889 9510992  SUBMITTED_REGION=LAMP5_EX6 
chr20 9510992 9511204  SUBMITTED_REGION=LAMP5_EX6 
chr20 9517953 9518106  GENE_ID=PAK7 
chr20 9518106 9518207  GENE_ID=PAK7 
chr20 9518207 9518330  GENE_ID=PAK7 
chr20 9518330 9518437  GENE_ID=PAK7 
chr20 9518437 9518636  GENE_ID=PAK7 
chr20 9518622 9518745  GENE_ID=PAK7 
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chr20 9518745 9518882  GENE_ID=PAK7 
chr20 9518882 9519055  GENE_ID=PAK7 
chr20 9519055 9519257  GENE_ID=PAK7 
chr20 9519257 9519468  GENE_ID=PAK7 
chr20 9519462 9519649  GENE_ID=PAK7 
chr20 9519633 9519813  GENE_ID=PAK7 
chr20 9519813 9519945  GENE_ID=PAK7 
chr20 9519945 9520170  GENE_ID=PAK7 
chr20 9520170 9520334  GENE_ID=PAK7 
chr20 9523119 9523226  GENE_ID=PAK7 
chr20 9523226 9523417  GENE_ID=PAK7 
chr20 9524890 9525082  GENE_ID=PAK7 
chr20 9525082 9525224  GENE_ID=PAK7 
chr20 9538137 9538287  GENE_ID=PAK7 
chr20 9538287 9538431  GENE_ID=PAK7 
chr20 9543434 9543534  GENE_ID=PAK7 
chr20 9543534 9543722  GENE_ID=PAK7 
chr20 9546464 9546591  GENE_ID=PAK7 
chr20 9546591 9546724  GENE_ID=PAK7 
chr20 9546686 9546902  GENE_ID=PAK7 
chr20 9546894 9547117  GENE_ID=PAK7 
chr20 9560711 9560882  GENE_ID=PAK7 
chr20 9560882 9561075  GENE_ID=PAK7 
chr20 9561075 9561177  GENE_ID=PAK7 
chr20 9561177 9561395  GENE_ID=PAK7 
chr20 9561395 9561627  GENE_ID=PAK7 
chr20 9624699 9624896  GENE_ID=PAK7 
chr20 9624896 9625042  GENE_ID=PAK7 
chr20 9691833 9691954  GENE_ID=PAK7 
chr20 9691954 9692150  GENE_ID=PAK7 
chr20 9799181 9799356  GENE_ID=PAK7 
chr20 9799356 9799511  GENE_ID=PAK7 
chr20 9819330 9819513  GENE_ID=PAK7 
chr20 9819530 9819755  GENE_ID=PAK7 
chr20 9966966 9967184  SUBMITTED_REGION=LOC101929371_EX1 
chr20 9987130 9987332  SUBMITTED_REGION=LOC101929371_EX2 
chr20 9987332 9987554  SUBMITTED_REGION=LOC101929371_EX2 
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chr20 9987554 9987780  SUBMITTED_REGION=LOC101929371_EX2 
chr20 10004418 10004633  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10004532 10004753  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10004753 10004915  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10004915 10005073  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005062 10005203  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005203 10005372  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005372 10005500  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005464 10005644  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005644 10005853  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005853 10005953  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10005953 10006123  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10006123 10006320  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10006320 10006502  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10006502 10006692  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10006706 10006872  SUBMITTED_REGION=SNAP25-AS1_EX1 
chr20 10007128 10007353  SUBMITTED_REGION=SNAP25-AS1_EX2 
chr20 10015672 10015809  GENE_ID=ANKRD5 
chr20 10015809 10016031  GENE_ID=ANKRD5 
chr20 10016144 10016372  GENE_ID=ANKRD5 
chr20 10018917 10019125  GENE_ID=ANKRD5 
chr20 10019125 10019348  GENE_ID=ANKRD5 
chr20 10023685 10023848  GENE_ID=ANKRD5 
chr20 10023848 10024041  GENE_ID=ANKRD5 
chr20 10024987 10025106  GENE_ID=ANKRD5 
chr20 10025106 10025259  GENE_ID=ANKRD5 
chr20 10026169 10026395  GENE_ID=ANKRD5 
chr20 10029973 10030144  GENE_ID=ANKRD5 
chr20 10030144 10030288  GENE_ID=ANKRD5 
chr20 10030288 10030483  GENE_ID=ANKRD5 
chr20 10030483 10030696  GENE_ID=ANKRD5 
chr20 10030693 10030902  GENE_ID=ANKRD5 
chr20 10032233 10032383  GENE_ID=ANKRD5 
chr20 10032383 10032600  GENE_ID=ANKRD5 
chr20 10033674 10033812  GENE_ID=ANKRD5 
chr20 10033812 10033981  GENE_ID=ANKRD5 
chr20 10035022 10035122  GENE_ID=ANKRD5 
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chr20 10035122 10035315  GENE_ID=ANKRD5 
chr20 10036093 10036226  GENE_ID=ANKRD5 
chr20 10036226 10036368  GENE_ID=ANKRD5 
chr20 10036368 10036573  GENE_ID=ANKRD5 
chr20 10036573 10036786  GENE_ID=ANKRD5 
chr20 10036786 10036906  GENE_ID=ANKRD5 
chr20 10036906 10037072  GENE_ID=ANKRD5 
chr20 10037072 10037252  GENE_ID=ANKRD5 
chr20 10037252 10037459  GENE_ID=ANKRD5 
chr20 10084882 10085087  SUBMITTED_REGION=SNAP25-AS1_EX3 
chr20 10177413 10177626  SUBMITTED_REGION=SNAP25-AS1_EX4 
chr20 10199370 10199491  GENE_ID=SNAP25 
chr20 10199490 10199710  GENE_ID=SNAP25 
chr20 10199843 10200012  SUBMITTED_REGION=SNAP25-AS1_EX5 
chr20 10255961 10256063  GENE_ID=SNAP25 
chr20 10256049 10256261  GENE_ID=SNAP25 
chr20 10258243 10258468  GENE_ID=SNAP25 
chr20 10265288 10265503  GENE_ID=SNAP25 
chr20 10273403 10273517  GENE_ID=SNAP25 
chr20 10273517 10273714  GENE_ID=SNAP25 
chr20 10273596 10273824  GENE_ID=SNAP25 
chr20 10273824 10273976  GENE_ID=SNAP25 
chr20 10277451 10277548  GENE_ID=SNAP25 
chr20 10277529 10277748  GENE_ID=SNAP25 
chr20 10279837 10279938  GENE_ID=SNAP25 
chr20 10279938 10280112  GENE_ID=SNAP25 
chr20 10286692 10286902  GENE_ID=SNAP25 
chr20 10286902 10287125  GENE_ID=SNAP25 
chr20 10287125 10287343  GENE_ID=SNAP25 
chr20 10287343 10287511  GENE_ID=SNAP25 
chr20 10287511 10287657  GENE_ID=SNAP25 
chr20 10287657 10287785  GENE_ID=SNAP25 
chr20 10287785 10288001  GENE_ID=SNAP25 
chr20 10288001 10288116  GENE_ID=SNAP25 
chr20 10385802 10385976  GENE_ID=MKKS 
chr20 10385976 10386168  GENE_ID=MKKS 
chr20 10386168 10386347  GENE_ID=MKKS 
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chr20 10388130 10388224  GENE_ID=MKKS 
chr20 10388224 10388430  GENE_ID=MKKS 
chr20 10389194 10389309  GENE_ID=MKKS 
chr20 10389309 10389520  GENE_ID=MKKS 
chr20 10393092 10393294  GENE_ID=MKKS 
chr20 10393294 10393504  GENE_ID=MKKS 
chr20 10393504 10393720  GENE_ID=MKKS 
chr20 10393720 10393937  GENE_ID=MKKS 
chr20 10393937 10394157  GENE_ID=MKKS 
chr20 10394157 10394379  GENE_ID=MKKS 
chr20 10394296 10394433  GENE_ID=MKKS 
chr20 10394433 10394648  GENE_ID=MKKS 
chr20 10401106 10401248  GENE_ID=MKKS 
chr20 10401248 10401466  GENE_ID=MKKS 
chr20 10412256 10412401  GENE_ID=MKKS 
chr20 10412401 10412623  GENE_ID=MKKS 
chr20 10414664 10414802  GENE_ID=MKKS 
chr20 10414741 10414917  GENE_ID=MKKS 
chr20 10415889 10416061  GENE_ID=C20orf94 
chr20 10416061 10416192  GENE_ID=C20orf94 
chr20 10438771 10438960  GENE_ID=C20orf94 
chr20 10536810 10537034  GENE_ID=C20orf94 
chr20 10541222 10541394  GENE_ID=C20orf94 
chr20 10541394 10541521  GENE_ID=C20orf94 
chr20 10579215 10579315  GENE_ID=C20orf94 
chr20 10579315 10579453  GENE_ID=C20orf94 
chr20 10582326 10582528  GENE_ID=C20orf94 
chr20 10601907 10602118  GENE_ID=C20orf94 
chr20 10603237 10603463  GENE_ID=C20orf94 
chr20 10603463 10603646  GENE_ID=C20orf94 
chr20 10603646 10603859  GENE_ID=C20orf94 
chr20 10603859 10604077  GENE_ID=C20orf94 
chr20 10618256 10618358  GENE_ID=JAG1 
chr20 10618358 10618534  GENE_ID=JAG1 
chr20 10618534 10618752  GENE_ID=JAG1 
chr20 10618752 10618849  GENE_ID=JAG1 
chr20 10618849 10619056  GENE_ID=JAG1 
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chr20 10619052 10619236  GENE_ID=JAG1 
chr20 10619236 10619404  GENE_ID=JAG1 
chr20 10619404 10619588  GENE_ID=JAG1 
chr20 10619498 10619709  GENE_ID=JAG1 
chr20 10619707 10619838  GENE_ID=JAG1 
chr20 10619836 10619936  GENE_ID=JAG1 
chr20 10619936 10620158  GENE_ID=JAG1 
chr20 10620158 10620345  GENE_ID=JAG1 
chr20 10620345 10620555  GENE_ID=JAG1 
chr20 10620555 10620656  GENE_ID=JAG1 
chr20 10621350 10621519  GENE_ID=JAG1 
chr20 10621511 10621732  GENE_ID=JAG1 
chr20 10621732 10621942  GENE_ID=JAG1 
chr20 10622057 10622187  GENE_ID=JAG1 
chr20 10622187 10622414  GENE_ID=JAG1 
chr20 10622370 10622593  GENE_ID=JAG1 
chr20 10623008 10623233  GENE_ID=JAG1 
chr20 10623233 10623340  GENE_ID=JAG1 
chr20 10624353 10624579  GENE_ID=JAG1 
chr20 10624907 10625126  GENE_ID=JAG1 
chr20 10625405 10625632  GENE_ID=JAG1 
chr20 10625632 10625821  GENE_ID=JAG1 
chr20 10625803 10626021  GENE_ID=JAG1 
chr20 10626021 10626183  GENE_ID=JAG1 
chr20 10626561 10626787  GENE_ID=JAG1 
chr20 10627510 10627616  GENE_ID=JAG1 
chr20 10627616 10627832  GENE_ID=JAG1 
chr20 10628520 10628746  GENE_ID=JAG1 
chr20 10628746 10628849  GENE_ID=JAG1 
chr20 10629113 10629212  GENE_ID=JAG1 
chr20 10629212 10629435  GENE_ID=JAG1 
chr20 10629589 10629818  GENE_ID=JAG1 
chr20 10629922 10630138  GENE_ID=JAG1 
chr20 10630138 10630348  GENE_ID=JAG1 
chr20 10630840 10631063  GENE_ID=JAG1 
chr20 10632105 10632208  GENE_ID=JAG1 
chr20 10632208 10632430  GENE_ID=JAG1 
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chr20 10632656 10632760  GENE_ID=JAG1 
chr20 10632760 10632971  GENE_ID=JAG1 
chr20 10632939 10633167  GENE_ID=JAG1 
chr20 10633128 10633322  GENE_ID=JAG1 
chr20 10636959 10637181  GENE_ID=JAG1 
chr20 10639036 10639250  GENE_ID=JAG1 
chr20 10639250 10639448  GENE_ID=JAG1 
chr20 10644546 10644764  GENE_ID=JAG1 
chr20 10653284 10653509  GENE_ID=JAG1 
chr20 10653509 10653705  GENE_ID=JAG1 
chr20 10654099 10654330  GENE_ID=JAG1 
chr20 10654330 10654499  GENE_ID=JAG1 
chr20 10654499 10654617  GENE_ID=JAG1 
chr20 10654604 10654777  GENE_ID=JAG1 
chr20 10855961 10856161  SUBMITTED_REGION=RP4-697P8.3_EX1 
chr20 10856161 10856311  SUBMITTED_REGION=RP4-697P8.3_EX1 
chr20 10856311 10856467  SUBMITTED_REGION=RP4-697P8.3_EX1 
chr20 10856467 10856677  SUBMITTED_REGION=RP4-697P8.3_EX1 
chr20 10856677 10856893  SUBMITTED_REGION=RP4-697P8.3_EX1 
chr20 10858898 10859088  SUBMITTED_REGION=RP4-697P8.3_EX2 
chr20 10874509 10874725  SUBMITTED_REGION=RP4-697P8.3_EX3 
chr20 10875201 10875300  SUBMITTED_REGION=RP4-697P8.3_EX4 
chr20 10875300 10875521  SUBMITTED_REGION=RP4-697P8.3_EX4 
chr20 10876610 10876794  SUBMITTED_REGION=RP4-697P8.3_EX5 
chr20 10876766 10876920  SUBMITTED_REGION=RP4-697P8.3_EX5 
chr20 10876920 10877071  SUBMITTED_REGION=RP4-697P8.3_EX5 
chr20 10877677 10877865  SUBMITTED_REGION=RP4-697P8.3_EX6 
chr20 10889548 10889726  SUBMITTED_REGION=RP4-697P8.3_EX7 
chr20 10889726 10889946  SUBMITTED_REGION=RP4-697P8.3_EX7 
chr20 11247250 11247359  SUBMITTED_REGION=LOC339593 
chr20 11247359 11247582  SUBMITTED_REGION=LOC339593 
chr20 11247582 11247750  SUBMITTED_REGION=LOC339593 
chr20 11247750 11247844  SUBMITTED_REGION=LOC339593 
chr20 11247844 11248037  SUBMITTED_REGION=LOC339593 
chr20 11248037 11248184  SUBMITTED_REGION=LOC339593 
chr20 11248184 11248403  SUBMITTED_REGION=LOC339593 
chr20 11248403 11248608  SUBMITTED_REGION=LOC339593 
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chr20 11248608 11248799  SUBMITTED_REGION=LOC339593 
chr20 11248799 11249006  SUBMITTED_REGION=LOC339593 
chr20 11249006 11249118  SUBMITTED_REGION=LOC339593 
chr20 11249118 11249344  SUBMITTED_REGION=LOC339593 
chr20 11249318 11249483  SUBMITTED_REGION=LOC339593 
chr20 11898477 11898683  GENE_ID=BTBD3 
chr20 11898679 11898893  GENE_ID=BTBD3 
chr20 11898893 11899085  GENE_ID=BTBD3 
chr20 11899085 11899299  GENE_ID=BTBD3 
chr20 11899652 11899883  GENE_ID=BTBD3 
chr20 11900233 11900407  GENE_ID=BTBD3 
chr20 11900407 11900537  GENE_ID=BTBD3 
chr20 11903199 11903349  GENE_ID=BTBD3 
chr20 11903349 11903565  GENE_ID=BTBD3 
chr20 11903565 11903785  GENE_ID=BTBD3 
chr20 11903785 11903961  GENE_ID=BTBD3 
chr20 11903961 11904186  GENE_ID=BTBD3 
chr20 11904186 11904413  GENE_ID=BTBD3 
chr20 11904413 11904629  GENE_ID=BTBD3 
chr20 11904629 11904824  GENE_ID=BTBD3 
chr20 11904824 11904967  GENE_ID=BTBD3 
chr20 11904967 11905181  GENE_ID=BTBD3 
chr20 11905181 11905294  GENE_ID=BTBD3 
chr20 11905292 11905504  GENE_ID=BTBD3 
chr20 11905504 11905694  GENE_ID=BTBD3 
chr20 11905694 11905922  GENE_ID=BTBD3 
chr20 11905922 11906127  GENE_ID=BTBD3 
chr20 11906127 11906332  GENE_ID=BTBD3 
chr20 11906332 11906521  GENE_ID=BTBD3 
chr20 11906520 11906703  GENE_ID=BTBD3 
chr20 11906703 11906860  GENE_ID=BTBD3 
chr20 11906855 11907060  GENE_ID=BTBD3 
chr20 11907055 11907240  GENE_ID=BTBD3 
chr20 11907208 11907302  GENE_ID=BTBD3 
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(Appendix B2) 
Loading of Ion 316 Chip v2 for PGM 
According to the manufacturers protocol Adapted from Life Technologies.  
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(Appendix B2) 
Loading of Ion Pi Chip v2 for Proton Sequencer 
According to the manufacturers protocol Adapted from Life Technologies.  
 
 
227 
 
 
 
228 
 
229 
 
 
 
 
 
230 
 
 
 
 
 
 
 
231 
 
(Appendix B3) 
 
PedCheck software 
The PedFile without the disease column was used and genotyping format was converted to 
numerical format (A,B >1,2). Also, MapFile included only the SNP ID as the output is expected 
to be SNPs with Mendelian errors.  
The Commands used for PedCheck analysis: 
-p PedFile_2.txt –n MapFile_2.txt -4 
 
 
Merlin for npl Analysis 
Merlin requires 3 files in order to operate as described in Chapter 6, Data File, Ped File and 
Map File.  
The commands used for Non- Parametric Linkage Analysis: 
-d DataFile.txt –p PedFile.txt –m MapFile.txt –npl –exp 
--swap –smalSwap –quiet 
--markerNames –pdf –prefix npl_1 >output_npl_1 
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